Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2018/057810
Kind Code:
A1
Abstract:
The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, n, R1, R2, R3, R4, R5, and R6 are as described herein. The compounds of formula I selectively inhibit the activities of PI3K isoforms and are therefore useful in therapeutic treatments, in particular in the treatment of cancer and inflammatory conditions.

Inventors:
CHANDRASEKHAR JAYARAMAN (US)
PERREAULT STEPHANE (US)
PATEL LEENA (US)
PHILLIPS GARY (US)
TILL NICHOLAS ALEXANDER (US)
TREIBERG JENNIFER ANNE (US)
Application Number:
PCT/US2017/052820
Publication Date:
March 29, 2018
Filing Date:
September 21, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
GILEAD SCIENCES INC (US)
International Classes:
C07D401/14; A61K31/4184; A61K31/4196; A61K31/4409; A61K31/4709; A61K31/506; A61K31/519; A61P29/00; A61P35/00; C07D487/02
Domestic Patent References:
WO2010096314A12010-08-26
Foreign References:
US8435988B22013-05-07
US6800620B22004-10-05
US8435988B22013-05-07
US8673906B22014-03-18
US20130274253A12013-10-17
US8486941B22013-07-16
US8450321B22013-05-28
US8557803B22013-10-15
US4965288A1990-10-23
US4997854A1991-03-05
US4943593A1990-07-24
US5021456A1991-06-04
US5059714A1991-10-22
US5120764A1992-06-09
US5182297A1993-01-26
US5252608A1993-10-12
US20040248871A12004-12-09
US3845770A1974-11-05
US4326525A1982-04-27
US4902514A1990-02-20
US5616345A1997-04-01
US5023252A1991-06-11
US4992445A1991-02-12
US5001139A1991-03-19
Other References:
MESHRAM H M ET AL: "Synthesis and Cytotoxicity of New Quinoline Derivatives", INDIAN JOURNAL OF CHEMISTRY, SECTION B, vol. 51B, no. 9, 22 January 2013 (2013-01-22), pages 1411 - 1416, XP055418074, ISSN: 0376-4699
RHEAULT T R ET AL: "Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: Potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 15, 1 August 2010 (2010-08-01), pages 4587 - 4592, XP029121101, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2010.06.009
RAMEH ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 8347 - 8350
PANAYOTOU ET AL., TRENDS CELL BIOL., vol. 2, 1992, pages 358 - 60
OTSU ET AL., CELL, vol. 65, 1991, pages 91 - 104
HILES ET AL., CELL, vol. 70, 1992, pages 419 - 29
ENGELMAN, NAT. REV. CANCER, vol. 9, 2009, pages 550 - 562
BERGE, JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, no. 1, January 1977 (1977-01-01)
J. MARCH: "Advanced Organic Chemistry 4th ed.", 1992, JOHN WILEY AND SONS
FOSTER: "Deuterium Isotope Effects in Studies of Drug Metabolism", TRENDS PHARMACOL. SCI., vol. 5, no. 12, 1984, pages 524 - 527, XP025943358, DOI: doi:10.1016/0165-6147(84)90534-0
AGNEW, CHEM. INTL. ED. ENGL, vol. 33, 1994, pages 183 - 186
FERRARA N.; ALITALO, K.: "Clinical application of angiogenic growth factors and their inhibitors", NATURE MEDICINE, vol. 5, 1999, pages 1359 - 1364, XP002217702, DOI: doi:10.1038/70928
CHESON, B.D.; LEONARD, J.P.: "Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 359, no. 6, 2008, pages 613 - 626, XP002573821, DOI: doi:10.1056/NEJMra0708875
WIERDA, W.G.: "Current and Investigational Therapies for Patients with CLL", HEMATOLOGY, 2006, pages 285 - 294
MORTON, L.M. ET AL.: "Lymphoma Incidence Patterns by WHO Subtype in the United States, 1992-2001", BLOOD, vol. 107, no. 1, 2006, pages 265 - 276
"Remington's Pharmaceutical Sciences. 17th Ed.", 1985, MACE PUBLISHING CO.
G.S. BANKER & C.T. RHODES,: "Modern Pharmaceutics 3rd Ed.", MARCEL DEKKER, INC.
Attorney, Agent or Firm:
REANEY, Shannon et al. (US)
Download PDF:
Claims:
What iscl aimed:

1. A compound having the structure of formula (I):

Formula I

wherein n is 1 , 2, 3 or 4; s is 1 or 2; t is 1 or 2; each R1 is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R£ -C(O)ORb, -C(O)NRaRb, -N(Ra)C(O)Rb, -S(O)NRaRb , -S(O)2NRaRb , -S(O)R9,- S(O)2Rg -NReRb, -ORa, -SRb C1-6 alkyl, al kenyl , C2-6 al kynyl , C3- 8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S; wherei n each C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3- 8 cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R ;

R2 isselected from hydrogen, halo, cyano, hydroxy, amino, -C(O)Ra, -C(O)ORb, -

C(O)NRaRb, -N(Ra)C(O)Rb, -S(O)NRaRb , -S(O)2NRaRb, -S(O)Rg -S(O)2Rg - N RaRb, -ORa, -SRb C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3-8 cycl oal kyl , C6-10 aryl , 5-10 membered heteroaryl contai ning 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms sel ected from the group consisti ng of N , O, and S; wherei n each C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , CM cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substi tuted wi th one to f our R ;

R3 isselected from hydrogen, halo, cyano, hydroxy, amino, -C(O)Ra, -C(O)ORb, - C(O)NRaRb, -N(Ra)C(O)Rb, -N(Ra)C(O)NRaRb, -OC(O) NRaRb , - NRaS(O)2NRaRb, - NRaS(O)2Ra -S(O)NRaRb, -S(O)2NRaRb, -S(O)Rg -S(O)2Rg - N RaRb, -ORa, -SRb C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3-8 cycl oal kyl , C6-10 aryl , 5-10 membered heteroaryl contai ning 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms sel ected from the group consisti ng of N , O, and S;

wherei n each C1-6 al kyl , C2_6 al kenyl , C2_6 al kynyl , C3- 8 cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R102;

R4 is a 5-10 membered heteroaryl ; wherein said 5-10 membered heteroaryl isoptionally substituted with one to four R103;

each R5 is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)Ra, -C(O)ORb, -C(O)NRaRb , -N(Ra)C(O)Rb -N(Ra)C(O)NRaRb , -OC(O)NRaRb , - NRaS(O)2NRaRb - NRaS(O)2Ra -S(O)NRaRb, -S(O)2NRaRb, -S(O)Rg, -S(O)2Rg, - N RaRb, -ORa, -SRb C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3- c 8ycl oal kyl , C6-10 aryl , 5-10 membered heteroaryl contai ning 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms sel ected from the group consisti ng of N , O, and S; wherei n each C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , cycl oCal3 k-8yl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl isoptionally substituted with one to four R104; each R is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R , -C(O)ORb, -CCCONRaRb , -N(Ra)C(O)Rb, -SCCONRaRb , -S(O)2NRaRb , -S(O)R9, - S(O)2R9 -NRaRb , -ORa, -SRb, C1-6 alkyl , C2-6 alkenyl or C2-6 alkynyl ; each Raand Rb is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; wherei n each C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , i s opti onal ly substituted with one to four R200; each R100, R101, R1Q2, R103 and R104 is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, -C(O)Rc, -C(O)ORc, -C(O)NRcRd, - N(Rc)C(O)Rd, -N(Ra)C(O)NRaRb, -OC(O)NRaRb , -NRaS(O)2NRaRb, - NRaS(O)2Ra, -S(O)NRcRd, -S(O)2NRcRd, -S(O)Rg -S(O)2Rg -NRcRd, -ORc, -SRd C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl , cycloalkyl, C6-10 aryl , 5-10 membered heteroaryl and 4-10 membered heterocyclyl ; wherei n each C-1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3-8 cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R ; each Rcand Rd is independently selected from hydrogen, C6-10 aryl ,C1-6 al kyl, C2-6 al kenyl and C2-6 al kynyl ; each R and R is independently selected from hydrogen, halo, cyano, hydroxy,

amino, oxo, thioxo, vinyl , -C(O)Re, -C(O)ORe, -C(O)NReRf, -Ν(R) C(O)Rf, - S(O)NReRf, -S(O)2NReRf, -S(O)R9, -S(O)2R9, -NReRf, -ORe, -SRe C1-6 alkyl, C2-6 al kenyl and C2-6 al kynyl ; each Reand Rf is independently selected from hydrogen, C1-6 alkyl , C2-6 alkenyl and C2-6 alkynyl; each R9 is i ndependentl y sel ected f rom C1-6 al ky I , C2-6 al kenyl , C2-6 al kynyl , C3-8

cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S; wherei n each C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3- 8 cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R200; a pharmaceutically acceptable salt, isomer, or a mixture thereof.

A compound of claim 1 having the structure of formula I A:

Formula I A:

wherein n, s, t, R1, R2, R4, R5and R6 are as defined above; X1 is N or C; each X2, X3, X4 and X5 is independently selected from S, O, CR10 and NR11; wherein each R10 is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)Ra, -C(O)ORb, -C(O)NRaRb, -N(Ra) Ca) R15, -S(O)NRaRb, - S(O)2N RaRb, -S(O)R9 -S(O)2R9 -N RaRb , -ORa, -SRb, CM al kyl , C2-6 al kenyl , C2-6 al kynyl, cycl oal kyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl contai ni ng 1 to 4 heteroatoms sel ected from the group consisting of N, O, and S; wherei n each C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3-8 cycl oal kyl , C6-ιο aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R104; wherein each R11 is independently selected from absent, hydrogen, halo, cyano, hydroxy, amino, -C(O)Ra, -C(O)ORb, -C(O)NRaRb, -N(Ra )C(OR6, - S(O)NRaRb , -S(O)2NRaRb, -S(O)R9 -SiO)2R9, -NRlaR,b -ORa, -SRb C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3-8 cycl oal kyl , C6-10 aryl , 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S; alternatively, one R10 and one R11 group, together with the atoms to which they are attached form a five, six or seven membered fused, or bridged ring; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

3. A compound according to any of claims 1 wherein R3 isselected from:

wherein t is 1 or 2;

wherein each R is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)Ra, -C(O)ORb, -C(O)NRaRb , -Ν(Ra) C(O)Rb , -S(O)NRaRb , -S(O)2NRaRb, - S((O)OR) g -S(O)2R9, -N RaRb , -0Ra, -SRb, C1-6 al kyl , C2.6 al kenyl , C2-6 al kynyl , C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

4. A compound of claim 3 having the structure of formula IB:

Formula IB

wherein each R is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)Ra, -C(O)ORb, -C(O)NRaRb , -NiRa)C(O)R13, -S(O)NRaRb , -S(O)2NRaRb , - S(O)R9, -S(O)2R9 -N RaRb , -ORa, -SRb C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

5. A compound of claim 1 having the structure of formula IC:

Formula I C

wherein each R is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)Ra, -C(O)ORb, -C(O)NRaRb , -N(Ra) C(O)R13, -S(O)NRaRb , -S(O)2NRaRb, - S(O)Rg, -S(O)2R9, -N RaRb , -ORa, -SRb C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

6. A compound of claim 3 having the structure of formula ID:

Formula ID or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

7. A compound of claim 3 having the structure of formula IE:

Formula IE

wherein each R13 is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)Ra, -C(O)ORb, -C(O)NRaRb , -N(Ra) C(O)R13, -S(O)NRaRb , -S(O)2NRaRb, - S(O)Rg, -S(O)2R9, -N RaRb, -ORa, -SRb, C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

8. A compound of claim 3 having the structure of formula IF:

Formula IF

a pharmaceutically acceptable salt, isomer, or a mixture thereof.

A compound of claim 3 having the structure of formula IG:

Formula IG or a pharmaceutical ly acceptable salt thereof; wherei n the atropisomer of formula I E or a pharmaceutically acceptable salt thereof, is present in excess of its corresponding enantiomer or a pharmaceutically acceptable salt thereof.

10. A compound of claim 3 having the structure of formula I H:

Formula I H

wherein each R13 is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)Ra, -C(O)ORb, -C(O)NRaRb , -N( Ra)C(O)R1', -S(O)NRaRb , -S(O)2NRaRb, - S(O)R9, -S(O)2R9, -N RaRb , -ORa, -SRb C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

11. A compound of claim 3 having the structure of formula I J:

Formula I J or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

12. A compound of any of the above claims wherein R4 is selected from the table below:

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

13. A compound accordi ng to any of claims 1-12 wherein R is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, butyl, fluoromethyl, difluoromethyl, tri fluoromethyl, fluoroethyl, difluoroethyl and trifluoroethyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

14. A compound according to any of claims 1-12 wherein R1 isfluoro or chloro; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

15. A compound accordi ng to any of claims 1-14 wherein R2 is C1-6 alkyl, C3.8 cycloalkyl , 5-6 membered heteroaryl containing 1 to 3 heteroatoms selected from the group consisting of N, O, and S, and 4-6 membered heterocyclyl containing 1 to 4 heteroatoms sel ected from the group consi sti ng of N , O, and S; wherei n each C1-6 al kyl , C3.8 cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocyclyl is optionally substituted with one to four R101;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

16. A compound accordi ng to any of claims 1-14 wherein R2 is sel ected from hydrogen, amino, methyl, ethyl , propyl, isopropyl, butyl, isobutyl, t-butyl, furanyl, tetrahydrof uranyl , oxetanyl, and cyclopropyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

17. A compound according to any of claims 1-16 wherein R3 is sel ected from 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, -C(O)OH, and -C(O)NH2; or a pharmaceutically acceptable salt, isomer, or a mixture thereof. A compound according to any one of claims 1-16, wherein R3isselected from

19. A compound according to any of claims 1-18 wherein R5 is selected from hydrogen, methyl, ethyl, trif I uoromethyl , carboxamide, cyano, piperazinyl, cyclopropyl, phenyl and triazolyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

20. A compound accordi ng to any of claims 1-18 wherein R is hydrogen or methyl.

21. The compound of claim 1, wherein the compound is selected from:

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

22. The compound of clai m 1 , sel ected from:

23. A pharmaceutical composition comprisesthecompound according to any one of cl ai ms 1 -22 and at I east one pharmaceuti cal I y acceptabl e vehi cl e.

24. A method of treating a disease or condition in a human in need thereof comprising administering to the human a therapeutically effective amount of the compound or composition according to any one of claims 1-23 wherein the disease or condition isselected from cancer, hematologic malignancies, leukemias, lymphomas, myeloproliferative disorders, myelodysplastic syndromes, plasma cell neoplasms, solid tumor, inflammation, fibrosis, autoimmune disorders, allergic conditions,

hypersensitivity, cardiovascular diseases, neurodegenerative diseases, renal disorders, viral infections, obesity, and autoimmune diseases.

25. The method of claim 24, wherein the disease or condition isselected from rheumatoid arthritis, osteoarthritis, atherosclerosis, psoriasis, systemic lupus

erythematosus, multiple sclerosis, inflammatory bowel disease, asthma, chronic obstructive airways disease, pneumonitis, dermatitis, alopecia, nephritis, vasculitis, atherosclerosis, Alzheimer's disease, hepatitis, primary biliary cirrhosis, sclerosing cholangitis, diabetes, acute rejection of transplanted organs, lymphomas, multiple myelomas, leukemias, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CN S cancers brai n tumors bone cancer, or soft ti ssue sarcoma.

26. The method of claim 24, wherein said disease or condition isselected from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors, bone cancer and soft tissue sarcoma.

27. A method of inhi biting the activity of a phosphatidyl inositol 3-kinase polypeptide by contacting the polypeptide with the compound or composition of claim 1-23. 28. A method of inhibiting excessive or destructive immune reactions or growth or a proliferation of cancer cells, comprising administering an effective amount of the compound or composition accordi g to any one of claims 1-23.

29. A method of treating a disease or condition in a human in need thereof comprising administering to the human a therapeutically effective amount of the compound or composition according to any one of claims 1-23 in combination with therapeutically effective amount of a compound that inhibits or modulates the activity of poly(ADP-ribose) polymerases (PARP), Tankyrases (TANKs), matrix

metalloproteinases or androgen receptor, wherein the disease or condition is selected from cancer, hematologic malignancies, leukemias, lymphomas, myeloproliferative disorders, myelodysplastic syndromes, plasma eel I neoplasms, solid tumor,

inflammation, fibrosis, autoimmune disorders, allergic conditions, hypersensitivity, cardiovascular diseases, neurodegenerative diseases, renal disorders, viral infections, obesity, and autoimmune diseases.

30. The method of claim 29, wherein said disease or condition isselected from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors, bone cancer and soft tissue sarcoma.

31. A method of treating a disease or condition in a human in need thereof comprising administering to the human a therapeutically effective amount of the compound or composition according to any one of claims 1-23 in combination with therapeutically effective amount of a compound selected from enzalutamide, abiraterone, abiraterone acetate, apalutamide, galeterone, olaparib, niraparib, veliparib, rucaparib, flutamide, nilutamide, bicalutamide, ketoconazole , orteronel, finasteride, dutasteride, bexlosteride, izonsteride, turosteride, episteride, dexamethasone, prednisone, leuprolide, goserelin, triptorelin, histrelin, estrogen, cyproterone acetate, spironolactone, flutamide and hydroxyflutamide, wherein the disease or condition isselected from cancer, hematologic malignancies, leukemias, lymphomas, myeloproliferative disorders, myelodysplastic syndromes, plasma cell neoplasms, solid tumor, inflammation, fibrosis, autoimmune disorders, allergic conditions, hypersensitivity, cardiovascular diseases, neurodegenerative diseases, renal disorders, viral infections, obesity, and autoimmune diseases.

32. The method according to claim 31, wherein said disease or condition is selected from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors, bone cancer and soft tissue sarcoma.

33. A kit comprising the compound or composition of any one of claims 1-23, a label and/or instructions for use.

34. The compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof accordi ng to any one of cl ai ms 1 -22 for use i n therapy.

35. The compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof accordi ng to any one of cl ai ms 1 -22 for use i n a method of treati ng of cl ai m 22.

36. Use of the compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof accordi ng to any one of clai ms 1-22 for the manufacture of a medicament for treatment of a disease or condition of claim 24.

A compound selected from the table bel

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

38. A pharmaceutical composition comprisesthecompound according to any one of cl ai ms 37 and at I east one pharmaceuti cal I y acceptabl e vehi cl e.

39. A method of treating a disease or condition in a human in need thereof comprising administering to the human a therapeutically effective amount of the compound or composi ti on accordi ng to any one of cl ai ms 37 or 38 wherei n the di sease or condition is selected from cancer, hematologic malignancies, leukemias, lymphomas, myeloproliferative disorders, myelodysplastic syndromes, plasma cell neoplasms, solid tumor, inflammation, fibrosis, autoimmune disorders, allergic conditions,

hypersensitivity, cardiovascular diseases, neurodegenerative diseases, renal disorders, viral infections, obesity, and autoimmune diseases.

40. The method of claim 39, wherein the disease or condition is selected from rheumatoid arthritis, osteoarthritis, atherosclerosis, psoriasis, systemic lupus

erythematosus, multiple sclerosis, inflammatory bowel disease, asthma, chronic obstructive airways disease, pneumonitis, dermatitis, alopecia, nephritis, vasculitis, atherosclerosis, Alzheimer's disease, hepatitis, primary biliary cirrhosis, sclerosing cholangitis, diabetes, acute rejection of transplanted organs, lymphomas, multiple myelomas, leukemias, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CN S cancers brai n tumors bone cancer, or soft ti ssue sarcoma.

41. The method of claim 39, wherein said disease or condition is selected from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors, bone cancer and soft tissue sarcoma.

42. A method of inhi biting the activity of a phosphatidyl inositol 3-kinase polypeptide by contacting the polypeptide with the compound or composition of claim 37 or 38.

43. A method of inhibiting excessive or destructive immune reactions or growth or a proliferation of cancer cells, comprising administering an effective amount of the compound or composi ti on accordi ng to any one of cl ai ms 37 or 38.

44. A method of treating a disease or condition in a human in need thereof comprising administering to the human a therapeutically effective amount of the compound or composi ti on accordi ng to any one of cl ai ms 35 or 36 in combi nati on wi th therapeutically effective amount of a compound that inhi bits or modulates the activity of poly(ADP-ribose) polymerases (PARP), Tankyrases (TANKs), matrix

metalloproteinases or androgen receptor, wherein the disease or condition is selected from cancer, hematologic malignancies, leukemias, lymphomas, myeloproliferative disorders, myelodysplastic syndromes, plasma eel I neoplasms, solid tumor,

inflammation, fibrosis, autoimmune disorders, allergic conditions, hypersensitivity, cardiovascular diseases, neurodegenerative diseases, renal disorders, viral infections, obesity, and autoimmune diseases.

45. The method of claim 44, wherein said disease or condition is selected from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors, bone cancer and soft tissue sarcoma.

46. A method of treating a disease or condition in a human in need thereof comprising administering to the human a therapeutically effective amount of the compound or composi ti on accordi ng to any one of cl ai ms 37 or 39 in combi nati on wi th therapeutically effective amount of a compound selected from enzalutamide, abiraterone, abiraterone acetate, apalutamide, galeterone, olaparib, niraparib, veliparib, rucaparib, flutamide, nilutamide, bicalutamide, ketoconazole , orteronel, finasteride, dutasteride, bexlosteride, izonsteride, turosteride, episteride, dexamethasone, prednisone, leuprolide, goserelin, triptorelin, histrelin, estrogen, cyproterone acetate, spironolactone, flutamide and hydroxyflutamide, wherein the disease or condition isselected from cancer, hematologic malignancies, leukemias, lymphomas, myeloproliferative disorders, myelodysplastic syndromes, plasma cell neoplasms, solid tumor, inflammation, fibrosis, autoimmune disorders, allergic conditions, hypersensitivity, cardiovascular diseases, neurodegenerative diseases, renal disorders, viral infections, obesity, and autoimmune diseases.

47. The method according to claim 46 wherein said disease or condition isselected from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors, bone cancer and soft tissue sarcoma.

48. A kit comprising the compound or composition of any oneof claims 37 or 38, a label and/or instructions for use.

49. The compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof accordi ng to cl ai m 37 for use i n therapy.

50. The compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof accordi ng to cl ai m 37 for use i n a method of treati ng of cl ai m 39. 51. Use of the compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof according to claim 37 for the manufacture of a medicament for treatment of a disease or condition of claim 39.

Description:
PHOSPHATI DYLI NOSITOL 3-KI NASE I NHI BITORS

FIELD

The present application relates to novel compounds that selecti ely inhibit the activities of PI3K isoforms and their uses in therapeutic treatments. BACKGROUND

Cell signaling via 3'-phosphorylated phosphoi nosi tides has been implicated in a variety of cellular processes, e.g., malignant transformation, growth factor signaling, inflammation, and immunity (Rameh et al., J. Biol. Chem., 274:8347-8350, 1999). Phosphatidyl inositol 3-kinase (PI 3-ki nase or PI 3K) is responsible for generating these phosphoryl ated si gnal i ng products. PI 3K was i ni ti al I y i denti f i ed as a protei n associ ated with viral oncoprotei ns and growth factor receptor tyrosi ne kinases that phosphoryl ate phosphatidyl inositol (PI) and its phosphoryl ated derivatives at the 3' -hydroxy I of the inositol ring (Panayotou et al., TrendsCell Biol., 2:358-60, 1992).

Three classes of the PI 3-kinase (PI3K) are proposed based on the substrate specificities. Class I PI 3Ks phosphoryl ate phosphatidyl inositol (PI),

phosphatidyl inositol -4- phosphate, and phosphatidyl inositol -4,5-bi phosphate (PI P2) to produce phosphati dyl i nositol-3-phosphate (PI P), phosphatidyl i nositol-3,4-bi phosphate, and phosphatidylinositol-3,4,5-triphosphate, respectively. Also, Class II PI3Ks phosphoryl ate PI and phosphati dyl i nosi tol-4-phosphate, and Class II I PI3Ks

phosphoryl ate PI .

The initial purification and molecular cloning of PI 3-ki nase revealed that it wasa heterodimer consisting of p85 and p110 subunits (Otsu et al., Cell, 65:91-104, 1991; Hilesei a/., Cell, 70:419-29, 1992). Later, four distinct Class I PI 3Ks were identified and designated as PI 3K α, β, δ, and γ isoforms. Each isoform consists of a distinct 110 kDa catalytic subunit and a regulatory subunit. The catalytic subunits of PI 3K α, β, and δ (i.e., ρ110α, ρ110β, and p110n, respectively) interacts, individually, with the same regulatory subunit p85, whereas the catalytic subunit of PI3K γ (ρ110γ) interacts with a distinct regulatory subunit p101. Studies have also showed that each PI3K isoform has distinct expression pattern. For example, PIK3CA which encodes PI3K□ isfrequently mutated in human cancers (Engelman, Nat. Rev. Cancer, 9: 550-562, 2009). Also, PI3Kδ is generally expressed in hematopoietic eel Is. Moreover, PI3K isoforms are shown to be associated with proliferation or survival signaling in cancers, inflammatory, or autoimmune diseases. As each PI3K isoform has different biological function, PI3K isoforms are potential targets to treat cancer or disorder (US Patent Nos. 6,800,620; 8,435,988; 8,673,906; US Patent Application Publication No. US2013/0274253).

Therefore, there i s a need for devel opi ng therapeuti c agents that i nhi bit PI 3K isoforms to treat diseases, disorders, or conditions that are mediated by PI3K.

SUM MARY

The present application provides novel compounds that are inhibitors of PI3K isoforms. The application also provides compositions, including pharmaceutical compositions, kits that i ncl ude the compounds, and methods of usi ng and maki ng the compounds. The compounds provi ded herei n are useful i n treati ng di seases, di sorders, or conditions that are mediated by PI3K isoforms. The application also provides compounds for use i n therapy. The appl i cati on further provi des compounds for use i n a method of treating a disease, disorder, or condition that is mediated by PI3K isoforms. Moreover, the application provides uses of the compounds in the manufacture of a medi cament for the treatment of a di sease, di sorder or condi ti on that i s medi ated by PI 3K isoforms. I n typical embodiments, provided are compounds of formula I :

Formula I

wherein n is 1 , 2, 3 or 4; s is 1 or 2; t is 1 or 2; each R 1 is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , -C(O)NR a R b , -N(R a ) C(O)R b , -S(O)NR a R b , -S(O) 2 NR a R b , -S(O)R 9 - S(O) 2 R 9 -NR e R b , -OR a , -SR b C1-6 alkyl, C 2-6 al kenyl , C 2-6 al kynyl , C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocycl yl contai ni ng 1 to 4 heteroatoms sel ected from the group consi sti ng of

N, O, and S; wherei n each C1-6 al kyl , C2-6 al kenyl , C 2-6 al kynyl , cycl oal kyl , C6-10aryl , 5- 10 membered heteroaryl and 4-10 membered heterocycl yl is optionally substituted with one to four R 100 ; R 2 isselected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , -

C(O)NR a R b , -N(R a )C(O)R b , -S(O)NR e R b , -S(O) 2 NR a R b , -S(O)R g -S(O) 2 R 9 - NR a R b , -OR a , -SR b C 1-6 alkyl, C 2-6 al kenyl, C 2-6 al kynyl, C M cycl oal kyl, C6-10 aryl , 5-10 membered heteroaryl contai ning 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms sel ected from the group consi sti ng of N , O, and S; wherei n each C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , C3-8 cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R 101 ;

R 3 isselected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , - C(O)NR a R b , -N(R a )C(O)R b , -N(Ra)C(O)NR e R b , -OC(O)NR a R b , -

NR a S(O) 2 NR a R b , - NR a S(O) 2 R a -S(O)NR a R b , -S(O)NR a R b , -S(O)R g , -S(O) 2 R 9 , - N R a R b , -OR a , -SR b C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , C3-8 cycl oal kyl , C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms sel ected from the group consisti ng of N , O, and S;

wherei n each wherei n each C1-6 al kyl , C2-6 al keny I , C2-6 al kynyl , C3-8 cycl oal kyl , C6-10 aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R ;

R 4 is a 5-10 membered heteroaryl ; wherein said 5-10 membered heteroaryl isoptionally substituted with one to four R 103 ;

each R 5 is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , -C(O)NR a R b , -N(R a )C(O)R b , -S(O)NR e R b , -S(O) 2 NR a R b , -S(O)R g -

S(O) 2 R g -NR e R b , -NiR a )C(O)NR a R b , -OC(O)NR a R b , -NR a S(O)2NR a R b - NR a S(O)2R a , -OR a -SR b C1-6 alkyl, C 2-6 alkenyl, C 2-6 al kynyl, C3-8 cycl oal kyl, C & . 10 aryl , 5-10 membered heteroaryl containing 1 to 4 heteroatoms sel ected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms sel ected from the group consi sti ng of N , O, and S; wherei n each C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , C3-8 cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl isoptionally substituted with one to four R 104 ; each R 6 is i ndependently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , -C(O)NR a R b , -N(R a )C(O)R b , -S(O)NRV, -S(O) 2 NR a R b , -S(O)R g , -

S(O) 2 R 9 -N R e R b , -OR a , -SR b C 1-6 al kyl , C 2-6 al kenyl or C 2-6 al kynyl ; each R a and R b is independently selected from hydrogen, C6-10 aryl, C1-6 alkyl, C 2- 6

al kenyl and C 2-6 al kynyl ; wherei n each C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , i s opti onal ly substituted with one to four R 200 ; each R 100 , R 101 , R 1Q2 , R 103 and R 104 is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, -C(O)R c , -C(O)OR c , -C(O)NR c R d , - N(R c )C(O)R d , -N(R a )C(O)NR , ft b I -OC(O)NR e R b , -NR e R(O)2NR e R b , - NR a S(O)2R a -S(O)NR c R d , -S(O) 2 NR c R d , -S(O)R g -S(O) 2 R 9 -NR c R d -OR 0 , -SR d C1-6 alkyl, C2-6 alkenyl, C 2-6 alkynyl , C3-8 cycloalkyl, C6-10 aryl , 5-10 membered heteroaryl and 4-10 membered heterocyclyl ; wherei n each C1-6 al kyl , C2-6 al kenyl , C 2-6 al kynyl , C3-8 cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R ; each R c and R d is independently selected from hydrogen, C6-10 aryl , C1-6 alkyl , C 2 - 6 al kenyl and C 2-6 al kynyl ; each R 200200 and R 201 is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl , -C(O)R e , -C(O)OR e , -C(O)NR e R f , -N(R e )CiO)R f , - S(O)NR e R f , -S(O) 2 NR e R f , -S(O)R g -S(O) 2 R g -N C(O)NR a R b ', -OC(O)NR e R f ,

-N R a S(O) 2 N R a R b , - N R a S(O) 2 R a , -N R e R f , -OR e , -SR e , CM al kyl , C 2-6 al kenyl and C2-6 al kynyl; each R e and R f is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl and C 2-6 al kynyl; each R 9 is independently selected from C1-6 alkyl , C 2-6 al kenyl, C 2-6 al kynyl, C3-8

cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S; wherei n each C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , C3-3 cycl oal kyl , C6-10 aryl , 5-

10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R 200 ; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

I n certai n embodi ments, the PI 3K i nhi bitors are the compounds selected from Table 1, a pharmaceutically acceptable salt, isomer, or a mixture thereof. In additional embodi ments, the compound i s an (S )-enanti omer. I n other embodi ments, the compound is an (R)e-nantiomer. In other additional embodiments, the compound isan atropisomer. The application also provides a pharmaceutical composition that comprises a compound of formula (I), a pharmaceutically acceptable salt, isomer, or a mixture thereof, together wi th at I east one pharmaceuti cal I y acceptabl e vehi cl e. Exampl es of a pharmaceuti cal I y acceptable vehicle may Deselected from carriers, adjuvants, and excipients.

Further provided herein is a method of treating a disease, disorder, or condition in a human in need thereof by administering to the human a therapeuti call y effective amount of a compound of formula (I ) or a pharmaceutical I y acceptable salt, isomer, or a mixture thereof. Further provided is a compound of formula (I ) for use i n a method of treating a disease, disorder or condition that is mediated by PI3K isoforms. The application also provides the use of a compound of formula (l) i n the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by H3K isoforms. In certain embodiments, thedisease, disorder, or condition isassociated or mediated by PI3K. In some embodi ments, thedisease, disorder, or condition isan inflammatory disorder. In other embodiments, thedisease, disorder, or condition isa cancer.

Also provided herein isa method of inhibiting the activity of a

phosphati dyl i nosi tol 3-ki nase pol ypepti de by contacti ng the pol ypepti de wi th a compound of formula (I) or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

Further provided isa method of inhibiting excessive or destructive immune reactions, comprising administering an effective amount of acompound of formula (I) or a pharmaceuti cal I y acceptabl e sal t, i somer, or a mixture thereof.

Also provided isa method of inhibiting growth or proliferation of cancer cells compri si ng contacti ng the cancer eel I s with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

Also provided isa kit that includes a compound of formula (I) or a

pharmaceutically acceptable salt, isomer, or a mixture thereof. The kit may further comprise a label and/or instructions for use of the compound in treating a disease, disorder, or condition in a human in need thereof. I n some embodi ments, the disease, disorder, or condition may be associated or mediated by PI3K activity.

Also provided are articles of manufacture that include a compound of formula (I) or a pharmaceutically acceptable salt, isomer, or a mixture thereof, and a contai ner. In one embodi ment, the container may be avial, jar, ampoule, preloaded syringe, or an intravenous bag.

DETAILED DESCRIPTION

The foil owing description sets forth exemplary methods, parameters and the like. Such descri pti on i s not i ntended as a I i mi tati on on the scope of the present appl i cati on but is instead provided as exemplary embodiments.

As used herei n, the f ol I owi ng words, phrases and symbol s are general I y i ntended to have the meani ngs as set forth below, except to the extent that the context i n whi ch they are used i ndi cates otherwi se. A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -CONH2 is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience;

chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named.

The prefix "C u-V " indicates that the following group has from u to v carbon atoms. For example, "C1.6 alkyl" indicates that thealkyl group has from 1 to 6 carbon atoms.

Reference to " about" a val ue or parameter herei n i ncl udes (and descri bes) embodi ments that are di rected to that val ue or parameter per se. In certai n embodiments, the term "about" includes the indicated amount ± 10%. In other embodiments, the term " about" i ncl udes the i ndi cated amount ± 5%. I n certai n other embodi ments, the term "about" includes the indicated amount ± 1%. Also, to the term "about X" includes description of "X". Also, the singular forms "a" and "the" include plural references unless the context clearly dictates otherwise. Thus, e.g., reference to "the compound" i ncl udes a pi ural ity of such compounds and reference to "the assay" i ncl udes reference to one or more assays and equivalents thereof known to those ski I led in the art.

"Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., Ci-2o alkyl), 1 to 8 carbon atoms (i.e., C1-8 alkyl), 1 to 6 carbon atoms (/ ' .e., C1-6 alkyl), or 1 to 4 carbon atoms (; ' .e, C1-4 alkyl). -Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl , tert-butyl , pentyl, 2-pentyl, isopentyl, neopentyl , hexyl , 2-hexyl , 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named, al I geometric isomers havi ng that number of carbons may be encompassed; thus, for example, "butyl" includes n-butyl, sec-butyl, isobutyl and t-butyl; "propyl" includes n- propyl and isopropyl .

"Alkenyl" refers to an aliphatic group containing at least one carbon-carbon double bond and havi ng from 2 to 20 carbon atoms (i.e., C2-20 alkenyl), 2 to 8 carbon atoms (i.e., C2-8 alkenyl), 2 to 6 carbon atoms (i.e., C2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C2-4 alkenyl). .Examples of alkenyl groups includeethenyl, propenyl , butadienyl (including 1,2- butadienyl and 1,3-butadienyl).

"Alkynyl" refers to an aliphatic group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C2..20 alkynyl), 2 to 8 carbon atoms (i.e., C2-8 alkynyl), 2 to 6 carbon atoms (i.e., C2-6 alkynyl), or 2 to 4 carbon atoms (i.e., C2-4 al kynyl ) . The term "al kynyl " al so i ncl udes those groups havi ng one tri pi e bond and one double bond.

"Alkoxy" refers to the group "alkyl-O-". EExamplesof alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-di methyl butoxy.

" Acyl " refers to a group -C(=0)R, wherei n R i s hydrogen, al kyl , cycl oal kyl , heterocycloalkyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of acyl includeformyl, acetyl,

cylcohexylcarbonyl, cycl ohexyl methyl -carbony I, and benzoyl . "Amido" refers to both a "C-amido" group which refers to the group -

C(=0)NR y R z and an "N-amido" group which refers to the group -NR y C(=0)R z , wherein R y and R z are independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted. "Ami no" refers to the group -NR y R z wherei n R y and R z are i ndependently sel ected from the group consi sti ng of hydrogen , al kyl , hal oal kyl , aryl , or heteroaryl ; each of which may be optionally substituted.

"Aryl" refers to an aromatic car bocyclic group having a single ring (e.g.

monocycl i c) or mul ti pi e ri ngs (e.g. bi cycl i c or tri cycl i c) i ncl udi ng fused systems. As used herein, aryl has 6 to 20 ring carbon atoms (/.e., C6-20 aryl), 6 to 12 carbon ring atoms (i.e., C6-12 aryl), or 6 to 10 carbon ri ng atoms (i.e., C6-10 aryl). Examples of aryl groups i ncl ude phenyl , naphthyl , f I uorenyl , and anthryl . Aryl , however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused wi th a heteroaryl ri ng, the resul ti ng ri ng system i s heteroaryl .

"Cyano" or "carbonitrile" refers to the group -CN.

" Cycl oal kyl " refers to a saturated or parti al I y saturated cycl i c al kyl group havi ng a si ngl e ri ng or mul ti pi e ri ngs i ncl udi ng fused, bri dged, and spi ro ri ng systems The term "cycl oal kyl" includes cycl oal kenyl groups (i.e. the cyclic group having at least one alkenyl). As used herein, cycloalkyl hasfrom 3 to 20 ring carbon atoms (/.e., C3-20 cycloalkyl), 3 to 12 ring carbon atoms (/ ' .e., C3-12 cycl oal kyl), 3 to 10 ring carbon atoms (i.e., C3.10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C3-3 cycl oal kyl). Examples of cycloalkyl groups include cycl opropyl, cyclobutyl, cyclopentyl, and cyclohexyl. "Halogen" or "halo" includesfluoro, chloro, bromo, and iodo. "Haloalkyl" refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by usi ng a prefix correspond! ng to the number of hal ogen moi eti es attached. D i hal oal kyl and tri hal oal kyl refer to al kyl substituted with two ("di") or three ("tri") halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl includedifluoromethyl (-CHF2) and trifluoromethyl (-CF3).

" Heteroal kyl " refers to an al kyl group i n whi ch one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group. By way of example, 1 , 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, -NR-, -0-, -S-, -S(O)-, -S(O)2-, and the like, where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroar l or heterocycloalkyl, each of which may be optionally substituted. Examplesof heteroalkyl groups include -OCH 3 , - CH2OCH3, -SCH3, -CH2SCH3, -NRCH3, and -CH2NRCH3, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl , each of which may be optionally substituted. As used herein, heteroalkyl include 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.

"Heteroaryl" refers to an aromatic group having a single ring, multiple rings, or multiple fused ri ngs, with one or more ri ng heteroatoms i ndependently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl include l to 20 ring carbon atoms, 3 to 12 ring carbon atoms, or 3 to 8 carbon ring atoms; and 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Examplesof heteroaryl groups include pyri mi dinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Heteroaryl does not encompassor overlap with aryl as defined above.

"Heterocycloalkyl" refers to a saturated or unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur. The term " heterocycl oal kyl " i ncl udes heterocycl oal keny I groups (i . e. the

heterocycl oal kyl group havi ng at I east one al keny I ) . A heterocycl oal kyl may be a si ngl e ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro. As used herei n, heterocycl oal kyl has 2 to 20 ri ng carbon atoms, 2 to 12 ri ng carbon atoms, 2 to 10 ring carbon atoms, 2 to 8 ring carbon atoms, 3 to 12 ring carbon atoms, 3 to 8 ring carbon atoms, or 3 to 6 ring carbon atoms; and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur or oxygen. Examples of heterocycloalkyl groups i ncl ude pyrrol i di nyl , pi peri di nyl , pi perazi nyl , oxetanyl , di oxol anyl , azeti di nyl , and morpholinyl.

"Hydroxy" or "hydroxyl" refers to the group -OH.

"Oxo" refers to the group (=0) or (O). "Sulfonyl" refers to the group -S(O)2 , where R isalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methyl sulfonyl, ethyl sulfonyl, phenyl sulfonyl, and toluenesulfonyl.

Certain commonly used alternative chemical names may be used. For example, a divalent group such asa divalent "alkyl" group, a divalent "aryl" group, etc., may also be referred to as an "alkyl ene" group or an "alkylenyl" group, an "arylene" group or an "arylenyl" group, respectively. Also, unless indicated explicitly otherwise, where combinations of groups are referred to herein as one moiety, e.g. arylalkyl , the last menti oned group contai ns the atom by whi ch the moi ety i s attached to the rest of the molecule.

The terms "optional" or "optionally" means that the subsequently described event or ci rcumstance may or may not occur, and that the descri pti on i ncl udes i nstances where said event or circumstance occurs and instances in which it does not. Also, the term "optionally substituted" refers to any one or more hydrogen atoms on the designated atom or group may or may not be repl aced by a moi ety other than hydrogen.

The term "substituted" means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom's normal valence is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, ami do, amidino, aryl , azido, carbamoyl , carboxyl , carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocycloalkyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkyl sulfonyl, thiocyanate, thiol , thione, or

combi nations thereof . By way of example, there may be one, two, three, four, five, or six substituents. Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. Unless otherwise noted, the maximum number of serial substitutions in compounds descri bed herein isthree. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to substituted aryl

(substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include impermissibl e substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the ski I led artisan. When used to modify a chemical group, the term "substituted" may describe other chemical groups defined herein. For example, the term "substituted aryl" includes, but is not limited to,

"alkylaryl." Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.

In some embodi ments, the term "substituted alkyl" refers to an alky I group having one or more substituents including hydroxyl, halo, alkoxy, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl. In additional embodiments, "substituted cycloalkyl" refers to a cycloalkyl group having one or more substituents including alkyl, haloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, halo, hydroxyl; "substituted aryl" refers to an aryl group havi ng one or more substi tuents i ncl udi ng hal o, al kyl , hal oal kyl , heterocycloalkyl, heteroaryl, alkoxy, and cyano, and "substituted sulfonyl" refers to a group -S(O)2R, in which R is substituted with one or more substituents of alkyl, cycl oal kyl , heterocycl oal kyl , ary I or heteroaryl . I n other embodi ments, the one or more substituents may befurther substituted with halo, alkyl, haloalkyl, alkoxy, cycloalkyl, heterocycl oal kyl , aryl , or heteroaryl , each of whi ch i s substituted. I n other embodi ments, the substituents may befurther substituted with halo, alkyl, haloalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is unsubstituted. Compounds of the invention are named using Chembiodraw Ultra (version 14).

List of Abbreviations and Acronyms

Abbreviation Meaning

°C Degree Celsius

Ac Acetyl aq. Aqueous

ATP Adenosi ne tri phosphate br Broad

BSA Bovi ne serum al bumi n Cbz Carboxybenzyl

COD Cyclooctadiene

COPD Chroni c obstruct! ve pul monary di sease

d Doublet

DCE Dichloroethene

DCM Dichloromethane

dd Doubl et of doubl ets

DIEA Diisopropyl ethyl amine

DMF D i methyl formamide

DMSO Dimethylsulfoxide

dt Doublet-triplet

DTT Dithiothreitol

EC50 The hal f maxi mal eff ecti ve concentrati on

eq Equivalents

ES/M S El ectrospray mass spectrometry

Et Ethyl

FBS Fetal bovine serum

g Grams

HEPES 2-[4-(2-hydroxyethyl)piperazi n-1-yl]ethanesul fonic acid

H PL C H i gh pressure I i qui d chromatography

hr or h or hrs Hours

Hz Hertz

IBD Inflammatory bowel disease i-pr Isopropyl

J Coupl i ng constant (M Hz)

Kg/kg Kilogram

LCMS Liquid chromatography- mass spectrometry

LPS Lipopolysaccharide

M Molar

m multiplet

M+ Mass peak

M + H + M ass peak pi us hydrogen

Me Methyl

mg M illigram

MHz M egahertz

ml/mL Milliliter

mM Millimolar

mmol Millimole

M OPS 3-M orphol i nopropane-1 -sulf oni c aci d

MS M ass spectroscopy

Ms methanesulfonyl

nBu/Bu Butyl

nL Nanoliter

nm Nanometer

N M R N ucl ear magneti c resonance

NMP N-methyl pyrrol idi none NP-40 Nonyl phenoxypolyethoxylethanol

Pd-C/ Pd/C Pal ladi um on Carbon

Ph Phenyl q Quartet q.s. Quantity sufficient to achieve a stated f uncti on

RP Reverse phase rt Room temperature s Singlet sat. Saturated

T Triplet

TEA Tri ethyl amine

Tf Trifluoromethanesulfonyl

TFA Trifluoroacetic acid

THF Tetrahydrofuran

TR-FRET Ti me-resol ved f I uorescence energy transfer δ Chemical shift (ppm) μL/ μΙ Microliter μΜ Micromolar

Compounds

The present application provides compounds that function as inhibitors of PI3K isof orms. I n one aspect, provi ded are the compounds havi ng the structure of Formul a I :

Formula I

wherein n is 1 , 2, 3 or 4; s is 1 or 2; t is 1 or 2; each R 1 is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , -C(O)NR a R b , -N(R a )C(O)R b , -S(O)NR a R b , -S(O)2NR e R b , -S(O)R g - S(O) 2 R 9 -NR a R b , -OR a , -SR b C1-6 alkyl, C 2-6 al kenyl , C 2-6 al kynyl , C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S; wherei n each C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substi tuted wi th one to four R 100 ;

R 2 isselected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , -

C(O)NR a R b , -N(R a )C(O)R 15 , -S(O)NR a R b , -S(O) 2 NR a R b , -S(O)R 9 -S(O)2R 9 - N R a R b , -OR a , -SR b C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , cycl oal kyl , C6-10 aryl , 5-10 membered heteroaryl contai ning 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to

4 heteroatoms sel ected from the group consisti ng of N , O, and S; wherei n each C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , C3- 8 cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R 101 ;

R 3 isselected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , - C(O)NR a R b , -NKR a )C(O)R 15 , -NiR a )C(O)NR a R b , -OC(O)NR a R b , -

NR a S(O)2NR a R b , - NR a S(O) 2 R a , -S(O)NR a R b , -S(O) 2 NR a R b , -S(O)R 9 , -S(O) 2 R 9 , - N R a R b , -OR a , -SR b C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , C3- 8 cycl oal kyl , C6-10 aryl , 5-10 membered heteroaryl contai ning 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms sel ected from the group consi sti ng of N , O, and S;

wherei n each wherei n each C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , cycl oal kyl , C6-10 aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R 102 ;

R 4 is a 5-10 membered heteroaryl ; wherein said 5-10 membered heteroaryl isoptionally substituted with one to four R 103 ;

each R 5 is i ndependently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , -C(O)NR a R b , -N(R a )C(O)R b , -ΝR a ) C(Ο)ΝΡ e R ό , -OC(O)NR e R b , - NR a S(O) 2 NR a R b , - NR a S(O) 2 R a -S(O)NR a R b , -S(O)2NR e R b , -S(O)R g , -S(O) 2 R a , - N R a R b , -OR a , -SR b C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , C3-8 cycl oal kyl , C6-10 aryl , 5-10 membered heteroaryl contai ning 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms sel ected from the group consi sti ng of N , O, and S; wherei n each C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , C3- 8 cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4- 10 membered heterocycl yl i s opti onal I y substituted with one to four R 104 ; each R 6 is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , -C(O)NR a R b , -N(R a )C(O)R b , -S(O)NR a R b , -S(O) 2 NR a R b , -S(O)R 9 - S(O) 2 R g -NR e R b , -OR a , -SR b C1- 6 alkyl , C 2-6 alkenyl or C 2-6 alkynyl ; each R a and R b is i ndependentl y sel ected from hydrogen, C1-6 al kyl , C 2-6 al kenyl and C 2- 6 alkynyl; wherei n each C1-6 al kyl , C 2-6 al kenyl , C 2-6 al kynyl , i s opti onal ly substituted with one to four R 200 ; each R , R , R , R and R 1W is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, -C(O)R c , -C(O)OR°, -C(O)NR c R d , - N(R c )C(O)R d , -N(R a )C(O)NR a R b , -OC(O)NR a R b , -NR a S(O)2NR a R b , - NR a S(O)2R a , -S(O)NR c R d , -S(O) 2 NR c R d , -S(O)R c -S(O) 2 R c , -NR°R d -OR 0 , -SR d , C1-6 alky!, C2-6 alkenyl, C 2-6 alkynyl , C3-8 cycloalkyl, C6-10 aryl , 5-10 membered heteroaryl and 4-10 membered heterocyclyl ; wherei n each C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , C3- 8 cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R 201 ; each R c and R d is independently selected from hydrogen, C6-10 aryl, C1-6 alkyl, C2- 6 al kenyl and C2-6 al kynyl ; each R and R is i ndependently selected from hydrogen, halo, cyano, hydroxy,

amino, oxo, thioxo, vinyl , -C(O)R e , -C(O)OR e , -C(O)NR e R f , -NiR a )CiO)R f , - S(O)NR e R f , -S(O) 2 NR e R f , -S(O)R e -S(O) 2 R e -NR e R f , -OR e , -SR e C3- 8alkyl, C 2-6 al kenyl and C 2-6 al kynyl ; each R e and R f is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl and C2-6 al kynyl; each R g is independently selected from C1-6 alky!, C2-6 al kenyl, C2-6 al kynyl, C3-8

cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S; wherei n each C1-6 al kyl , C 2 _6 al kenyl , C 2 _6 al kynyl , C3- 8 cycl oal kyl , C6-10 aryl , 5- 10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R 200 ; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

I n another aspect, provided are compounds of Formula I A:

Formula I A:

wherein n, s, t, R 1 , R 2 , R 4 , R 5 and R 6 are as defined above;

X 1 is N or C; each X 2 , X 3 , X 4 and X 5 is independently selected from S, O, CR 10 and NR 11 ;

10

wherein each R is independently selected from hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , -C(O)NR a R b , -N(R a ) C(O)R b , -S(O)NR a R b , - S(O) 2 N R e R b , -S(O)R 9 -S(O) 2 R 9 , -N R e R b , -OR a , -SR b , C1-6 al kyl , C 2-6 al kenyl , C 2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl contai ni ng 1 to 4 heteroatoms sel ected from the group consisting of N, O, and S; wherei n each C1-6 al kyl , C 2- e al kenyl , C 2- e al kynyl , C3-8 cycl oal kyl , C6-10 aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R 104 ; wherein each R 11 is independently selected from absent, hydrogen, halo, cyano, hydroxy, amino, -C(O)R a , -C(O)OR b , -C(O)NR a R b , -N(R a ) C(O)R b , - S(O)NR e R b , -S(O) 2 NR e R b I -S(O)R g -S(O) 2 R 9 , -NR a R b , -OR a , -SR b C M al kyl , C2-6 al kenyl , C2-6 al kynyl , C3-8 cycl oal kyl , C6-10 aryl , 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

10 11

al ternati vel y , one R and one R group, together wi th the atoms to whi ch they are attached form a five, six or seven membered fused, or bridged ring;; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

I n another aspect, provi ded are compounds of Formul a I B :

Formula IB

wherei n n, s, t, R 1 , R 2 , R 4 and R 5 are as defi ned above; each R is independently selected from hydrogen, halo, cyano, hydroxy, amino, -

C(O)R a , -C(O)OR b , -C{0)NR a R b , -N(R a )C(O)R b , -S(O)NR e R B , -S(O) 2 NR a R b , - S(O)R g , -S(O) 2 R 9 , -N R a R b , -OR a , -SR b C1-6 al kyl , C 2-6 al kenyl , C2-6 al kynyl , C3-8 cycl oal kyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S; each R a and R b is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; wherei n each C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , i s opti onal ly substituted with one to four R 200 ; each R 200 is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, -C(O)R e , -C(O)OR e , -C(O)NR e R f , -N(R e ) C(O)R f , -S(O)NR e R f , - S(O) 2 NR e R f , -S(O)R e -S(O)2R e -NR e R f , -OR e , -SR e d-s alkyl, C 2-6 alkenyl and C2-6 alkynyl ; each R e and R f is independently selected from hydrogen, C1-6 alkyl, C2.6 alkenyl and C2-6 alkynyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

I n another aspect, provided are compounds of Formula IC:

Formula I C

wherein n, s, R 1 , R 2 , R 4 , R 5 , and R 13 are as defined above; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

I n another aspect, provi ded are compounds of Formul a I D :

Formula ID

wherein n, s, R 1 , R 2 , R 4 , R 5 , X 1 , X 2 , X 3 , X 4 and X 5 are as defined above; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

I n another aspect, provi ded are compounds of Formul a I E:

Formula IE

wherein n, s, t, R 1 , R 2 , R 4 , R 5 , and R 13 are as def i ned above; or a pharmaceutically acceptable salt, isomer, or a mixture thereof. I n another aspect, provi ded are compounds of Formul a I F:

or a pharmaceutically acceptable salt, isomer, or a mixture thereof. I n another aspect, provided are compounds of Formula IG:

Formula IG

wherein n, s, R 1 , R 2 , R 4 , R 5 , X 1 , X 2 , X 3 , X 4 and X 5 are as defined above; or a pharmaceutically acceptable salt, isomer, or a mixture thereof. I n another aspect, provi ded are compounds of Formul a I H :

Formula I H

wherein n, s, t, R 1 , R 2 , R 4 , R 5 , and R 13 are as def i ned above; or a pharmaceutically acceptable salt, isomer, or a mixture thereof. I n another aspect, provided are compounds of Formula IJ:

Formula I J wherein n, s, R 1 , R 2 , R 4 , R 5 , and R 13 are as defined above; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

I n another aspect, provided are compounds of Formula (IK):

Formula 1K

wherein n, s, R 1 , R 2 , R 5 , and R 13 are as defined above; m is 1, 2 or 3;

each R 14 is independently selected from hydrogen, halo, cyano, hydroxy, amino, -

C(O)R a , -C(O)OR b , -C(O)NR e R b , -N(R a )C(O)R b , -S(O)NR e R b , -S(O) 2 NR a R b , - S(O)R g -S(O) 2 R 9 , -NR a R b , -OR a , -SR b C1-6 al kyl , C 2 . 6 alkenyl, C 2-6 alkynyl and C3- 8 cycloalkyl ;

each R a and R b is independently selected from hydrogen, C1-6 alkyl, C 2-6 alkenyl and C 2- 6 alkynyl; wherei n each C1-6 al kyl , C2-6 al kenyl , C2-6 al kynyl , i s opti onal ly substituted with one to four R 200 ; each R 200 is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, -C(O)R e , -C(O)OR e , -0(O)Ν(O) 2 , -N(R e )C(O)R f , -S(O)NR e R f , - S(O) 2 NR e R f , -S(O)R 9 -S(O) 2 R 9 -NR e R f , -OR e , -SR e C 1-6 alkyl, C 2-6 alkenyl and C 2-6 alkynyl ; each R e and R f is independently selected from hydrogen, C1-6 alkyl , C 2-6 alkenyl and C 2 _6 alkynyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

I n another aspect, provi ded are compounds of Formul a I L :

Formula I L

wherein n, m, s, R 1 , R 2 , R 4 , R 5 , R 13 and R 14 are as defined above;

or a pharmaceutically acceptable salt thereof.

I n certain embodiments, provided is a compound of Formula I , wherein R is

wherein t is 1 or 2;

each R 13 is independently selected from hydrogen, halo, cyano, hydroxy, amino, -

C(O)R a , -C(O)OR b , -C(O)NR a R b , -Ν(Ra)C(O)R b , -S(O)NR a R b , -S(O) 2 NR a R b , - S(O)R 9 , -S(O)2R 9 , -NR a R b , -OR a , -SR b C 1-6 al kyl , C 2-6 alkenyl, C 2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

I n certain embodiments, provided is a compound of Formula I D or IG, or a

pharmaceutically acceptable salt, isomer, or a mixture thereof; wherein the

substituent is selected from:

In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ or IK, wherein R 4 isselected from:

In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK or IL, wherein R 1 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, butyl, f I uoromethyl , difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl andtrifluoroethyl; or a pharmaceutically acceptable salt, isomer, ora mixture thereof. In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, I H , I J, IK or I L , wherein R 1 isfluoro or chloro; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, I H , I J, IK or IL, wherein R 1 isfluoro and n is2.

In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, I H , I J, IK or I L , wherei n R 2 i s C a1-6l kyl , C3- 8cycl oal kyl , 5-6 membered heteroaryl containing 1 to 3 heteroatoms selected from the group consisting of N, O, and S, and 4-6 membered heterocycl yl contai ni ng 1 to 4 heteroatoms sel ected from the group consi sti ng of N, O, and S; wherein each C1-6 alkyl , C3-8 cycl oal kyl , 5-6 membered heteroaryl and 4- 6 membered heterocyclyl isoptionally substituted with one to four R 101 ; or a

pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, I H , I J, I K or I L , wherei n R 2 i s C1-5 al kyl , C3-8 cycl oal kyl , or 4-6 membered heterocycl yl contai ni ng 1 heteroatom sel ected from the group consi sti ng of N , O, and S; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, I J, IK or IL, wherein R 2 is sel ected from hydrogen, amino, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, furanyl, tetrahydrofuranyl, oxetanyl, and cyclopropyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, I J, IK or IL, wherein R 5 is sel ected from hydrogen, methyl, ethyl, trifluoromethyl, carboxamide, cyano, piperazinyl, cyclopropyl, phenyl and triazolyl; or a

pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK or IL, wherein R 5 is selected from hydrogen or methyl. In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, I H , I J, IK or I L , wherein R 1 is selected from hydrogen, CI, F and methyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, or I L, wherein R 2 is selected from hydrogen or a substituent selected from the table below:

or a pharmaceutically acceptable salt thereof.

In certain embodiments, provided isacompound of Formula I, wherein R 3 is

from hydrogen or a substituent selected from -C(O)OH, -C(O)NH2,

and or a pharmaceuti cal I y acceptabl e sal t thereof .

In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, I H or IJ, wherei n R 4 i s a 5- 10 membered heteroaryl havi ng one or two ni trogens, optional ly substituted with one to four R .

In certain embodiments, R 103 is selected from cyano, amino, halo, and C1-6 alkyl. In certain embodiments, provided isacompound of Formula I, IA, IB, IC, ID, IE, IF, IG, I H or I J, wherein R 4 is selected from hydrogen or a substituent selected from the table below:

I n certain embodiments, provided is a compound selected from Table 1 , or a pharmaceutically acceptable salt, isomer, or a mixture thereof:

Table 1

The present application provides pharmaceutically acceptable salts, hydrates, solvates, isomers, tautomers, stereoisomers, enantiomers, racemates, atropisomers, polymorphs, prodrugs, or a mixture thereof, of the compounds described herein. The tarns "a compound of the present application," "a compound described herein," "a compound of any of the formulae described herein," or variant thereof refer to a compound having the structure of any of theformulae, I, IA, IB, IC, ID, IE, IF, IG, I H, IJ, I K or IL. In some embodi ments, compounds of the present appl i cati on are

Com pounds 1 - 114 as descri bed herei n . " Pharmaceuti cal I y acceptabl e" or " physi ol ogi cal I y acceptabl e" ref a to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitablefor veterinary or human pharmaceutical use. "Pharmaceutically acceptable salts" or "physiologically acceptable salts" refer to salts of pharmaceutical compounds that retain the biological effectiveness and properties of the underlying compound, and which are not biologically or otherwise undesi rabl e. There are aci d addi ti on sal ts and ba9e addi ti on sal ts. Pharmaceuti cal I y acceptabl e aci d addi ti on sal ts may be prepared from i norgani c and organi c aci ds. A ci ds and bases useful for reaction with an underlying compound to form pharmaceutically acceptable salts (acid addition or base addition salts respectively) are known to one of skill in theart. Similarly, methodsof preparing pharmaceutically acceptable salts from an underlying compound (upon disclosure) are known to one of skill in the art and are disclosed in for example, Berge, at al. Journal of Pharmaceutical Science, Jan. 1977 vol. 66, No.1 , and other sources. I f the compounds descri bed herei n are obtai ned as an aci d addition salt, the free base can be obtai ned by basifying a solution of the acid salt.

Conversely, if the product is afree base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Salts derived from organic acids include acetic acid, propionic acid, glycol ic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleicacid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonicacid, salicylic acid, and the like. Salts derived from mineral acids include, hydrochloride, hydrobromide, hydroiodide, nitrate, phosphate, and sulfate. L i kewi se, pharmaceuti cal I y acceptabl e base addi ti on sal ts can be prepared from i norgani c and organi c bases. Sal ts deri ved from i norgani c bases i ncl ude, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines (i .e., NH2(alkyl)), dialkyl amines (i.e., HN(alkyl)2), trial kyl amines (i.e., N(alkyl)3), substituted alkyl amines (i.e., NH2(substituted alkyl)), di (substituted alkyl) amines (i.e., HN (substituted alkyl )2), tri (substituted alkyl) amines (i .e., N(substituted alkyl )3), alkenyl amines (i .e.,

NH2(alkenyl)), dialkenyl amines (i.e., HN(alkenyl)2), trial kenyl amines (i.e.,

N(alkenyl)3), substituted alkenyl amines (i.e., NH2( substituted alkenyl)), di (substituted alkenyl) amines (i.e., HN (substituted alkenyl )2), tri (substituted alkenyl) amines(i.e., N(substituted alkenyl)3, mono-, di- or tri- cycloalkyl amines (i.e., NH2(cycloalkyl), HN(cycloalkyl)2, N(cycloalkyl)3), mono-, di- or tri- arylamines (i.e., NH2(aryl),

HN(aryl) 2 , N(aryl)3), or mixed amines, etc. Specific examples of suitable amines include, by way of example only, isopropyl amine, tri methyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanol amine, 2-di methyl ami noethanol, pi perazi ne, pi peri di ne, morphol i ne, N-ethyl pi peri di ne, and the I i ke.

"Isomers" refers to compounds that have the same molecular formula As used herein, the term isomers include double bond i somas, racemates, stereoisomers, enanti omers, di astereomers, and atropi somers. 3 ngl e i somers, such as enanti omers or diastereomers, can be obtained by asymmetric synthesis or by resol ution of a mixture of isomers. Resolution of a mixtureof isomers (e.g. racemates) maybe accomplished, for exampl e, by conventi onal methods such as crystal lization in the presence of a resol vi ng agent, or chromatography, using, for example a chiral high pressure liquid

chromatography (HPLC) column. "Double bond isomers" refer to Z- and E- forms (or cis- and trans- forms) of the compounds with carbon-carbon double bonds.

"Atropi somers" refers to conformational stereoisomers which occur when rotation about a single bond in the molecule is prevented, or greatly hindered, as a result of steri c i nteracti ons wi th other parts of the mol ecul e and the substi tuents at both ends of the single bond are asymmetrical, i.e., they do not require a stereocenter. Wherethe rotational barrier about the single bond is high enough, and interconversion between conformations is slow enough, separation and isolation of the isomeric species may be permitted. Atropisomers may be separated by the methods well known in the art. Unless otherwise indicated, the description is intended to include individual atropisomers as well as mixtures. Also, as understood by those ski I led in the art, the atropisomers may be represented by the same chemical name with different atropi somer designations. By way of example, the below structures are atropi somers of compound 48.

Compound- 103 Com pound- 104 " Racemates" refers to a mixture of enanti omers. "Stereoisomers" or "stereoisomeric forms" refer to compounds that differ in the chi ral i ty of one or more stereocenters. Stereoi somers i ncl ude enanti omers and diastereomers. The compounds may exist i n stereoisomeric form if they possess one or more asymmetric centers or a double bond with asymmetric substitution and, therefore, can be produced as individual stereoisomers or as mixtures. Unless otherwise i ndicated, the description is intended to include individual stereoi somers as well as mixtures. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see, e.g., Chapter 4 of Advanced Organic Chemistry, 4th ed., J. March, John Wiley and Sons, New York, 1992). "Tautomers" or "tautomeri c forms" refer to alternate forms of a compound that differ i n the posi ti on of a proton, such as enol -keto and i mi ne-enami ne tautomers, or heteroaryls such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.

A "solvate" isformed by the interaction of asolvent and a compound. Solvates of salts of the compounds of any of the formulae descri bed herei n are also provided. Hydratesof the compounds of any of the formulae are also provided.

A "prodrug" is defined in the pharmaceutical field as a biologically inactive derivative of a drug that upon admi nistration to the human body is converted to the biological ly active parent drug according to some chemical or enzymatic pathway. A prodrug i s thus a coval entl y modi f i ed anal og or I atent form of a therapeuti cal I y acti ve compound. Non-limiting examples of prodrugs include ester moieties, quaternary ammonium moieties, glycol moieties, and the like.

The application also provides a composition containing a mixture of enantiomers of the compound or a pharmaceuti cal ly acceptable salt thereof. I n one embodi ment, the mixture is a racemic mixture. I n other embodiments, the composition comprises the (S)- enanti omer of a compound i n excess of the correspond! ng (R)-enanti omer of the compound. In some embodiments, the composition contains the (S)-enantiomer of the compound and is substantially free of its corresponding (R)-enantiomer. In certain embodi ments, a composi ti on substanti al I y free of the (R)-enantiomer has less than or about 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1 %, 0.05%, or 0.01% of the (R)- enanti omer. In other embodiments, the composition containing the (S)-enantiomer of a compound or a pharmaceutically acceptable salt thereof, predominates over its corresponding (R)-enantiomer by a molar ratio of at least or about 9:1, at least or about 19:1 , at least or about 40:1 , at least or about 80:1 , at least or about 160: 1 , or at least or about 320:1.

The composition containing a compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof, may also contain the compound in enantiomeric excess (e.e.). By way of example, a compound with 95% isomer and 5% (R) -isomer will have an e.e. of 90%. In some embodiments, the compound has an e.e. of at least or about 60%, 75%, 80%, 85%, 90%, 95%, 98% or 99%. In any one of the f oregoi ng embodi ments, the compound or a pharmaceutical I y acceptable salt thereof, isan atropisomer. Another embodiment provides the composition containing a mixture of atropisomersof the compound or a

pharmaceutically acceptable salt thereof. By way of example, a compound with 95% of one atropi somer and 5% of the other atropi somers. I n some embodi ments, a compound wi th about 90, 80, 70, 60, 50, 40, 30, 20, or 10% of one atropi somer and 10, 20, 30, 40, 50, 60, 70, 80, or 90%, respectivel , of the other atropi somers.

The appl i cati on al so provi des the free base forms of the compounds descri bed herei n. I n certai n embodi ments, provi ded herei n are the enantiomers, (R) or ($$, of the compounds of the formulae descri bed herei n. I n other embodi ments, provided herei n are the atropisomers of the compounds of the formulae descri bed herein.

The application further provides compositions comprisi ng the compounds described herein or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof. The composition may include racemic mixtures, mixtures containing an enantiomeric excess of one enantiomer or single diastereomers or diastereomeric mixtures. All such isomeric forms of these compounds are expressly included herein, the same as if each and every isomeric form were specifically and individually listed.

In certain embodiments, provided herein are also polymorphs, such as crystal line and amorphous forms, of the compounds descri bed herei n. I n some embodi ments, provided are also chelates, non-covalent complexes, and mixtures thereof , of the compounds of the formula descri bed herei n or pharmaceuti cal ly acceptabl e salts, prodrugs, or solvates thereof. A "chelate" isformed by the coordination of acompound to a metal ion at two (or more) points. A "non-covalent complex" is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through van der Waal s interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).

In certain embodiments, provided are also chelates, non-covalent complexes, and mixtures thereof, of the compounds descri bed herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof. A "chelate" isformed by the coordination of a compound to a metal ion at two (or more) points. A "non-covalent complex" isformed by the interaction of a compound and another molecule wherei n a covalent bond is not formed between the compound and the mol ecul e. For exampl e, compl exati on can occur through van der Waal s i nteracti ons, hydrogen bonding, and electrostatic interactions (also called ionic bonding).

Some of the compounds exi st as tautomers. Tautomers are i n equi I i bri urn wi th one another. For example, amide containing compounds may exist in equilibrium with i mi die acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equi I i bri urn among tautomers, the compounds are understood by one of ordi nary ski 11 i n the art to compri se both ami de and i mi di c aci d tautomers. Thus, the ami de contai ni ng compounds are understood to i ncl ude thei r i mi di c aci d tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.

Any formula or structure given herein, is also intended to represent unlabeled formsaswell as isotopically labeled forms of the compounds. I sotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are repl aced by an atom havi ng a sel ected atomi c mass or mass

number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to 2 H (deuterium, D), 3 H (tritium), 11 C, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 35 S 36 CI and 125 l. Various i sotopically labeled compoundsof the present disci osure, for exampl e those i nto whi ch radi oacti ve i sotopes such as 3 H , 13 C and 14 C are incorporated. Such i sotopically labeled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.

The disclosure also includes"deuterated analogs" of compounds of Formula I in which from 1 to n hydrogens attached to a carbon atom isare replaced by deuterium, in which n is the number of hydrogens in the molecule. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound of Formula I when administered to a mammal , particularly a human. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol . Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for exampl e by empl oyi ng starti ng materi al s i n whi ch one or more hydrogens have been replaced by deuterium.

Deuterium labeled or substituted therapeutic compounds of the disclosure may have i mproved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism and excretion (ADM E). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index. An 18 F labeled compound may be useful for PET or SPECT studi es. I sotopi cal I y I abel ed compounds of this disci osure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the exampl es and preparati ons descri bed bel ow by substi tuti ng a readi I y avai I abl e isotopically labeled reagent for a non-i sotopi cal I y labeled reagent. It is understood that deuteri urn i n thi s context i s regarded as a substi tuent i n the compound of Formul a I .

The concentration of such a heavier isotope, specifically deuterium, may be defi ned by an i sotopi c enri chment factor. I n the compounds of thi s di sd osure any atom not sped f i cal I y desi gnated as a parti cul ar i sotope i s meant to represent any stabl e i sotope of that atom. Unless otherwise stated, when a position is designated specifically as " H" or "hydrogen", the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuteri urn (D) is meant to represent deuterium. Therapeutic Uses of the Compounds The compounds of the f ormul ae descri bed herei n or a pharmaceuti cal I y acceptable salt, isomer, prodrug, or solvate thereof may be used for the treatment of diseases and/or conditions mediated by PI3K isoforms. In addition, the application provides the compounds for use in therapy. Also, provided herein are methods for inhibiting one or more PI 3K isoforms. I n one embodiment, provided are methods for inhibiting ΡΙ3Κβ activity using the compound described herein or a pharmaceutically acceptable salt, isomer, prodrug, or sol ate thereof. I n other embodi ment, provided are methods for inhibiting ΡΙ3Κβ activities using the compound or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof. The application further provides methods for use i n such methods. The PI3K isoforms may be selectively or specifically inhibited. Additionally, the compounds may be used to inhibit PI3K activity

therapeutically or prophylactically, such as ΡΙ3Κβ.

The compounds accordi ng to the present application may be used in combination with one or more additional therapeutic agents. The therapeutic agents may be in the forms of compounds, anti bodi es, pol y pepti des, or pol ynucl eoti des. The therapeuti c agent includes, but is not limited to, a chemotherapeutic agent, an immune-therapeutic agent, a radiotherapeutic agent, an anti -neoplastic agent, an anti -cancer agent, an anti- proliferation agent, an anti-fibrotic agent, an anti -angiogenic agent, a therapeutic antibody, or any combination thereof. In one embodi ment, the application providesa product compri si ng a compound descri bed herei n and an addi ti onal therapeuti c agent as a combined preparation for simultaneous, separate or sequential use i n therapy, e.g. a method of treating a disease, disorder, or condition that is mediated by PI3K isoforms. The compounds of the invention can be used in combination with compounds that inhibit or modulate the activities of poly(ADP-ribose) polymerases (PARP), such as PARP-1, PARP-2, PARP-3 and Vault-PARP; Tankyrases (TANKs), such as, TANK-1, TANK-2 and TANK-3; matrix metal I oproteinases such as M MP-2 and MM P-9; and androgen receptor.

Therapeuti c agents that can be used i n combi nati on wi th compounds of the invention include enzalutamide, abiraterone, abi raterone acetate, apalutamide, gal eterone, ol apari b, ni rapari b, vel i pari b, rucapari b, f I utami de, ni I utami de, bi cal utami de, ketonazole, orteronel, finasteride, dutasteride, bexlosteride, izonsteride, turosteride, episteride, dexamethasone, prednisone, leuprolide, goserelin, triptorelin, histrelin, estrogen, cyproterone acetate, spironolactone, flutamide, hydroxyflutamide, docetaxel, cabazitaxel, sipuleucel-T, ODM-201 , VT-464, EPI-506, and combinations thereof.

Also, the therapeutic agents may be those that inhibit or modulate the activities of Bruton's tyrosine kinase, spleen tyrosine kinase, apoptosis signal -regulating kinase, Janus ki nase, I ysyl oxi dase, I ysy I oxi dase-l i ke protei ns, matri x metal I opepti dase, bromodomain-containing protein, adenosine A2B receptor, isocitrate dehydrogenase, serine/threonine kinaseTPL2, discoi din domain receptor, serine/threonine-protein kinases, IKK, MEK, EGFR, histonedeacetylase, protein kinaseC, or any combination thereof. I n certai n embodi ments, the therapeuti c agent may be sel ected from a PI 3K (including PI3Kq PI3KD, PI3KD, PI3KD, and/or pan-PI3K) inhibitor, a JAK (Janus kinase, including JAK 1, JAK2, and/or JAK 3) inhibitor, aSYK (spleen tyrosine kinase) inhibitor, a BTK (Bruton's tyrosine kinase) inhibitor, an A2B (adenosine A2B receptor) inhibitor, an ACK (activated CDC kinase, including ACK1) inhibitor, an ASK (apoptosis signal -regulating kinase, including ASK 1) inhibitor, Aurora kinase, a BRD

(bromodomain-containing protein, including BRD4) inhibitor, a Bel (B-cell

CLL/lymphoma, including Bcl-1 and or Bcl-2) inhibitor, a CAK ( CD K -activating kinase) inhibitor, a CaMK (calmodul in-dependent protein kinases) inhibitor, a CDK (cycl in-dependent kinases, including CDK1, 2, 3, 4, and/or 6) inhibitor, a CK (casein kinase, including CK1 and/or CK2) inhibitor, a DDR (discoi din domain receptor, including DDR1 and/or DDR2) inhibitor, a EGFR inhibitor, a FX R (farnesoid x receptor) inhibitor, a FAK (focal adhesion kinase) inhibitor, a GSK (glycogen synthase kinase) inhibitor, a HDAC (histone deacetylase) inhibitor, an IDO (indoleamine 2,3- dioxygenase) inhibitor, an I DH (isocitrate dehydrogenase, including IDH1) inhibitor, an I KK (l-Kappa-B kinase) inhibitor, a KDM5 (lysine demethylase) inhibitor, a LCK (lymphocyte-specific protei n tyrosi ne kinase) inhibitor, a LOX (lysyl oxidase) inhibitor, a LOXL (lysyl oxidase like protein, including LOXL1, LOXL2, LOXL3, LOXL4, and/or LOXL5) inhibitor, a MTH (mut T homolog) inhibitor, a MEK (mitogen-activated protein kinase kinase) inhibitor, a matrix metalloprotease (MMP, including M M P2 and/or M MP9) inhibitor, a mitogen-activated protein kinases (MAPK) inhibitor, a PD-1 (programmed eel I death protei n 1 ) i nhi bitor, a PD-L 1 (programmed death-l igand 1 ) inhibitor, a PDGF (platelet-derived growth factor) inhibitor, a phosphorylase kinase (PK) inhibitor, a PL K (polo-like kinase, including PLK1 , 2, 3) inhibitor, a protein kinase (PK, including protein kinase A, B, C) inhibitor, aSTK (serinethreonine kinase) inhibitor, a STAT (signal transduction and transcription) inhibitor, aserine/threonine-protein kinase inhibitor, a TBK (tank-binding kinase) inhibitor, aTLR (toll-l ike receptor modulators, including TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR- 10, TLR-11 , TLR-12, and/or TLR-13) inhibitor, aTK (tyrosine kinase) inhibitor, a TPL2 (serine/threonine kinase) inhibitor, a NEK9 inhibitor, an Abl inhibitor, a p38 kinase inhibitor, a PYK inhibitor, a PYK inhibitor, a c-K it inhibitor, a NPM -A LK inhibitor, a Flt-3 inhibitor, a c-Met inhibitor, a KDR inhibitor, a TI E-2 inhibitor, aVEGFR inhibitor, a SRC inhibitor, a HCK inhibitor, a LYN inhibitor, a FY N inhibitor, a YES inhibitor, a chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, an anti- neoplastic agent, an anti-cancer agent, an anti -proliferation agent, an anti-fibrotic agent, an anti-angiogenic agent, a therapeutic antibody, or any combination thereof. I n some embodiments, the JAK inhibitor is N-(cyanomethyl)-4-[2-(4- morpholinoanilino)pyrimidin-4-yl]benzamide as named by ChemDraw (may also be referred to as CYT0387 or momel oti ni b) and may be synthesized by the methods described in U.S. F¾tent No. 8,486,941. In certain embodiment, the SyK inhibitor is6- ( 1 H-i ndazol-6-yl )-N-(4-morphol i nophenyl )i mi dazo[ 1 ,2-a] pyrazi n-8-ami ne as named by ChemDraw (may also be referred to as 6-(1 H-indazol-6-yl)-N-[4-(morpholin-4- yl)phenyl]imidazo[1,2-a] pyrazi n-8-amine) and may be synthesized by the methods described in U.S. F¾tent No. 8,450,321. I n other embodi ments, the BTK inhibitor is (S)- 6-ami no-9-( 1 -(but-2-ynoyl )py rrol i di n-3-yl )-7-(4-phenoxyphenyl )-7H-puri n-8(9H )-one as named by ChemDraw (may also be 6-ami no-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7- (4-phenoxyphenyl )-7,9-di hydro-8H -purin-8-one) and may be synthesized by the methods in U.S. Pat. No. 8,557,803.

Chemotherapeutic agents may be categorized by their mechanism of action into, for example, the following groups: anti -metabolites/anti -cancer agents, such as pyri mi dine anal ogs (floxuri dine, capecitabine, and cytarabine); purine analogs, folate antagonists and related inhibitors, anti proliferative/antimitotic agents including natural products such as vinca alkaloid (vinblastine, vincristine) and microtubule such astaxane (paclitaxel, docetaxel), vinblastin, nocodazole, epothilonesand navelbine,

epi di podophyl I otoxi ns (etoposi de, teni posi de) ; DNA damagi ng agents (acti nomyci n, amsacrine, busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide, Cytoxan, dacti nomyci n, daunorubicin, doxorubicin, epirubicin, iphosphamide, melphalan, merchlorehtarnine, mitomycin, mitoxantrone, nitrosourea, procarbazine, taxol , taxotere, teniposide, etoposide, triethylenethiophosphoramide); antibiotics such asdactinomycin (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; enzymes (L- asparagi nase whi ch systemi cal I y metabol i zes L -asparagi ne and depri ves eel I s whi ch do not have the capaci ty to sy nthesi ze thei r own asparagi ne) ; antiplatelet agents;

antiproliferative/ antimitotic alkylating agents such as nitrogen mustards

cyclophosphamide and analogs, melphalan, chlorambucil), and (hexamethylmel amine and thiotepa), alkyl nitrosoureas (BCNU) and analogs, streptozocin), trazenes- dacarbazi ni ne ( DTI C) ; anti prol i f erati ve/anti mi toti c anti metabol i tes such as f ol i c aci d analogs (methotrexate); platinum coordination complexes (cisplatin, oxiloplatinim, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel ; anti migratory agents; antisecretory agents (breveldin); immunosuppressives (tacrolimus, sirolimusazathioprine, mycophenolate); phytoestrogens (daidzein, glycitein, genisteinand growth factor inhibitors (vascular endothelial growth factor inhibitors, fibroblast growth factor inhibitors); angiotensin receptor blocker, nitric oxide donors; anti -sense ol i gonucl eoti des; anti bodi es (trastuzumab, rituxi mab); eel I cycl e i nhi bi tors and differentiation inducers (tretinoin); inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin), daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin, irinotecan and mitoxantrone, topotecan, irinotecan, camptothesin), corticosteroids (cortisone, dexamethasone, hydrocortisone, methyl prednisolone, prednisone, and prednisolone); growth factor signal transduction kinase inhibitors; dysfunction inducers, toxins such as Choi era toxin, ricin, Pseudomonas exotoxin, Bordetel I a pertussis adenylate cycl ase toxi n, or di phtheria toxi n, and caspase activators; and chromati n.

As used herein the term "chemotherapeutic agent" or "chemotherapeutic" (or "chemotherapy," in the case of treatment with a chemotherapeutic agent) is meant to encompass any non-proteinaceous (i.e., non-peptidic) chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN); alkyl sulfonates such as busulfan, improsulfan and piposulfan; azi ri dines such as benzodopa, carboquone, meturedopa, and uredopa; emyleruminesand memylamel amines including alfretamine, triemylenemel amine, tri ethyl enephosphoramide, tri ethyl enethiophosphoramide and trimemylolomel amine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including synthetic analogue topotecan); bryostatin; callystatin; CC-1065 ( i ncl udi ng i ts adozel esi n , carzel esi n and bi zel esi n sy ntheti c anal ogues) ; cry ptophyci ns (articularly cryptophycin 1 and cryptophyci n 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CBI-TM I); eleutherobin; pancrati statin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosf amide, mechlorethamine, mechlorethamine oxide hydrochl ori de, mel phal an, novembi chi n, phenesteri ne, predni musti ne, trof osf ami de, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, foremustine, lomustine, nimustine, ranimustine; antibiotics such as the enediyneantibiotics (e.g., calicheamicin, especially calicheamicin gammall and calicheamicin phi 11 , see, e.g., Agnew, Chem. Intl . Ed. Engl, 33:183-186 (1994); dynemicin, including dynemicin A; bisphosphonates, such asclodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cacti nomycin, carabicin, carrninomycin, carzinophilin, chromomycins, dacti nomycin, daunorubicin, detorubicin, 6-diazo-5-oxo- L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino- doxorubi ci n, 2-pyrrol i no-doxorubi ci n and deoxydoxorubi ci n), epi rubi ci n, esorubi ci n, idarubicin, marcel I omycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti- metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as demopterin, methotrexate, pteropterin, trimetrexate; purine analogssuch asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyri mi dine anal ogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifl uridine, enocitabine, floxuridine; androgens such ascalusterone, dromostanol one propionate, epitiostanol , mepitiostane, testolactone; anti -adrenals such as ami noglutethi mi de, mi totane, tri I ostane; f ol i c aci d repl i ni sher such as f rol i ni c aci d; acegl atone;

aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; hestrabucil; bisantrene; edatraxate; def of amine; demecolcine; diaziquone; elformthine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; leucovorin; lonidamine; maytansinoids such as maytansi ne and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; losoxantrone; fluoropyrimidine; folinic acid; podophyllinic acid; 2-ethylhydrazide; procarbazine;

PSK®; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone;

2,2',2"-tricUorotriemylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol;

mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiopeta; taxoids, e.g., paclitaxel (TAXOL® and docetaxel (TAXOTERE®); chlorambucil;

gemcitabine (Gemzar®); 6-thioguanine; mercaptopuri ne; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitroxantrone; vancristine; vinorelbine (Navelbine®); novantrone; teniposide;

edatrexate; daunomycin; aminopterin; xeoloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DM FO); reti noids such as retinoic acid; capecitabine; FOLFI RI (fluorouracil, leucovorin, and irinotecan) and pharmaceutically acceptabl e sal ts, aci ds or deri vati ves of any of the above. One or more chemotherapeuti c agent are used or i ncl uded i n the present appl i cati on .

Also included in the definition of " chemotherapeuti c agent" are anti -hormonal agents that act to regulate or inhibit hormone action on tumors such as anti -estrogens and sel ecti ve estrogen receptor modul ators (SERM s) , i ncl udi ng , for exampl e, tamoxi fen (including Nolvadex™), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston®); inhibitors of the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate (Megace®), exemestane, formestane, fadrozole, vorozole (Ri visor®), letrozole (Femara®), and anastrozole (Arimidex®.); and anti -androgens such asflutamide, nilutamide, bi cal utami de, I euprohde, and goserel i n; and pharmaceuti cal I y acceptabl e sal ts, aci ds or derivatives of any of the above.

The anti -angi ogeni c agents i ncl ude, but are not I i mi ted to, reti noi d aci d and derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN®, ENDOSTATIN®, suramin, squal amine, tissue inhibitor of metal I oproteinase-1, tissue inhibitor of metalloproternase- 2, plasminogen activator inhibitor-1, plasminogen activator inbibitor-2, cartilage-derived inhibitor, paclitaxel (nab-paclitaxel), platelet factor 4, protamine sulphate (clupeine), sulphated chitin derivatives (prepared from queen crab shells), sulphated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism, including for example, proline analogs ((1-azetidine-2-carboxylic acid (LACA), cishydroxyproline, d,l-3,4-dehydroproline, thiaproline, .alpha-dipyridyl, beta- ami nopropi onitri le f umarate, 4-propyl -5-(4-pyridi nyl )-2(3h)-oxazolone; methotrexate, mitoxantrone, heparin, interferons, 2 macroglobulin-serum, chimp-3, chymostatin, beta- cyclodextrin tetradecasulfate, eponemycin; fumagillin, gold sodium thiomalate, d- penicillamine (CDPT), beta- 1 -anti col I agenase- serum, alpba-2-antiplasmin, bisantrene, lobenzarit disodium, n-2-carboxyphenyl-4-chloroanthroni lie acid disodium or "CCA", thai i domi de; angi ostati c steroi d, carboxynami noi mi dazol e; metal I oprotei nase i nhi bi tors such as BB94. Other anti -angi ogenesis agents include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF and Ang-1/Ang-2. See Ferrara N. and Alitalo, K. "Clinical application of angiogenic growth factors and their inhibitors" (1999) Nature Medicine 5:1359-1364. The anti -fibrotic agents include, but are not limited to, the compounds such as beta-ami noproprionitrile (BAPN), as well as the compounds disclosed in U.S. Pat. No. 4,965,288 to Palfreyman, et al ., issued Oct. 23, 1990, entitled "Inhibitorsof lysyl oxidase," relating to inhibitorsof lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen; U.S. Pat. No.

4,997,854 to Kagan, et al., issued Mar. 5, 1991, entitled "Anti-fibrotic agentsand methods for inhibiting the activity of lysyl oxidase in situ using adjacently positioned diamine analogue substrate," relating to compounds which inhibit LOX for the treatment of various pathological fibrotic states, which are herein incorporated by reference.

Further exemplary inhibitors are described in U.S. Pat. No. 4,943,593 to Palfreyman, et al., issued Jul. 24, 1990, entitled "Inhibitorsof lysyl oxidase," relating to compounds such as2-isobutyl-3-fluoro-, chloro-, or bromo-allylamine; as well as, e.g., U.S. Pat. No. 5,021,456; U.S. Pat. No. 5,5059,714; U.S. Pat. No. 5,120,764; U.S. Pat. No. 5,182,297; U.S. Pat. No. 5,252,608 (relating to 2-(1-naphthyloxymemyl)-3-fluoroallylamine); and U.S. Patent Application No. 2004/0248871, which are herein incorporated by reference. Exemplary anti-fibrotic agents also include the primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce, after binding with the carbonyl, a product stabilized by resonance, such as the following primary amines: emylenemamine, hydrazine, phenyl hydrazine, and their derivatives, semicarbazide, and urea derivatives, aminonitriles, such as beta- ami nopropionitri I e (BAPN), or 2-nitroethyl amine, unsaturated or saturated haloamines, such as 2-bromo-ethyl amine, 2-chloroethyl amine, 2-trifluoroethyl amine, 3- bromopropyl ami ne, p-halobenzy I amines, selenohomocysteine lactone. Also, the anti- f i broti c agents are copper chel ati ng agents, penetrati ng or not penetrati ng the eel I s. Exemplary compounds include indirect inhibitors such compounds blocking the al dehyde deri vati ves ori gi nati ng from the oxi dati ve deami nati on of the I ysy I and hydroxylysyl residues by the lysyl oxidases, such as the thiol amines, in particular D- penicillamine, or i ts analogues such as 2-amino-5-mercapto-5-methylhexanoic acid, D-2- amino-3-methyl-3-((2-acetamidoethyl)dithio)butanoic acid, p-2-amino-3-methyl-3-((2- ami noethyl )di thi o)butanoi c aci d, sodi um-4-((p- 1 -di methyl -2-ami no-2- carboxyethyl)dithio)butane sulphurate, 2-acetamidoethyl-2-acetamidoethanethiol sul phanate, sodi um-4-mercaptobutanesul phi nate tri hydrate.

The i mmunotherapeuti c agents i ncl ude and are not I i mi ted to therapeuti c antibodies suitable for treating patients; such as abagovomab, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, bl i natumomab, brentuximab, cantuzumab, catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab, ensituximab, ertumaxomab, etaracizumab, farietuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, ganitumab, gemtuzumab, girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab, ipilimumab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab, narnatumab, naptumomab, necitumumab, nimotuzumab, nofetumomabn, ocaratuzumab,

ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, panitumumab, parsatuzumab, patritumab, pemtumomab, pertuzumab, pintumomab, pritumumab, racotumomab, radretumab, rilotumumab, rituximab, robatumumab, satumomab, sibrotuzumab, siltuximab, simtuzumab, solitomab, tacatuzumab, taplitumomab, tenatumomab, teprotumumab, tigatuzumab, tositumomab, trastuzumab, tucotuzumab, ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, obi nutuzumab, CC49 and 3F8. The exempl i f i ed therapeuti c anti bodi es may be further I abel ed or combined with a radioisotope particle, such as indium In 111, yttrium Y 90, iodine 1-131.

The appl i cati on al so provi des method for treati ng a subj ect who i s undergoi ng one or more standard therapies, such as chemotherapy, radiotherapy, immunotherapy, surgery, or combination thereof. Accordingly, one or more therapeutic agent or inhibitors may be administered before, during, or after administration of chemotherapy, radiotherapy, immunotherapy, surgery or combination thereof.

Other examples of chemotherapy treatments (including standard or experimental chemotherapies) are described below. In addition, treatment of certain lymphomas is reviewed in Cheson, B.D., Leonard, J.P., "Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma" The New Engl and Journal of Medicine 2008, 359(6), p. 613-626; and Wierda, W.G., "Current and Investigational Therapiesfor Patients with CLL" Hematology 2006, p. 285-294. Lymphoma incidence patterns in the United States is profiled in Morton, L.M ., er a/. "Lymphoma Incidence Patterns by WHO Subtype in the United States, 1992-2001" Blood/2006, 107(1), p. 265-276.

-Examples of immunotherapeutic agents include, but are not limited to, rituximab (such as Rituxan), alemtuzumab (such as Campath, MabCampath), anti-CD19 antibodies, anti-CD20 antibodies, anti-M N-14 antibodies, anti-TRAI L, Anti -TRAIL DR4 and DR5 antibodies, anti-CD74 antibodies, apolizumab, bevacizumab, CHIR-12.12, epratuzumab (hLL2- anti-CD22 humanized antibody), galiximab, ha20, ibritumomab tiuxetan, lumiliximab, milatuzumab, ofatumumab, PR0131921, SGN-40, WT-1 analog peptide vaccine, WT1 126-134 peptide vaccine, tositumomab, autologous human tumor- derived HSPPC-96, and veltuzumab. Additional immunotherapy agents includes using cancer vaccines based upon the genetic makeup of an individual patient's tumor, such as I y mphoma vacci ne exampl e i s GTOP-99 ( M y V ax®) .

.Examples of chemotherapy agents include aldesleukin, alvocidib, antineoplaston AS2-1 , antineoplaston A 10, anti -thymocyte globulin, amifostinetri hydrate,

ami nocamptotheci n, arsenictri oxide, betaalethine, Bcl-2 family protein inhibitor ABT- 263, ABT-199, BMS-345541, bortezomib (Velcade®), bryostatin 1, busulfan, carbopl ati n, campath-1 H , CC-5103, carmusti ne, caspof ungi n acetate, clofarabi ne, cisplatin, Cladribine (Leustarin), Chlorambucil (Leukeran), Curcumin, cyclosporine, Cyclophosphamide (Cyloxan, Endoxan, Endoxana, Cyclostin), cytarabine, denileukin diftitox, dexamethasone, DT PACE, docetaxel, dolastatin 10, Doxorubicin

(Adriamycin ® , Adriblastine), doxorubicin hydrochloride, enzastaurin, epoetin alfa, etoposide, Everolimus (RADOOI), fenretinide, filgrastim, melphalan, mesna,

Flavopiridol, Fludarabine (Fludara), Geldanamycin (17-AAG), ifosfamide, irinotecan hydrochloride, ixabepilone, Lenalidomide (Revlimid ® , CC-5013), lymphokine-activated killer cells, melphalan, methotrexate, mi toxantrone hydrochloride, motexafin gadolinium, mycophenolate mofetil, nelarabine, oblimersen (Genasense) Obatoclax (GX15-070), oblimersen, octreotide acetate, omega-3 fatty acids, oxaliplatin, paclitaxel, PD0332991, PEGylated liposomal doxorubicin hydrochloride, pegfilgrastim, Pentstatin (Nipent), perifosine, Prednisolone, Prednisone, R-roscovitine (Selicilib, CYC202), recombinant interferon alfa, recombinant interleukin-12, recombinant interleukin-11 , recombinant flt3 ligand, recombinant human thrombopoietin, rituximab, sargramosti m, sildenafil citrate, simvastatin, sirolimus, Styryl sul phones, tacrolimus, tanespimycin, Temsirolimus (CCI-779), Thalidomide, therapeutic allogeneic lymphocytes, thiotepa, tipifarnib, Velcade ® (bortezomib or PS-341), Vincristine (Oncovin), vincristine sulfate, vinorelbinedi tartrate, Vorinostat (SAHA), vorinostat, and FR (fludarabine, rituximab), CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CVP

(cyclophosphamide, vincristine and prednisone), FCM (fludarabine, cyclophosphamide, mi toxantrone), FCR (fludarabine, cyclophosphamide, rituximab), hyperCVAD

(hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine), ICE (iphosphamide, carboplatin and etoposide), MCP (mitoxantrone, chlorambucil, and prednisolone), R-CHOP (rituximab plus CHOP), R- CVP (rituximab plus CVP), R-FCM (rituximab plus FCM), R-ICE (rituximab-ICE), and R-MCP (R-MCP).

The therapeuti c treatments can be suppl emented or combi ned wi th any of the abovementi oned therapies with stem cell transplantation or treatment. One example of modified approach is radioi immunotherapy, wherein a monoclonal antibody iscombined with a radioisotope particle, such as indium In 111, yttrium Y 90, iodi ne 1-131.

Examples of combination therapies include, but are not limited to, lodine-131 tositumomab (Bexxar ® ), Yttrium-90 ibritumomab tiuxetan (Zevalin ® ), Bexxar ® with CHOP. Other therapeutic procedures i ncl ude peri pheral blood stem eel I transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow

transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, in vit ro-treated peripheral blood stem cell transplantation, umbilical cord blood

transplantation, immunoenzyme technique, pharmacological study, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, and

nonmyeloablative allogeneic hematopoietic stem cell transplantation.

I n some embodi ments, the methods i ncl ude admi nisteri ng a compound of the formula described herein or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof, in a therapeutically effecti e amount to a human in need thereof. The method can be employed to treat a patient who has or is bel ieved to have a disease or condition whose symptoms or pathology is mediated by expression or activity of ΡΙ3K□. The patient may be a mammal or a human. In certain embodiment, the patient may be a human.

"Treatment" or "treating" is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired clinical results may include one or more of the foil owing: a) inhibiting the disease or condition (e.g., decreasi ng one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) si owing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (e.g., metastasis) of the disease or condition); and/or c) relieving the disease, that is, causing the regression of clinical symptoms (e.g. , amel i orati ng the di sease state, provi di ng parti al or total remi ssi on of the disease or condition, enhancing the effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival .

"Prevention" or "preventing" mean any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodi ments, be administered to asubject (including a human) who isat risk or has a family history of the disease or condition. "Subject" or "patient" refer to an animal, such as a mammal (including a human), that has been or wi 11 be the obj ect of treatment, observati on or experi ment. The methods described herein may be useful in human therapy and/or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human. " H uman i n need thereof" refers to a human who may have or i s suspect to have diseases, or disorders, or conditions that would benefit from certai n treatment; for example, being treated with the PI3K inhibitor of the compounds according to the present appl i cati on. I n certai n embodi ments, the subj ect may be a human who (i ) has not received any treatment including chemotherapy treatment, (ii) is substantially refractory to at least one chemotherapy treatment, (ii i) is i n relapse after treatment with

chemotherapy, or both (i) and (ii). In some of embodiments, the subject is refractory to at least one, at least two, at least three, or at least four chemotherapy treatments

(including standard or experimental chemotherapies).

The terms "therapeutically effective amount" or "effective amount" of a compound of the present appl i cati on or a pharmaceuti cal I y acceptabl e sal t, i somers, prodrug, or solvate thereof, mean an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression. For example, a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to inhibition of PI3K□ and PI3K□ activity. The therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art.

In addition to the therapeutic uses, the compounds described herein have the selectivity or selective inhibiti on to certain PI 3K isoforms. In one embodi ment, the compounds have selectivity to ΡΙ3K□. The selectivity to PI3K isoforms may be determined by measuring the compound's activity in inhibiting certain PI3K isoforms using the assay described in the example below or the methods commonly used. It is understood that the conditions (e.g. the reagent concentration or the incubation temperature) may be varied and the results of the assay may vary. In some instances, the val ue may vary withi n a range of one to three-fold. The term "inhibition" indi cates a decrease i n the basel i ne acti vi ty of a bi ol ogi cal activity or process. The term "inhibition of activity of PI3K isoforms" or variants thereof refer to a decrease in activity in any PI3K isoform {e.g., alpha, beta, gamma, or del ta) as a di rect or i ndi rect response to the presence of a compound of any of the f ormul a descri bed herei n rel ati ve to the acti vi ty of PI 3K i sof orm i n the absence of such compound. "Inhibition of PI 3K□ and/or ΡΙ3K□ activities" or variants thereof refer to a decrease i n PI 3K□ and/or PI 3K□ acti vi ties as a di rect or i ndi rect response to the presence of the compounds described herein, relative to the activities of PI 3K□ and/or ΡΙ3K□ in the absence of such compound. I n some embodi ments, the i nhi bition of PI 3K i soform activities may be compared in the same subject prior to treatment, or other subjects not recei vi ng the treatment.

Without being bound to any theory, the decrease in the activity of PI3K may be due to the direct interaction of the compound with PI3K, or due to the interaction of the compounds descri bed herei n with one or more other factors that affect PI 3K activity. For example, the presence of the compounds may decrease the activities of PI3K□ and/or PI3K□ by directly binding to PI 3K□ and/or PI3KD, by causing (directly or indirectly) another factor to decrease PI3K□ and/or PI3K□ activities, or by (directly or indirectly) decreasing the amount of PI3K□ and/or PI3K□ present in the eel I or organism.

The term "PI3K inhibitor" or variant thereof refers to a compound that inhibits the activity of PI3K. The term "PI3K isoform selective inhibitor" or variant thereof refers to a compound that i nhi bi ts the acti vi ty of one or more PI 3K i sof orms more effectively than the other remaining PI3K isoforms. By way of example, the term "ΡΙ3Κβ selective inhibitor" generally refers to a compound that inhibits the activity of the PI3Κβ isoform more effectively than other isoforms of the PI3K family, and the term "PI3Kδ selective inhibitor" generally refers to a compound that inhibits the activity of the PI3Kδ isoform more effectively than other isoforms of the PI3K family. The term "dual ΡΙ3K□/β selective inhibitor" generally refers to a compound that inhibits the activity of both PI3K□and ΡΙ3Κβ isoforms more effectively than other isoforms of the PI3K family (e.g., PI3K□ οτγ). The relative efficacies of compounds as inhibitors of an enzyme activity (or other biological activity) can be established by determining the concentrations at which each compound inhibits the activity to a predefined extent and then comparing the results. In one embodi ment, the efficacy of a compound as an inhibitor of one or more PI 3K isoforms can be measured by the compound concentration that i nhi bits 50% of the activity in a biochemical assay, i.e., the 50% inhibitory concentration or "IC50". The determi nation of I C50 val ues can be accompl ished using conventional techniques known in the art, including the techniques described in the Examples below. In general, an IC 5 0 can be determi ned by measuri ng the activity of a given enzyme i n the presence of a range of concentrations of thecompound under the study. The experimentally obtained values of enzyme activity may then be pi otted agai nst the compound concentrations used. The concentration of the inhibitor that shows 50% enzyme activity (as compared to the activity in the absence of any inhibitor) i s taken as the I C50 value. Analogously, other inhibitory concentrations can be defined through appropriate determinations of activity. For exampl e, i n some setti ngs it may be desi rable to establ i sh a 90% i nhi bitory concentration, i.e., IC 90 . According to the present application, a ΡΙ3K□ selective inhibitor isa compound that exhibits a 50% inhibitory concentration (IC50) with respect to ΡΙ3K□ that is at least 10-fold, at least 20-fold, at least 30-fold, at least 50-fold, at least 100-fold, at least 200- fold, or at least 500-fold lower than the IC50 with respect to either ΡΙ3K□ or ΡΙ3Κγ or both PI3K□ and ΡΙ3Κγ. In addition, a PI 3Κδ/β selective inhibitor isacompound that exhibitsa 50% inhibitory concentration (IC50) with respect to ΡΙ3Κβ and PI3Kδ that is at least 10-fold, at least 20-fold, at least 30-fold, at least 50-fold, at least 75-fold, at least 100-fold, at least 200-fold, and at least 500-fold lower than the IC50 with respect to either PI3K□or PI3K□ Thedual PI 3Κδ/β selective inhibitor may have the same or similar ICato both PI3Kδ and ΡΙ3Κβ or may have different IC50 to either ΡΙ3Κδ or ΡΙ3Κβ. As used herein, the term "potency," "potent," or variants thereof refer to the compound exhibiting an IC50 value that is less than 100 nM . When comparing two compounds, the compound that exhi bi ts a I ower I C50 val ue i s referred to as a more potent i nhi bi tor.

The methods described herein may be applied to cell populations in vivo or ex vivo. "In vivo" means within a living individual, as within an animal or human. In this context, the methods descri bed herein may be used therapeutically in an individual. "Ex vivo" means outside of a living individual. Examplesof ex vivocell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in theart. .Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exempl ary ti ssue sampl es i ncl ude tumors and bi opsi es thereof. I n thi s context, the compounds may be used for a variety of purposes, including therapeutic and

experi mental purposes. For example, it may be used ex vivo to determi ne the opti mal schedule and/or dosing of administration of a PI3K selective inhibitor for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experi mental purposes or i n the cl i ni c to set protocol s for in vivo treatment. Other ex vivo uses for whi ch the compound descri bed herei n may be sui ted are descri bed bel ow or wi 11 become apparent to those ski I led i n the art. The compounds of the formula descri bed herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, may be further character! zed to exami ne the safety or tol erance dosage i n human or non-human subjects. Such properties may be examined using commonly known methods to those ski I led i n the art. Compared to other PI3K isoforms, ΡΙ3K□ isgenerally mis-regulated in certain cancer cells. Aberrant proliferation of cellsoften interferes with normal tissue function, which may result in abnormal cellular response such as immunity, inflammation, and/or apoptosis. The selective inhibitors to PI 3Κβ are useful in treating, inhibiting, or preventing aberrant proliferation of cancerous and/or hematopoietic eel I sand amel i orati ng the symptoms and secondary condi ti ons.

The compounds descri bed herei n may be used to treat subj ects havi ng vari ous disease states, disorders, and conditions (also collectively referred to as "indications") associated with PI3K isoforms or their activities. As used herein, the terms "diseases," "disorders," "conditions" are used interchangeably. Such indications may include, for exampl e, cancer, i ncl udi ng hematol ogi c mal i gnanci es (e.g. I eukemi as and I ymphomas, myeloproliferative disorders, myelodysplastic syndromes, plasma cell neoplasms) and sol i d tumors, i nf I animation, f i brosis, al I ergi c conditions (i ncl udi ng hypersensitivity), cardiovascular diseases, neurodegenerative diseases, renal disorders, viral infections, obesity, and autoimmune diseases. I n other embodi ments, the compounds descri bed herei n may be used to treat cancers that are mediated by, dependent on, or associated with PI3K activity. I n certain embodiments, the disease or condition is an autoimmune disease, an inflammatory disease, or a cancer. In some embodiments, the disease or condition ischosen from rheumatoid arthritis, osteoarthritis, atherosclerosis, psoriasis, systemic lupus

erythematosus, multiple sclerosis, inflammatory bowel disease, asthma, chronic obstructive airways disease, pneumonitis, dermatitis, alopecia, nephritis, vasculitis, atheroscl erosi s, A I zhei mer' s di sease, hepati ti s, pri mary bi I i ary ci rrhosi s, scl erosi ng cholangitis, diabetes (including type I diabetes), acute rejection of transplanted organs, lymphomas, multiple myelomas, leukemias, neoplasms and solid tumors.

In other embodiments, the disease is a solid tumor. By way of examples, the solid tumor includes but is not limited to prostate cancer, (including castration-resistant prostate cancer), pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers (e.g., neuroblastoma), brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, or soft ti ssue sarcoma. I n some embodi ments, the sol i d tumor i s non-smal I eel I I ung cancer, small-cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, pancreatic cancer, prostate cancer, or breast cancer.

The present application also provides a method for treating a human in need thereof, who has or issuspected of having a disease or condition responsive or believed to be responsi ve to the inhibition ΡΙ3Κβ acti vi ty by admi ni steri ng to the subj ect a compound of the f ormul ae descri bed herei n or a pharmaceuti cal I y acceptabl e sal t, enantiomer, atropisomer, tautomer, prodrug, or solvate thereof.

Additionally, the application provides a method of inhibiting kinase activity of a ΡΙ3Κβ polypeptides by contacting the polypeptides with a compound of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, solvate, or a mixture thereof.

Moreover, the application provides a method of decreasing cell viability, increasing cell death or apoptosis, increasing interference with PI3K signaling pathways (i ncl udi ng A KT, S6RP, ERK phosphoryl ati on), and/or reducti on i n chemoki ne production with an effective amount of a compound of any of the formulae descri bed herein or a pharmaceutically acceptable salt, isomer, prodrug, solvate, or a mixture thereof.

The application further provides a method of disrupting leukocyte function comprising contacting the leukocytes with an effective amount of a compound of any of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, solvate, or a mixture thereof, i n a human i n need thereof.

Provi ded i s al so a method of i nhi bi ti ng growth or prol i f erati on of cancer eel I s compri si ng contacti ng the cancer eel I s with an effective amount of a compound of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, solvate, or a mixture thereof.

Kits

Provided herei n are also kits that i ncl ude a compound of the formulae of the present application or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof, and suitable packaging. I n one embodiment, a kit further includes instructions for use. I n one aspect, a ki t i ncl udes a compound of the f ormul ae descri bed herei n or a pharmaceuticall acceptable salt, isomer, prodrug, or sol vate thereof , and a label and/or i nstructi ons for use of the compounds i n the treatment of the i ndi cati ons, i ncl udi ng the diseases or conditions, described herein.

Provi ded herei n are al so arti cl es of manufacture that i ncl ude a compound of any of the f ormul ae descri bed herei n or a pharmaceuti cal I y acceptabl e sal t, i somer, prodrug, or solvate thereof, in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe, and intravenous bag.

Pharmaceutical Compositions and Modes of Administration

Compounds provided herein are usually administered in the form of

pharmaceutical compositions. Thus, provides herein arealso pharmaceutical compositions that contain one or more of the compounds of any of the formulae disclosed herein or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof, and one or more pharmaceutically acceptable vehicles selected from carriers, adj uvants and exci pi ents. Sui tabl e pharmaceuti cal I y acceptabl e vehi cl es may i ncl ude, for example, inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic sol vents, permeation enhancers, solubilizersand adjuvants. Such compositions are prepared in a manner well known in the pharmaceutical art. See, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds.).

The pharmaceutical compositions may be administered in either single or multiple doses. The pharmaceutical composition may be administered by various methods including, for example, rectal, buccal, intranasal and transdermal routes. In certai n embodi ments, the pharmaceuti cal composi ti on may be admi ni stered by i ntra- arterial injection, intravenously, intraperitoneal ly, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant. I n some embodi ments, the pharmaceutical composition is administered orally.

One mode for administration is parenteral, for example, by injection. The forms in which the pharmaceutical compositions described herein may be i ncorporated for administration by injection include, for example, aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.

Oral administration may be another route for administration of the compounds described herein. Administration may be via, for example, capsule or enteric coated tablets. In making the pharmaceutical compositions that include at least one compound of any of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, the active ingredient is usually dil uted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be in theform of a solid, semi-solid, or

I i qui d materi al , whi ch acts as a vehi cl e, carri er or medi um for the acti ve i ngredi ent. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a sol id or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gel ati n capsul es, steri I e i nj ectabl e sol uti ons, and steri I e packaged powders. In certain embodiments, the pharmaceutical composition is in the form of tablets. As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptableexcipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the I ike. The use of such mediaand agentsfor pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated.

Supplementary active ingredients can also be incorporated into the compositions.

Some examples of sui table exci pi ents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, cal ci urn si I i cate, mi crocrystal I i ne eel I ul ose, pol yvi nyl pyrrol i done, eel I ul ose, steri I e water, syrup, and methyl cellulose. The formulations can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propyl hydroxy-benzoates; sweetening agents; and flavoring agents. The compositions that include at least one compound of any of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof, can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and di ssol uti onal systems contai ni ng pol ymer-coated reservoi rs or drug- polymer matrix formulations. Examples of controlled release systems are given in U.S. Patent Nos. 3,845,770; 4,326,525; 4,902,514; and 5,616,345. Another formulation for use i n the methods of the present i nventi on empl oys transdermal del i very devi ces ("patches"). Such transdermal patches may be used to provide continuous or

discontinuous infusion of the compounds described herein in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. For prepari ng sol i d composi ti ons such as tabl ets, the pri nci pal acti ve i ngredi ent may be mi xed wi th a pharmaceuti cal exci pi ent to form a sol i d pref ormul ati on composition contai ni ng a homogeneous mixture of a compound of any of the above formulae or a pharmaceutically acceptable salt, prodrug, or solvate thereof. When referring to these preformulation compositions as homogeneous, the active ingredient may be dispersed evenly throughout the composition so that the composition may be readi I y subdi vi ded i nto equal I y ef f ecti ve uni t dosage forms such as tabl ets, pi 11 s and capsules.

The tabl ets or pi 11 s of the compounds descri bed herei n may be coated or otherwi se compounded to provi de a dosage form af f ordi ng the advantage of prol onged action, or to protect from the acid conditions of the stomach. For example, the tablet or pi 11 can i ncl ude an i nner dosage and an outer dosage component, the I atter bei ng i n the form of an envel ope over the former. The two components can be separated by an enteri c I ayer that serves to resist disi ntegrati on i n the stomach and permi t the i nner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteri c I ayers or coati ngs, such materi al s i ncl udi ng a number of pol y meri c acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

Compositions for inhalation or insufflation may include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The I iquid or solid compositions may contain suitable

pharmaceuti cal I y acceptabl e exci pi ents as descri bed supra. I n some embodi ments, the composi ti ons are admi ni stered by the oral or nasal respi ratory route for I ocal or systemi c effect. I n other embodi ments, compositions in pharmaceutically acceptable sol vents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a f acemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.

Dosing

The specif i c dose I evel of a compound of the f ormul ae descri bed herei n for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease in the subject undergoing therapy. For example, a dosage may be expressed as a number of mil ligrams of a compound of the formula per kilogram of the subject's body weight (mg/kg). Dosages of between about 0.01 and 200 mg/kg may be appropriate. I n some embodi ments, about 0.01 and 150 mg/kg may be appropri ate. I n other embodi ments a dosage of between 0.05 and 100 mg/kg may be appropriate. Normalizing according to the subject's body weight is particularly useful when adj usti ng dosages between subj ects of wi del y di sparate si ze, such as occurs when using the drug in both children and adult humans or when converting an effective dosage in a non-human subject such as dog to a dosage suitable for a human subject. The daily dosage may also be described as a total amount of a compound of the formulae administered per dose or per day. Daily dosage of a compound may be between about 1 mg and 2,000 mg, between about 1 ,000 to 2,000 mg/day, between about 1 to 1,000 mg/day, between about 1 to 500 mg/day, between about 100 to 150 mg/day, between about 1 to 100 mg day, between about between about 1 to 50 mg day, between about 50 to 100 mg/day, between about 100 to 125 mg/day, between about 100 to 150 mg/day, between about 100 to 175 mg/day, between about 100 to 200 mg/day, between about 100 to 225 mg/day, between about 100 to 250 mg/day, between about 100 to 350 mg/day, between about 100 to 400 mg/day, between about 100 to 450 mg/day, or between about 100 to 500 mg/day. When administered orally, the total daily dosage for a human subject may be between 1 mg and 1,000 mg day, between about 1 to 100 mg/day, between about 1 to 50 mg/day, between about 50 to 100 mg/day, between 50 to 300 mg/day, between 50 to 200 mg/day, between 75 to 200 mg day, between 75 to 150 mg/day, between 100 to 200 mg/day, between about 200 to 300 mg/day, between about 300 to 400 mg/day, between about 400 to 500 mg/day, between about 100 to 150 mg/day, between about 150 to 200 mg/day, between about 200 to 250 mg/day, between about 75 to 150 mg/day, or between about 150 to 300 mg/day.

The compounds of the present appl i cati on or the composi ti ons thereof may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, admini strati on or treatment with the compounds according to any of the f ormul ae descri bed herei n may be conti nued for a number of days; for exampl e, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. I n some treatment, the compound or the composition thereof is administered continuously, i.e. every day. Treatment cycles are well known in cancer chemotherapy, and are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodi ments, may al so be conti nuous.

I n a parti cul ar embodi ment, the method compri ses admi ni steri ng to the subj ect an initial daily dose of about 1 to 500 mg of a compound of the above formula and i ncreasi ng the dose by i ncrements unti I clinical effi cacy i s achi eved. I ncrements of about 1 , 5, 10, 25, 50, 75, or 100 mg can be used to i ncrease the dose. The dosage can be i ncreased dai I y, every other day, twi ce per week, or once per week.

Synthesis of the Compounds

The compounds of the present application may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent given the di scl osure herei n and methods wel I known i n the art. Conventi onal and wel I -known synthetic methods may be used in addition to the teachings herein. The synthesis of typi cal compounds descri bed herei n may be accompl i shed as descri bed i n the f ol I owi ng examples. If available, reagents may be purchased commercially, e.g., from Sigma Al dri ch or other chemical suppl iers. I n general , compounds descri bed herei n are typi cal I y stabl e and i sol atabl e at room temperature and pressure. General Synthesis

Typical embodi ments of compounds descri bed herein may be synthesized using the general reacti on schemes descri bed beJ ow. 11 wi 11 be apparent given the descri pti on herei n that the general schemes may be altered by substitution of the starti ng materials with other materials having similar structures to result in products that are

correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Given a desi red product for which the substituent groups are defined, the necessary starting materials generally may be determined by inspection. Starting materialsare typically obtained from commercial sources or synthesized using published methods. For sy nthesi zi ng compounds whi ch are embodi ments descri bed i n the present di scl osure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the exampl es herei n.

S nthetic Reaction Parameters The terms " sol vent" , " i nert organi c sol vent" , or " i nert sol vent" refer to a sol vent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), di methyl formamide ("DM F"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, and the like). Unless specified to the contrary, the solvents used i n the reacti ons of the present i nventi on are i nert organi c sol vents, and the reacti ons are carried out under an inert gas, preferably nitrogen or argon.

The compounds of formula (I M ) may be prepared using the method similar to the Reaction Scheme I shown below:

Reaction Scheme I

Step 1 - Preparation of a compound of formula (1 )

The compounds of formula (1) can be made by combining compounds (A) and (B). Compounds (A) and (B) are commercial ly avai lable or can be made by methods known in the art. With respect to compound (A), Y 1 is CI, Br or neopentylglycolatoboron. With respect to compound (B), R and R are independently selected from R or B(OH) 2 ; and, X 6 and X 7 are independently selected from N and CR 103 wherei n R 103 i s as defined above. Compounds (A) and (B) can be mixed in the presence of a catalyst such as tetraki s(tri phenyl phosphi ne)pal I adi um(0) and a base such as potassi urn phosphate tri basic in asui table solvent such as a mi xtureof dioxaneand water. After further stirring at a temperature between 70 and 110 °C for between 1 and 24 hours, the reaction mixture is all owed to cool to room temperature. To extract the compound of formula (1), an organic solvent such as ethyl acetate may be added, followed by washing with water and bri ne. The organi c phase can be concentrated to obtai n the compound of f ormul a (1). The compound of formula (1) may be purified by any suitable methods known in the art such as chromatography on si I i ca gel , tri turati on , preci pi tati on or crystal lizati on.

Step 2 - Preparation of a compound of formula (2)

The compounds of formula (2) can be made by combining compounds (1) and (C).

Compound (C) is commercially avail able or can be made by methods known i n the art. With respect to compound (C), (R 1 ) n and (R 5 ) s isas defined herein. Compounds (1) and (C) can be mixed i n the presence of a catalyst such as pal I adi um(l I ) acetate, a phosphi ne ligand such asdicyclohexyl(2',4',6'-triisopropyl-[1 ,T-biphenyl]-2-yl)phosphine, and a base such as potassi urn phosphate i n a neutral sol vent such as tol uene. The reacti on i s carried out at a temperature between 70 and 120°C for between 4 and 72 hours or unti I the reaction iscomplete. Upon completion, the solvent is removed under reduced pressure and the compound of formula (2) may be purified by any suitable methods known in the art such as chromatography on silica gel, trituration, precipitation or crystallization.

Step 3 - Preparation of a compound of formula (3) The compounds of f ormul a (3) can be made by combi ni ng compounds (2) and (D).

Compound (D) is commercially available or can be made by methods known in the art. With respect to compound (D), R 2 is as defined herein. Compounds (2) and (D) can be mixed in the presence of a reducing agent such as sodium dithionite in a solvent such as a mixture of dimethylsulfoxide and ethanol. The reaction is carried out at a temperature between 30 and 120 °C for between 4 and 72 hours or unti I the reacti on i s compl ete. The reaction mixture isthen partitioned between water and an organic solvent such as ethyl acetate or methylene chloride, followed by washing with water and brine. The organic phase can be concentrated to obtai n the compound of formul a (3). The compound of formula (3) may be purified by any suitable methods known in the art such as chromatography on silica gel, trituration, precipitation or crystallization. Step 4 - Preparati on of a compound of formul a (4)

The compounds of formul a (4) may be prepared by hydrol ysi s of the compounds of formula (3) by standard methods. A compound of formula (3) is dissolved or slurried i n a solvent such astetrahydrofuran or dioxane and lithium hydroxide may be added either as a sol uti on i n water or wi th some water. The reacti on i s carri ed out at ambi ent temperature for between 1 and 24 hours or unti I the reacti on i s compl ete. The reacti on i s then acidified with an acid such as hydrochloric acid and the solvent is removed under reduced pressure to give a compound of formula (4).

Step 5 - Preparation of a compound of formula (5)

The compounds of formula (5) may be prepared by amidation of the compounds of formula (4) by standard methods. A compound of formula (4) may be reacted with ammonium chloride in the presence of hydroxybenzotriazole (HOBt), a base such as triethylamineor diisopropyl ethyl amine, and N-(3-dimethylaminopropyl)- V'- ethylcarbodiimide hydrochloride (EDC) in a solvent such asdimethylformamide. The reaction is carried out at a temperature between ambient temperature and 60°C for between 2 and 96 hours or until the reaction is complete. To extract the compound of formula (5), an organic solvent such as ethyl acetate may be added, followed by washing with water and bri ne. The organic phase can be concentrated under reduced pressure to obtain the compound of formula (5). Alternatively, the compound of formul a (5) may precipitate with the addition of water and may be recovered by filtration. The compound of formula (5) may be purified by any suitable methods known in the art such as chromatography on silica gel, preparative HPLC, trituration, precipitation or crystallization.

Step 6 - Preparation of a compound of formula (IM )

The compounds of formula (IM) can be made from the compounds of formula (5) by a two-step procedure. A compound of formul a (5) may be reacted wi th a I arge excess of an appropriate reagent such as 1,1 -di methoxy-N,N-di methyl ethanamine or 1,1 -di methoxy- N, N-di methyl methanami neat a temperature between ambient temperature and 140 °C for between 0.5 and 24 hours or until the reaction is complete. The reagent is removed under reduced pressure and the residue can be dissolved in acetic acid followed by addition of hydrazine. The reaction isstirred at atemperature between ambient temperature and 100°C for between 0.5 and 24 hours or until the reaction iscomplete. The sol vent i s removed under reduced pressure and the compound of f ormul a ( I M ) can be dissolved in an organic solvent such as ethyl acetate, followed by washing with a solution of saturated sodium bicarbonate and brine. The organic phase is concentrated under reduced pressure to obtain the compound of formula (I M). The compound of formula (I M) may be purified by any suitable methods known in the art such as chromatography on silica gel, preparative HPLC, trituration, precipitation or crystallization.

If protecting groups are present on the compound of formula (I M) at this point, they may be removed by appropri ate methods. For exampl e, Boc or T H P groups may be removed by treatment wi th an aci d such as tri f I uoroaceti c aci d i n a sol vent such as methyl ene chloride. The compound of formula (IM) may be purified by any suitable methods known in the art such as chromatography on silica gel, preparative HPLC, trituration, precipitation or crystallization. If the compound of formula (IM) isa mixture of atropisomers, the isomers may be separated using a chiral chromatography method. The sol vents and chromatography column used will depend on the specific compound being separated, but normal phase, reverse phase or supercritical fl uid chromatography may be used.

Alternatively, compounds of formula (IM) can be made as shown in Reaction Scheme 2.

Reaction Scheme 2

11

Step 1 - Preparation of a compound of formula (6) The compounds of formul a (6) can be made by combi ni ng ethyl 3-ami no-2-nitrobenzoate with the compounds (C). Ethyl 3-amino-2-nitrobenzoate iscommercially availableor can be made by methods known i n the art. Compound (C) i s commerci al I y avai I abl e or can be made by methods known in the art. With respect to compound (C), (R 1 ) n and (R 5 )s i s as defi ned herei n. Ethyl 3-ami no-2-nitrobenzoate and compound (C) can be mixed i n the presence of a base such as cesi urn carbonate i n a suitable solvent such as di methyl formamide. After further stirring at a temperature between 70 and 130°C for between 2 and 48 hours, the reaction mixture isallowed to cool to room temperature. To extract the compound of formula (6), an organic solvent such as ethyl acetate may be added, fol lowed by washing with water and brine. The organic phase can be concentrated under reduced pressure to obtai n the compound of formula (6). The compound of formula (6) may be purified by any suitable methods known in the art such as chromatography on silica gel , trituration, precipitation or crystallization.

Step 2 - Preparation of a compound of formula (7)

The compounds of formula (7) can be made by reduction of the nitro group of the compounds of f ormul a (6) usi ng standard methods. A reduci ng agent such as zi nc dust can be added to a sol ution of a compound of formula (6) in a suitable solvent such as acetic acid. After further stirring at ambient temperature for between 0.5 and 24 hours, the reaction mixture can be filtered and the solvent can be removed under reduced pressure. The compound of formula (7) can be dissolved in an organic solvent such as ethyl acetate and washed with asolution of sodium bicarbonate, water and brine. The organi c phase can be concentrated under reduced pressure to obtai n the compound of formula (7). The compound of formula (7) may be purified by any suitable methods known in the art such as chromatography on silica gel, trituration, precipitation or crystallization. Step 3 - Preparati on of a compound of f ormul a (8)

The compounds of formul a (8) can be made by bromi nation of the compounds (7) usi ng standard methods. A bromi nati ng agent such as bromi ne can be added to a sol uti on of a compound of formul a (7) i n a sui tabl e sol vent such as di chl oromethane. After further sti rri ng at a temperature between 0 and 40°C for between 0.5 and 24 hours, the reaction mixture can be quenched with a reducing agent such as sodium thiosulfate. The mixture can then be diluted with an organic solvent such as ethyl acetate and washed with a sol uti on of sodi urn carbonate, water and bri ne. The organi c phase can be concentrated under reduced pressure to obtai n the compound of formula (8). The compound of formula (8) may be purified by any suitable methods known in the art such as chromatography on silica gel, trituration, precipitation or crystallization.

Step 4 - Preparation of a compound of formula (9)

The compounds of formula (9) can be made by combining the compounds (8) with an acid anhydride (E). Compound (E) is commercially available or can be made by methods known in the art. With respect to compound (E), R 2 is as defined herein. A solution of a compound of formula (8) and an excess of an acid anhydride (E) in a solvent such as acetic acid can bestirred at atemperature between 80 and 140°C for between 1 and 24 hours. The solvent can then be removed under reduced. The compound of formula (9) can be dissolved in an organic solvent such as ethyl acetate and washed with a solution of sodium bicarbonate, water and brine. The organic phase can be concentrated under reduced pressure to obtain the compound of formula (9). The compound of formula (9) may be purified by any suitable methods known in the art such as chromatography on silica gel , trituration, precipitation or crystallization.

Step 5 - Preparation of a compound of formula (10)

The compounds of formula (10) can be made by combining the compounds (9) with bis(neopentyl glycolato)di boron. A compound of formula (9) and bis(neopentyl glycol ato)di boron can be mixed in the presence of a catalyst such as [1,1 - bis(di phenyl phosphino)-ferrocene]dichloropalladium(ll) (complex with

di chl oromethane) and a base such as potassi urn acetate i n a sui tabl e sol vent such as dioxane. After further stirring at atemperature between 70 and 120°C for between 1 and 48 hours, the reaction mixture is allowed to cool to room temperature. After filtration and concentration under reduced pressure, the compound of formula (10) may be purified by any suitable methods known in the art such as chromatography on si I ica gel , trituration, precipitation or crystallization.

Step 6 - Preparation of a compound of formula (11) The compounds of formula (11) can be made by combining compounds (10) and (B). Compound (B) is commercially available or can be made by methods known i n the art. With respect to compound (B), X 6 , X 7 , and R 103 are as defined herein and Y 2 is Br or I. Compounds (10) and (B) can be mixed in the presence of a catalyst such as

tetraki s(tri phenyl phosphi ne)pal I adi um(0) and a base such as potassi urn phosphate tri basic in a sui table solvent such as a mi xtureof dioxane and water. After further stirring at atemperature between 70 and 110 °C for between 1 and 24 hours, the reaction mixture is all owed to cool to room temperature. To extract the compound of formula (11), an organic sol vent such as ethyl acetate may be added, followed by washing with water and bri ne. The organi c phase can be concentrated under reduced pressure to obtai n the compound of formula (11). The compound of formula (11) may be purified by any suitable methods known in the art such as chromatography on silica gel, trituration, precipitation or crystallization.

Step 7 - Preparation of a compound of formula (4) from a compound of formula (11 )

The compounds of f ormul a (4) may be prepared by hydrol ysi s of the compounds of formula (11) by standard methods. A compound of formula (11) isdissolved or slurred in a solvent such astetrahydrofuran or dioxane and lithium hydroxide may be added either as a solution in water or with some water. The reaction is carried out at ambient temperature for between 1 and 24 hours or until the reaction is complete. The reaction is then acidified with an acid such as hydrochloric acid and the solvent is removed under reduced pressure to give a compound of formula (4).

Alternatively, compounds of formula (IM) can be made as shown in Reaction Scheme 3.

Reaction Scheme 3

Step 1 - Preparation of a compound of formula (12)

The compounds of formula (12) can be made by combining the compounds (8) and (F). Compound (8) is made as described is Reaction Scheme 2. Compound (F) is commercially available or can be made by methods known in the art. With respect to compound (F), R 2 isas defined herein. A solution of compound (8) in an excess of compound (F) can be stirred at a temperature between 60 and 140 °C for between 1 and 48 hours. The solvent can then be removed under reduced pressure. The compound of formula (12) may be purified by any suitable methods known in the art such as chromatography on silica gel, trituration, precipitation or crystallization. Step 2 - Preparati on of a compound of f ormul a ( 13)

The compounds of formula (13) may be prepared by hydrolysis of the compounds of formula (12) by standard methods. A compound of formula (12) is dissolved or slurred in a solvent such astetrahydrofuran or dioxane and lithium hydroxide may be added either as a solution in water or with some water. The reaction is carried out at ambient temperature for between 1 and 24 hours or unti I the reacti on i s compl ete. The reacti on i s then acidified with an acid such as hydrochloric acid and the solvent is removed under reduced pressure to give a compound of formula (13).

Step 3 - Preparation of a compound of formula (14)

The compounds of formula (14) may be prepared by amidation of the compounds of formula (13) by standard methods. A compound of formula (13) may be reacted with ammonium chloride in the presence of hydroxybenzotriazole (HOBt), a base such as triethylamineor diisopropyl ethyl amine, and N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide hydrochloride (EDC) in a solvent such asdimethylformamide. The reaction is carried out at a temperature between ambient temperature and 60°C for between 12 and 96 hours or unti I the reaction is complete. To extract the compound of formula (14), an organic solvent such as ethyl acetate may be added, followed by washi ng wi th water and bri ne. The organi c phase can be concentrated under reduced pressure to obtain the compound of formula (14). Alternatively, the compound of formula (14) may precipitate with the addition of water. The compound of formula (14) may be purified by any suitable methods known in the art such as chromatography on si I i ca gel , tri turati on, preci pi tati on or crystal I i zati on.

Step 4- Preparation of a compound of formula (15)

The compounds of formula (15) can be made by combining the compounds (14) and bis(neopentyl glycolato)di boron. A compound of formula (14) and bis(neopentyl glycol ato)di boron can be mixed in the presence of a catalyst such as [1,1'- bis(di phenyl phosphino)-ferrocene]dichloropalladium(ll) (complex with

di chl oromethane) and a base such as potassi urn acetate i n a sui tabl e sol vent such as dioxane. After further stirring at a temperature between 70 and 120°C for between 5 and 48 hours, the reaction mixture is allowed to cool to room temperature. If the compound of formula (15) precipitate upon cooling, the material can be recovered by filtration, washing with water and drying under vacuum. Alternatively, to extract the compound of formula (15), an organic solvent such as ethyl acetate may be added, followed by washi ng wi th water and bri ne. The organi c phase can be concentrated under reduced pressure to obtain the compound of formula (15). The compound of formula (15) may be purified by any suitable methods known in the art such as chromatography on silica gel, trituration, precipitation or crystallization.

Step 5 - Preparation of a compound of formula (5) from a compound of formula (15)

The compounds of formula (5) can be made by combining compounds (15) and (B). Compound (B) is commercially available or can be made by methods known i n the art. With respect to compound (B), X 6 , X 7 , R 30 and R 31 are as defined herein and Y 2 is Br or I . Compounds (15) and (B) can be mixed in the presence of a catalyst such

tetraki s(tri phenyl phosphi ne)pal I adi um(0) and a base such as potassi urn phosphate tri basic i n a suitable solvent such as a mixture of dioxane and water. After further stirring at a temperature between 70 and 110°C for between 1 and 24 hours, the reaction mixture is all owed to cool to room temperature. To extract the compound of formula (5), an organi c sol vent such as ethyl acetate may be added , f ol I owed by washi ng wi th water and bri ne. The organi c phase can be concentrated under reduced pressure to obtai n the compound of formula (5). The compound of formula (5) may be purified by any suitable methods known in the art such as chromatography on silica gel , preparative H PLC, trituration, precipitation or crystallization.

Preparation of the compounds of formula (4) according to Reaction Scheme 1

A. Preparation of methyl 3-amino-2-nitro-5-(pyridin-4-yl)benzoate Tetrakis(tri phenyl phosphi ne)pal I adium(O) (2.50 g, 2.17 mmol) was added to asolution of methyl 3-amino-5-chloro-2-nitrobenzoate (5.0 g, 21.7 mmol), pyridin-4-ylboronic acid (2.7 g, 21.7 mmol), and potassium phosphate tri basic (13.8 g, 65 mmol) in THF (200 ml.) and water (50 ml_). Nitrogen was bubbled for 10 minutes, the vessel was sealed, and the reaction mixture was stirred at 90 °C for 16 hours. Upon cooling, the reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried with magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography duting with 5 to 100% of (5% methanol in ethyl acetate) in hexaneto afford methyl 3-amino-2- nitro-5-(pyridin-4-yl)benzoate.

B. Preparation of methyl 3-amino-5-(2,3-difluoropyridin-4-yl)-2-nitrobenzoate.

Palladium(l l) acetate (0.49 g, 2.17 mmol) was added to asolution of methyl 3-amino-5- chloro-2-nitrobenzoate (10 g, 43.4 mmol), bis(neopen†yl glycol ato)di boron (19.6 g, 86.7 mmol), 1,3-bis(2,6-diisopropylphenyl)-1H-imidazol-3-ium chloride (1.8 g, 4.3 mmol), and potassium acetate (10.6 g, 108 mmol) in THF (400 ml_). Nitrogen was bubbled for 10 minutes, the flask was closed with a septum, and the reaction mixture was stirred at 50 °C for 72 hours. The reaction mixture was cooled to ambient temperature and the solid was filtered. The filtrate was dry loaded onto silica gel and purified by silica gel col umn chromatography el uti ng with 5 to 70% ethyl acetate i n hexane to afford methyl 3-ami no-5-(5,5-di methyl -1 ,3,2-di oxabori nan-2-yl )-2-ni trobenzoate. ES M S m/z = 263.2 (ArB(OH) 2 + Na) + .

Tetrakis(tri phenyl phosphi ne)pal I adium(O) (1.91 mg, 1.66 mmol) was added to a sol uti on of methyl 3-amino-5-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-2-nitrobenz oate (6.1 g, 19.9 mmol), 2,3-difluoro-4-iodopyri dine (4.0 g, 16.6 mmol), and potassium phosphate tri basic (10.6 g, 49.8 mmol) in dioxane (80 mL) and water (20 ml_). Nitrogen was bubbled for 10 minutes and the reaction mixture was stirred at 80° C for 10 hours. Upon cooling, the reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried with magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography eluting with 5 to 70% of (5% methanol in ethyl acetate) in hexaneto afford methyl 3- amino-5-(2,3-difluoropyridin-4-yl)-2-nitrobenzoate . ES/MSm/z= 310.2 (M+H) + .

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure:

methyl 3-amino-5-(3-fluoropyridin-4-yl)-2-nitrobenzoate methyl 3-ami no-5-(2-methyl pyri di n-4-yl )-2-ni trobenzoate methyl 3-ami no-5-(2,5-dif I uoropyri di n-4-yl )-2-ni trobenzoate methyl 3-ami no-5-(2-((di-tert-butoxycarbonyl )ami no)pyri di n-4-yl )-2-nitrobenzoate methyl 3-ami no-5-(2-((di-tert-butoxycarbonyl )amino)pyri midin-4-yl )-2-ni trobenzoate methyl 3-ami no-5-(2,6-bi s((di -tert-butoxycarbonyl )ami no)pyri midi n-4-yl )-2- ni trobenzoate methyl 3-ami no-5-(6-((di -tert-butoxycarbonyl )amino)pyri midin-4-yl )-2-ni trobenzoate methyl 3-ami no-2-ni tro-5-(9-(tetrahydro-2H-pyran-2-yl )-9H-puri n-6-yl )benzoate methyl 3-ami no-5-(2,5-dif I uoropyri di n-4-yl )-2-ni trobenzoate C. Preparation of methyl 3-((8-chloroquinolin-4-yl)amino)-5-(2,3-difluoropyridin-4-yl )- 2-nitrobenzoate.

To a solution of 4,8-dichloroquinoline (384 mg, 1.94 mmol) and methyl 3-ami no-5-(2,3- difl uoropyri din-4-yl)-2-ni trobenzoate (500 mg, 1.62 mmol) in toluene (8.0 ml_) was added XPhos (185 mg, 0.39 mmol), palladium acetate(29 mg, 0.13 mmol) and potassium phosphate tri basic (686 mg, 3.23 mmol). Nitrogen was bubbled for 5 min. The vessel was closed and the reaction mixture was stirred at 100 °C for overnight. Upon cooling, the reaction mixture was filtered. The filtrate was dry loaded onto silica gel and purified using silica gel chromatography eluting with 5 to 100% of (10% methanol in ethyl acetate) in hexane to afford methyl 3-((8-chl oroqui nol in-4-yl)amino)-5-(2,3- difluoropyridin-4-yl)-2-nitrobenzoate. ES MS/r z= 471.1 (M+H) + .

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure:

methyl 3-((8-chl oroqui nol i n-4-yl )ami no)-2-ni tro-5-(pyri di n-4-yl )benzoate methyl 3-((5,8-dif I uoroqui nol i n-4-yl )ami no)-2-ni tro-5-(pyri di n-4-yl )benzoate methyl 3-((5,8-di chl oroqui nol i n-4-yl )ami no)-2-ni tro-5-(pyri di n-4-yl )benzoate methyl 3-((5-f I uoroqui nol i n-4-yl )ami no)-2-nitro-5-(pyridi n-4-yl )benzoate methyl 3-((5-methyl qui nol i n-4-yl )ami no)-2-ni tro-5-(pyri di n-4-yl )benzoate methyl 3-((8-chl oro-2-methyl qui nol i n-4-yl )ami no)-2-ni tro-5-(pyri di n-4-yl )benzoate methyl 3-((2-methyl qui nol i n-4-yl )ami no)-2-ni tro-5-(pyri di n-4-yl )benzoate methyl 3-((8-chl oro-5-f I uoroqui nol i n-4-yl )ami no)-2-nitro-5-(pyri di n-4-yl )benzoate methyl 3-((8-chl oroqui nol i n-4-yl )ami no)-5-(3-f I uoropy ri di n-4-yl )-2-nitrobenzoate methyl 3-((8-chl oroqui nol i n-4-yl )ami no)-5-(2-methy I pyri di n-4-yl )-2-ni trobenzoate methyl 5-(2,5-dif I uoropyridi n-4-yl )-3-((5,8-dif I uoroqui nol i n-4-yl )ami no)-2- ni trobenzoate methyl 5-(2,3-dif I uoropyridi n-4-yl )-3-((5,8-dif I uoroqui nol i n-4-yl )ami no)-2- ni trobenzoate methyl 5-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-3-((5,8-dif I uoroqui nol i n-4- yl)amino)-2-nitrobenzoate methyl 5-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-3-((8-chl oroqui nol i n-4- yl )ami no)-2-nitrobenzoate methyl 5-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-3-((8-chl oro-5-f I uoroqui nol i n- 4-yl )ami no)-2-nitrobenzoate methyl 5-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-3-((7-f I uoroqui nol i n-4- yl )ami no)-2-nitrobenzoate methyl 5-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-3-((5-f I uoroqui nol i n-4- yl )ami no)-2-nitrobenzoate methyl 5-(2-((di-tert-butoxycarbonyl)amino)pyrimidin-4-yl)-3-((8-ch loroquinolin-4- yl )ami no)-2-nitrobenzoate methyl 5-(2,6-bi s((di -tert-butoxycarbonyl )ami no)pyri mi di n-4-yl )-3-((8-chl oroqui nol i n-4- yl )ami no)-2-nitrobenzoate methyl 5-(6-((di-tert-butoxycarbonyl)amino)pyrimidin-4-yl)-3-((8-ch loroquinolin-4- yl)amino)-2-nitrobenzoate methyl 3-((8-chl oroqui nol i n-4-yl )ami no)-2-nitro-5-(9-(tetrahydro-2H-pyran-2-yl )-9H- puri n-6-yl )benzoate methyl 5-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-3-((8-f I uoroqui nol i n-4- yl )ami no)-2-nitrobenzoate methyl 5-(2,3-dif I uoropyridi n-4-yl )-3-((5,8-dif I uoroqui nol i n-4-yl )ami no)-2- nitrobenzoate methyl 3-((8-chloro-5-f I uoroqui nol i n-4-yl )ami no)-5-(2,3-dif I uoropyridi n-4-yl )-2- nitrobenzoate methyl 5-(2,3-dif I uoropyridi n-4-yl )-3-((5,8-dif I uoroqui nol i n-4-yl )ami no)-2- nitrobenzoate methyl 5-(2,5-dif I uoropyridi n-4-yl )-3-((5,8-dif I uoroqui nol i n-4-yl )ami no)-2- nitrobenzoate methyl 5-(2,3-dif I uoropyridi n-4-yl )-3-((8-f I uoroqui nol i n-4-yl )ami no)-2-ni trobenzoate methyl 3-((8-chl oro-3-methyl qui nol i n-4-yl )ami no)-5-(2,3-di f I uoropyri di n-4-y I )-2- nitrobenzoate methyl 3-((3-chloro-8-f I uoroqui nol i n-4-yl )ami no)-5-(2,3-dif I uoropyridi n-4-yl )-2- nitrobenzoate methyl 5-(2,3-dif I uoropyridi n-4-yl )-3-((5-f I uoroqui nol i n-4-yl )ami no)-2-ni trobenzoate methyl 3-((5-chloro-8-f I uoroqui nol i n-4-yl )ami no)-5-(2,3-dif I uoropyridi n-4-yl )-2- ni trobenzoate

D . Preparati on of a methyl 1 -(8-chl oroqui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-yl )-2- methyl - 1 H -benzo[d] i mi dazol e-4-carboxyl ate.

Acetaldehyde (0.15 ml_, 2.74 mmol) was added to a solution of methyl 3-((8- chl oroqui nol in-4-yl)amino)-5-(2,3-difl uoropyri din-4-yl )-2-ni trobenzoate (215 mg, 0.46 mmol) and sodium dithionite (281 mg, 1.37 mmol) in ethanol (2.5 ml_) and DMSO (2.5 ml_). The reaction vessel was dosed and the reaction mixture was stirred at 80 °C for overnight. Upon cooling, the reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried with magnesium sulfate, filtered, and concentrated under reduced pressure to afford methyl 1 -(8-chl oroqui nol i n-4-yl )-6- (2,3-dif I uoropyri di n-4-yl )-2-methyl -1 H -benzo[d] i mi dazol e-4-carboxyl ate. ES M S m/z = 465.2 (M+H) + .

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure:

methyl 1 -(8-chl oroqui nol i n-4-yl )-6-(py ri di n-4-yl )- 1 H-benzo[d] i mi dazol e-4-carboxyl ate methyl 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl-6-(pyri di n-4-yl )-1 H-benzo[d] i mi dazol e-4- carboxylate methyl 1 -(5,8-di chl oroqui nol i n-4-yl )-2-methyl -6-(pyridi n-4-yl )-1 H-benzo[d] i mi dazol e- 4-carboxylate methyl 1 -(5-f I uoroqui nol i n-4-yl )-2-methyl -6-(pyri di n-4-yl )- 1 H -benzo[d] i mi dazol e-4- carboxylate methyl 2-methyl - 1 -(5-methy I qui nol i n-4-yl )-6-(pyri di n-4-yl )- 1 H -benzo[d] i mi dazol e-4- carboxylate methyl 1 -(8-chl oro-2-methyl qui nol i n-4-yl )-2-methyl -6-(pyridi n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 2-methyl - 1 -(2-methyl qui nol i n-4-yl )-6-(pyri di n-4-yl )- 1 H -benzo[d] i mi dazol e-4- carboxylate methyl 1 -(8-chl oroqui nol i n-4-yl )-2-(oxetan-3-yl )-6-(pyri di n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2-methyl-6-(pyridi n-4-yl )-1 H- benzo[d]i mi dazol e-4-carboxyl ate methyl 1 -(8-chl oroqui nol i n-4-y I )-2-methyl -6-(pyri di n-4-y I )- 1 H -benzo[d] i mi dazol e-4- carboxylate methyl 1 -(8-chl oroqui nol i n-4-yl )-6-(3-f I uoropyri di n-4-yl )-2-methyl- 1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 1 -(8-chl oroqui nol i n-4-yl )-2-methyl -6-(2-methyl pyri di n-4-yl )- 1 H - benzo[ d] i m i dazol e-4-carboxy I ate methyl 6-(2,5-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methy I - 1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 6-(2,3-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methy I - 1 H- benzo[d]i mi dazol e-4-carboxyl ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(5,8-di f I uoroqui nol i n-4-yl )- 2-methyl -1 H-benzo[d] i mi dazol e-4-carboxylate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(8-chl oroqui nol i n-4-yl )-2- methyl - 1 H -benzo[d] i mi dazol e-4-carboxyl ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(8-chl oro-5-f I uoroqui nol i n- 4-yl )-2-methyl-1 H-benzo[d]i mi dazol e-4-carboxyl ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-2-ethyl -1 -(7-f I uoroqui nol i n-4- y I )- 1 H - benzo[ d] i mi dazol e-4-carbox I ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(7-f I uoroqui nol i n-4-yl )-2- methyl - 1 H -benzo[d] i mi dazol e-4-carboxyl ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-2-ethyl -1 -(5-f I uoroqui nol i n-4- y I )- 1 H - benzo[ d] i mi dazol e-4-carboxy I ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(5-f I uoroqui nol i n-4-yl )-2- methyl - 1 H -benzo[d] i mi dazol e-4-carboxyl ate methyl 6-(2-((di-tert-butoxycarbonyl)amino)pyrimidin-4-yl)-1-(8-chl oroquinolin-4-yl)-2- methyl - 1 H -benzo[d] i mi dazol e-4-carboxyl ate methyl 6-(2,6-bi s((di -tert-butoxycarbonyl )ami no)pyri mi di n-4-yl )- 1 -(8-chl oroqui nol i n-4- yl )-2-methyl -1 H-benzo[d] i mi dazol e-4-carboxyl ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(8-chl oroqui nol i n-4-yl )-2- methyl - 1 H -benzo[d] i mi dazol e-4-carboxyl ate methyl 1 -(8-chl oroqui nol i n-4-yl )-2-methyl -6-(9-(tetrahydro-2H-pyran-2-yl )-9H-puri n-6- y I )- 1 H - benzo[ d] i mi dazol e-4-carboxy I ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no) py ri di n-4-yl )-2-cycl opropyl - 1 -(8- f I uoroqui nol i n-4-yl )-1 H-benzo[d] i midazole-4-carboxylate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(8-f I uoroqui nol i n-4-yl )-2- methyl-1 H-benzo[d]imidazole-4-carboxylate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(8-chl oro-5-f I uoroqui nol i n- 4-yl )-2-cycl opropyl -1 H-benzo[d] i mi dazol e-4-carboxylate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(8-chl oro-5-f I uoroqui nol i n- 4-yl )-2-propyl -1 H-benzo[d] i midazol e-4-carboxyl ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(8-chl oro-5-f I uoroqui nol i n- 4-yl )-2-i sopropy I - 1 H-benzo[ d] i mi dazol e-4-carboxy I ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(8-chl oro-5-f I uoroqui nol i n- 4-yl )-2-(oxetan-3-yl )- 1 H -benzo[d] i mi dazol e-4-carboxyl ate methyl 6-(2-((di-tert-butoxycarbonyl)amino)pyridin-4-yl)-2-cyclopro pyl-1-(5,8- dif I uoroqui nol i n-4-yl )-1 H-benzo[d] i mi dazole-4-carboxyl ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(5,8-di f I uoroqui nol i n-4-yl )- 2-ethyl-1 H-benzo[d] i mi dazol e-4-carboxyl ate methyl 6-(2-((di -tert-butoxycarbonyl )amino)pyri di n-4-yl )-2-(cyclopropyl methyl )-1 -(5,8- dif I uoroqui nol i n-4-yl )-1 H-benzo[d] i mi dazole-4-carboxyl ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(5,8-di f I uoroqui nol i n-4-yl )- 2-propyl-1 H-benzo[d] i mi dazol e-4-carboxyl ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(8-chl oroqui nol i n-4-yl )-2- (cycl opropyl methyl )-1 H-benzo[d] i mi dazol e-4-carboxyl ate methyl 6-(2-((di -tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(8-chl oroqui nol i n-4-yl )-2- cycl opropyl - 1 H -benzo[ d] i mi dazol e-4-carboxyl ate methyl 6-(2,3-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-propyl - 1 H - benzo[ d] i m i dazol e-4-carboxy I ate methyl 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2-cycl opropyl -6-(2,3-dif I uoropyri di n-4-yl )- 1 H-benzo[d] i midazol e-4-carboxyl ate methyl 6-(2,3-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methy I - 1 H- benzo[d]i mi dazol e-4-carboxyl ate methyl 6-(2,5-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methy I - 1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 1 -(8-chl oroqui nol i n-4-yl )-2-cycl opropyl -6-(2,3-dif I uoropyri di n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 2-cycl opropyl -6-(2,3-di f I uoropyri di n-4-yl )- 1 -(5,8-di f I uoroqui nol i n-4-yl )- 1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-6-(2,3-dif I uoropyridi n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-6-(2,3-dif I uoropyri di n-4-yl )-2-propyl -1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 6-(2,3-dif I uoropyridi n-4-yl )-1-(8-f I uoroqui nol i n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 6-(2,3-dif I uoropyridi n-4-yl )-1-(8-f I uoroqui nol i n-4-yl )-2-propyl-1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 2-cycl opropyl -6-(2,3-di f I uoropyri di n-4-yl )- 1 -(8-f I uoroqui nol i n-4-yl )- 1 H- benzo[d]i mi dazol e-4-carboxyl ate methyl 1 -(8-chl oro-3-methyl qui nol i n-4-yl )-6-(2,3-dif I uoropyridi n-4-yl )-2-methyl-1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 1 -(3-chl oro-8-f I uoroqui nol i n-4-yl )-6-(2,3-dif I uoropyridi n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 6-(2,3-dif I uoropyridi n-4-yl )-1-(5-f I uoroqui nol i n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 6-(2,3-dif I uoropyridi n-4-yl )-2-ethyl -1-(5-f I uoroqui nol i n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I ate methyl 6-(2,3-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-ethyl - 1 H- benzo[d]i mi dazol e-4-carboxyl ate methyl 2-(cycl opropyl methyl )-6-(2,3-dif I uoropyri di n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )- 1 H-benzo[d] i midazol e-4-carboxyl ate methyl 1 -(5-chl oro-8-f I uoroqui nol i n-4-yl )-6-(2,3-dif I uoropyridi n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I ate E. Preparation of 1-(8-chloroquinolin-4-yl)-6-(2,3-difluoropyridin-4-yl)-2-met hyl-1H- benzo[ d] i m i dazol e-4-carboxy I i c aci d .

Aqueous IM lithium hydroxide (1.0 mL) was added to asolution of methyl 1-(8- chloroquinol in-4-yl )-6-{2,3-dif I uoropyridi n-4-yl)-2-methyl-1 H-benzo[d] i mi dazol e-4- carboxylate (206 mg, 0.44 mmol) in THF (4 mL). The reaction was stirred at ambient temperature for 1 hour. The reaction mixture was acidified with 4N HCI in dioxane. The resulting solution was concentrated to afford 1 -(8-chloroqui nol in-4-yl)-6-(2,3- dif I uoropyridi n-4-yl)-2-methyl-1 H-benzo[d]imidazole-4-carboxylic acid which was used without further purification for the next step. ES/MS /TVZ451.10 (M+H) + .

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure:

1 -{8-chloroqui nol i n-4-yl )-6-(pyri di n-4-yl )-1 H-benzo[d] i mi dazol e-4-carboxyl i c aci d

1-(5,8-difl uoroqui nolin-4-yl)-2-methyl-6-(pyridin-4-yl)-1H-benzo[d]imidazole-4 - carboxylic acid

1- {5,8-di chloroqui nol i n-4-yl )-2-methyl-6-(pyridi n-4-yl )-1 H-benzo[d] i mi dazol e-4- carboxylic acid 1 -{5-f I uoroqui nol i n-4-yl )-2-methyl -6-(py ri di n-4-yl )- 1 H-benzo[d] i mi dazol e-4-carboxyl i c acid

2- methyl -1-(5-methylqui nol i n-4-yl )-6-(pyri di n-4-yl )-1 H-benzo[d] i mi dazol e-4-carboxyl ic acid

1 -{8-chloro-2-methyl qui nol i n-4-yl )-2-methyl -6-(pyri di n-4-yl )-1 H-benzo[d] i midazol e-4- carboxylic acid

2-methyl -1-(2-methyl qui nol i n-4-yl )-6-(pyri di n-4-yl )-1 H-benzo[d] i mi dazol e-4-carboxyl ic acid

1 -{8-chloroqui nol i n-4-yl )-2-(oxetan-3-yl )-6-(pyridi n-4-yl )-1 H-benzo[d] i midazol e-4- carboxylic acid 1 -{8-chloro-5-f I uoroqui nol i n-4-yl )-2-methyl -6-(pyri di n-4-yl )- 1 H-benzo[d] i mi dazol e-4- carboxylic acid

1 -{8-chl oroqui nol i n-4-yl )-6-(3-f I uoropyri di n-4-yl )-2-methyl - 1 H-benzo[d] i mi dazol e-4- carboxylic acid 1 -{8-chl oroqui nol i n-4-yl )-2-methyl -6-(2-methy I py ri di n-4-yl )- 1 H -benzo[d] i mi dazol e-4- carboxylic acid

6-{2,5-dif I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

6-{2, 3-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl - 1 H - benzo[ d] i m i dazol e-4-carboxy I i c aci d

6-{2-((tert-butoxycarbonyl )ami no)pyri di n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl- 1 H-benzo[d] i mi dazol e-4-carboxy I i c aci d

6-{2-((tert-butoxycarbonyl )ami no)pyri di n-4-yl )- 1 -(8-chl oroqui nol i n-4-yl )-2- methyl - 1 H - benzo[ d] i m i dazol e-4-carboxy I i c aci d 6-{2-((tert-butoxycarbonyl )ami no)pyri di n-4-yl )- 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2- methyl-1 H-benzo[d]imidazole-4-carboxyl ic acid

6-{2-((tert-butoxycarbonyl )ami no)pyri di n-4-yl )-2-ethyl -1 -(7-f I uoroqui nol i n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

6-{2-((tert-butoxycarbonyl )ami no)pyridi n-4-yl )-1-(7-f I uoroqui nol i n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

6-{2-((tert-butoxycarbonyl )ami no)pyri di n-4-yl )-2-ethyl -1 -(5-f I uoroqui nol i n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

6-{2-((tert-butoxycarbonyl )ami no)pyridi n-4-yl )-1-(5-f I uoroqui nol i n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d 6-{2,6-bi s((tert-butoxycarbonyl )ami no)pyri midi n-4-yl )-1 -(8-chl oroqui nol i n-4-yl )-2- methyl-1 H-benzo[d]imidazole-4-carboxyl ic acid 6-{6-((tert-butoxycarbonyl )ami no)pyri mi di n-4-yl )- 1 -(8-chl oroqui nol i n-4-yl )-2-methyl - 1 H-benzo[d] i mi dazol e-4-carboxy I i c aci d

6-{2-((tert-butoxycarbonyl )ami no)pyri di n-4-yl )-2-cycl opropyl - 1 -(8-f I uoroqui nol i n-4-yl )- 1 H-benzo[d] i mi dazol e-4-carboxy I i c aci d 6-{2-((tert-butoxycarbonyl )ami no)pyridi n-4-yl )-1-(8-f I uoroqui nol i n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

6-{2-((tert-butoxycarbonyl )ami no)py ri di n-4-yl )- 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2- cycl opropyl - 1 H -benzo[ d] i mi dazol e-4-carboxyl i c aci d

6-{2-((tert-butoxycarbonyl )ami no)py ri di n-4-yl )- 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2- propyl - 1 H-benzo[d] i mi dazol e-4-carboxyl i c aci d

6-(2-((tert-butoxycarbonyl )ami no)py ri di n-4-yl )- 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2- i sopropy I - 1 H - benzo[ d] i mi dazol e-4-carboxy I i c aci d

6-(2-((tert-butoxycarbonyl )ami no)pyri di n-4-yl )- 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2- (oxetan-3-yl )- 1 H-benzo[ d] i mi dazol e-4-carboxyl i c aci d 6-(2-((tert-butoxycarbonyl )ami no)pyri di n-4-yl )-2-cycl opropyl -1 -(5,8-dif I uoroqui nol i n-4- y I )- 1 H - benzo[ d] i mi dazol e-4-carboxy I i c aci d

6-(2-((tert-butoxycarbonyl )ami no)pyri di n-4-yl )- 1 -(5,8-di f I uoroqui nol i n-4-yl )-2-ethyl - 1 H-benzo[d] i mi dazol e-4-carboxy I i c aci d

6-(2-((tert-butoxycarbonyl )ami no)pyri di n-4-yl )-2-(cycl opropyl methyl )-1 -(5,8- difluoroquinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid

6-(2-((tert-butoxycarbonyl )ami no)pyridi n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-2-propyl- 1 H-benzo[d] i mi dazol e-4-carboxy I i c aci d

6-(2-((tert-butoxycarbonyl )ami no)py ri di n-4-yl )- 1 -(8-chl oroqui nol i n-4-yl )-2- (cycl opropyl methyl )-1 H-benzo[d] i mi dazol e-4-carboxyl i c aci d 6-(2-((tert-butoxycarbonyl )ami no)py ri di n-4-yl )- 1 -(8-chl oroqui nol i n-4-yl )-2-cycl opropyl - 1 H-benzo[d] i mi dazol e-4-carboxy I i c aci d 6-{2,3-dif I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-propyl -1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 -{8-chl oro-5-f I uoroqui nol i n-4-yl )-2-cycl opropy I -6-(2,3-di f I uoropyri di n-4-y I )- 1 H - benzo[ d] i m i dazol e-4-carboxy I i c aci d 6-{2,3-dif I uoropyri di n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-2- methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

6-{2,5-dif I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 -(8-chl oroqui nol i n-4-yl )-2-cycl opropyl -6-(2,3-di f I uoropyri di n-4-yl )- 1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 -(8-chl oroqui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-y I )-2-methy I - 1 H -benzo[d] i mi dazol e- 4-carboxylic acid

2-cycl opropyl -6-(2,3-di f I uoropyri di n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-yl )-2-methyl - 1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 - (8-chl oro-5-f I uoroqui nol i n-4-yl )-6-(2,3-dif I uoropyri di n-4-yl )-2-propyl -1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

6-(2, 3-di f I uoropyri di n-4-yl )- 1 -(8-f I uoroqui nol i n-4-yl )-2-methyl - 1 H-benzo[ d] i mi dazol e- 4-carboxylic acid

6-(2, 3-di f I uoropyri di n-4-yl )- 1 -(8-f I uoroqui nol i n-4-yl )-2-propyl -1 H-benzo[d] i mi dazol e- 4-carboxylic acid

2- cycl opropyl -6-(2,3-di f I uoropyri di n-4-yl )-1 -(8-f I uoroqui nol i n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d 6-(2, 3-di f I uoropyri di n-4-yl )- 1 -(5-f I uoroqui nol i n-4-yl )-2-methyl - 1 H-benzo[ d] i mi dazol e- 4-carboxylic acid 1 -{8-chl oro-3-methyl qui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-yl )-2-methyl - 1 H - benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 -{3-chl oro-8-f I uoroqui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-yl )-2-methyl - 1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d 6-{2, 3-di f I uoropyri di n-4-yl )-2-ethyl - 1 -(5-f I uoroqui nol i n-4-yl )- 1 H-benzo[d] i mi dazol e-4- carboxylic acid

6-(2,3-dif I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-ethyl-1H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

2-{cyclopropyl methyl )-6-(2,3-dif I uoropyri di n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 -{5-chl oro-8-f I uoroqui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-yl )-2-methyl - 1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

F. Preparation of 6-(2-aminopyrimidin-4-yl)-1-(8-chloroquinolin-4-yl)-2-methyl -1H- benzo[d]imidazole-4-carboxamide.

6-(2-((tert-butoxycarbonyl )ami no)pyri mi di n-4-yl )- 1 -(8-chl oroqui nol i n-4-yl )-2-methyl - 1H-benzo[d]imidazole-4-carboxylic acid (17 mg, 0.032 mmol) was dissolved in dichloromethane (1.0 ml.) and trifluoroacetic acid (50 pL, 0.64 mmol) was added. The reaction mixture was stirred at ambient temperature for 1 hour, after which the reaction was concentrated under reduced pressure. The resultant was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 6-(2-aminopyridimin-4-yl)-1-(8-chloroquinolin-4- yl)-2-methyl-1H-benzo[d]imidazole-4-carboxamideasa 2,2,2-trifluoroacetic acid salt (Example 2).

G. Preparation of 6-(2-amino-3-fluoropyridin-4-yl)-1-(5,8-difluoroquinolin-4-y l)-2- methyl-1 H-benzo[d]imidazole-4-carboxyl ic.

Ammonium hydroxide (28-30% solution in water, 0.75 mL) was added to asolution of crude 6-(2,3-difluoropyridin-4-yl)-1-(5,8-difluoroquinolin-4-yl)-2 -methyl-1H- benzo[d] i mi dazol e-4-carboxylic acid (0.17 mmol) in DMSO (2.0 mL). The reaction vessel was sealed and the reaction mixture was stirred at 100 °C overnight. The excess ammonia was removed under reduced pressure and the resulting solution was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 6-(2-amino-3-fluoropyridin- 4-yl )-1-(5,8-dif I uoroquinoli n-4-yl)-2-methyl-1 H-benzo[d] i midazole-4-carboxylic acid as a2,2,2-trifluoroacetic acid salt (Example 4).

Preparation of the compounds of formula (4) according to Reaction Scheme 2 A. Preparation of tert-butyl 4-(4-chloroquinolin-2-yl)piperazine-1-carboxylate

A suspension of 2,4-dichloroquinoline (6.4 g, 32.2 mmol), tert-butyl piperazine-1- carboxylate (5.0 g, 26.8 mmol) and di ethyl isopropy I amine (6.5 ml_, 38.0 mmol) was stirred in a sealed at 100 °C for 2 days. Upon cooling, the reaction mixture was concentrated in vacuuo to afford material which was purified by column chromatography on Si 02 eluting with EtOAc in hexanes (0-15%) to afford tert-butyl 4-(4-chloroquinolin- 2-yl)piperazine-1-carboxylate (3.2 g, 34%). ES/MS m/z = 348.1 (M+H)+.

B. Preparation of 4-chloro-2-(1-trityl-1H-pyrazol-4-yl)quinoline

A sealed tubewascharged with 2,4-dichloroquinoline (1.0 g, 5.05 mmol), 4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-1H-pyrazole (2.2 g, 5.05 mmol), K 3 P0 4 (3.2 g, 15.1 mmol) and Pd(PPh 3 ) 4 (0.58 g, 0.50 mmol) followed by dioxane (50 mL) and water (12 mL). The reaction mixture was stirred at 90 °C for 3 h. Upon cooling, the reaction mixture was absorbed on Si02 followed by purification on column chromatography on Si 02 eluting with EtOAc in hexanes (0-100%) to afford 4-chloro-2- ( 1 -tri tyl - 1 H -py razol -4-yl )qui nol i ne ( 1.15 g, 48%). ES/MS m/z = 472.2 (M+H)+.

C. Preparation of ethyl 3-((5,8-difluoroquinolin-4-yl)amino)-2-nitrobenzoate.

To a cooled solution of 4-chloro-5,8-difluoroquinoline (171 g, 859.3 mmol) in DMF (1.7 L) were added ethyl 3-amino-2-nitrobenzoate (181.5 g, 859.3 mmol) and CS2CO3 (614.4 g, 1890 mmol). The reaction mixture was stirred at 90 °C for 18 hours. The reaction mixture was cooled down and filtered through a pad of Celite. The filtrate was partitioned between ethyl acetate and water. The organi c phase was washed with bri ne, dried with sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography eluting with 30% ethyl acetate in petroleum ether to afford ethyl 3-((5,8-difluoroquinolin-4-yl)amino)-2- nitrobenzoate. ES/MS m/z= 374.4 (M+H) + .

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure:

ethyl 3-((5,8-dichloroquinolin-4-yl)amino)-2-nitrobenzoate

ethyl 3-((5-chl oroqui nol i n-4-yl )ami no)-2-ni trobenzoate

ethyl 3-((5-chl oro-8-f I uoroqui nol i n-4-y I )ami no)-2-ni trobenzoate

D. Preparation of ethyl 3-((8-chloroquinolin-4-yl)amino)-2-nitrobenzoate.

Palladium (I I) acetate (103 mg, 0.46 mmol ) was added to a mixture of ethyl 3-amino-2- nitrobenzoate (1.2 g, 5.7 mmol), 4,8-dichl oroqui nol ine (1.24 g, 6.3 mmol),

dicyclohexyl(2',4 , ,6 , -triisopropyl-[1 , 1'-bi phenyl ]-2-yl)phosphine (653 mg, 1.37 mmol), and potassium phosphate (2.42 g, 11.4 mmol) in toluene (23 ml_). The resultant was degassed and stirred at 90 °C for 16 hours. The reaction mixture was cooled to room temperature and dry loaded onto silica gel and purified eluting with 0 to 100% ethyl acetate in hexanesto afford the title compound as a brown solid. ESIMSm/z= 372.1 (M+H) + .Thefollowing compounds were prepared using a similar procedure: ethyl 3-((5,7-dif I uoroqui nol i n-4-yl )ami no)-2-ni trobenzoate

ethyl 3-((8-f I uoroqui nol i n-4-yl )ami no)-2-ni trobenzoate

ethyl 3-((8-chl oroqui nol i n-4-yl )ami no)-2-ni trobenzoate

ethyl 3-((5-f I uoroqui nol i n-4-yl )ami no)-2-ni trobenzoate

ethyl 3-((8-chl oro-5-f I uoroqui nol i n-4-y I )ami no)-2-ni trobenzoate

tert-butyl 4-(4-((3-(ethoxycarbonyl )-2-nitrophenyl )ami no)qui nol i n-2-yl )pi perazi ne-1 - carboxylate

ethyl 2-nitro-3-((2-(1-trityl-1 H-pyrazol-4-yl)quinolin-4-yl)amino)benzoate tert-butyl 4-(4-((2-ni trophenyl )ami no)qui nol i n-2-yl )pi perazi ne-1 -carboxyl ate E. Preparation of a compound of formula (7) in which n=2, (R 1 ) n = 5,8-difluoro

To a solution of ethyl 3-((5,8-difl uoroqui nol in-4-yl)amino)-2-nitrobenzoate (158 g, 423.49 mmol) in AcOH (1.3 L) and MeOH (320 mL) at 0 °C, Zn-dust (166.1 g, 2541 mmol) was slowly added and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was filtered through a pad of Cel ite and evaporated under reduced pressure. The resulting residue was suspended in DCM and washed with an aqueous saturated solution of NaHC03 foil owed brine. The organic layer was dried over anhydrous Na2S0 4 and concentrated under reduced pressure to give ethyl 2-ami no-3- ((5,8-difl uoroqui nol i n-4-yl )ami no)benzoate. ESIMS nVz= 344.0 (M+H) + . Thefollowing compounds were prepared using asimilar procedure:

ethyl 2-ami no-3-((5,7-dif I uoroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-3-((5,8-di chl oroqui nol i n-4-y I )ami no)benzoate ethyl 2-ami no-3-((5-chl oro-8-f I uoroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-3-((5-chl oroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-3-((8-f I uoroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-3-((8-chl oroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-3-((5-f I uoroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-3-((8-chl oro-5-f I uoroqui nol i n-4-yl )ami no)benzoate tert-butyl 4-(4-((2-ami no-3-(ethoxycarbonyl)phenyl)amino)quinol in-2-yl)piperazine-1- carboxylate ethyl 2-ami no-3-((2-( 1 -tri ty I - 1 H-pyrazol-4-yl)qui nol in-4-yl )amino)benzoate tert-butyl 4-(4-((2-ami nophenyl )ami no)qui nol i n-2-yl )pi perazi ne-1 -carboxylate F. Preparation of ethyl 2-ami no-5-bromo-3-((5,8-difl uoroqui nol in-4-yl)amino)benzoate.

To a stirred solution of ethyl 2-amino-3-((5,8-difluoroquinolin-4-yl)amino)benzoate (135 g, 393 mmol) in DCM (2.7 L) at 0°C, bromine (30.4 imL, 1180 mmol ) was added and the mixture was stirred at 0°C for 1 hour. The reaction mixture was quenched with aqueous Na 2 S 2 O 3 , diluted with DCM and washed with an aqueous saturated solution of NaHC0 3 followed by brine. The organic layer was dried over anhydrous Na 2 S0 4 and concentrated under reduced pressure to give ethyl 2-ami no-5-bromo-3-((5,8-dif I uoroqui noli n-4- yl)amino)benzoate. ES/MS m/z= 422.0 (M +H) + .

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure:

ethyl 2-ami no-5-bromo-3-((5,7-dif I uoroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-5-bromo-3-((5,8-di chl oroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-5-bromo-3-((5-chl oro-8-f I uoroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-5-bromo-3-((5-chl oroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-5-bromo-3-((8-f I uoroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-5-bromo-3-((8-chl oroqui nol in-4-yl)amino)benzoate ethyl 2-ami no-5-bromo-3-((5-f I uoroqui nol i n-4-yl )ami no)benzoate ethyl 2-ami no-5-bromo-3-((8-chl oro-5-f I uoroqui nol i n-4-yl )ami no)benzoatetert-butyl 4- (4-((2-ami no-5-bromo-3-(ethoxycarbonyl )phenyl )ami no)qui nol i n-2-yl )pi perazi ne-1 - carboxylateethyl 2-amino-5-bromo-3-((2-(1-trityl-1H-pyrazol-4-yl)quinolin-4- yl)amino)benzoate tert-butyl 4-(4-((2-ami no-5-bromophenyl )ami no)qui nol i n-2-yl )pi perazi ne- 1 -carboxyl ate

G. Preparation of ethyl 6-bromo-1-(5,8-difluoroquinolin-4-yl)-2-methyl-1 H- benzo[ d] i m i dazol e-4-carboxy I ate.

A solution of ethyl 2-amino-5-bromo-3-((5,8-difluoroquinolin-4-yl)amino)benzoate (103 g, 244 mmol) in Ac 2 0 (515 mL) and AcOH (1 L) was ref I uxed f or 18 hours. The reaction mixture was concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with an aqueous saturated solution of NaHC0 3 foil owed by bri ne. The organi c I ayer was dri ed over anhydrous Na 2 S 2 O 4 and concentrated under reduced pressure. The crude compound was tri turated with petrol eum ether to gi ve ethyl 6-bromo-1 -(5,8-di f I uoroqui nol i n-4-yl )-2-methyl - 1 H-benzo[d] i mi dazol e-4-carboxyl ate. ES/MS /r/z= 446.2 (M+H) + .

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure: ethyl 6-bromo-1-(5,7-dif I uoroqui nol i n-4-yl )-2-methyl-1 H-benzo[d] i mi dazol e-4- carboxylate ethyl 6-bromo- 1 -(5,8-di chl oroqui nol i n-4-yl )-2-methyl - 1 H -benzo[d] i mi dazol e-4- carboxylate ethyl 6-bromo- 1 -(5-chl oro-8-f I uoroqui nol i n-4-yl )-2-methyl - 1 H -benzo[d] i mi dazol e-4- carboxylate ethyl 6-bromo- 1 -(5-chl oroqui nol i n-4-yl )-2-methyl - 1 H-benzo[d] i mi dazol e-4-carboxyl ate ethyl 6-bromo- 1 -(8-f I uoroqui nol i n-4-yl )-2-methyl - 1 H -benzo[d] i mi dazol e-4-carboxyl ate ethyl 6-bromo- 1 -(8-chl oroqui nol i n-4-yl )-2-methyl - 1 H-benzo[d] i mi dazol e-4-carboxyl ate ethyl 6-bromo- 1 -(5-f I uoroqui nol i n-4-yl )-2-methyl - 1 H -benzo[d] i mi dazol e-4-carboxyl ate ethyl 6-bromo- 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2-methyl - 1 H -benzo[d] i mi dazol e-4- carboxylateH. Preparation of ethyl 6-bromo-1-(2-(4-(tert-butoxycarbonyl)piperazin-1- yl )qui nol i n-4-yl )-1 H-benzo[d] i mi dazol e-4-carboxylate.

A solution tert-butyl 4-(4-((2-amino-5-bromo-3-(ethoxycarbonyl)phenyl)amino)quinol in- 2-yl)piperazine-1-carboxylate (2.29 g, 4.0 mmol) in tri methyl orthof ormate (30 mL) was ref I uxed for 30 mi nutes. The reaction mixture was cooled to room temperature and dry loaded onto silica gel and purified eluting with 0 to 100% ethyl acetate in hexanesto afford the title compound as a brown solid. ES MSrjVz= 580.1 (M+H) + .

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure:

ethyl 6-bromo- 1 -(2-( 1 -tri tyl - 1 H-pyrazol -4-yl )qui nol i n-4-yl )- 1 H-benzo[d] i mi dazol e-4- carboxylate tert-butyl 4-(4-(6-bromo- 1 H-benzo[d] i mi dazol -1 -yl )qui nol i n-2-yl )pi perazi ne- 1 - carboxylate I . Preparation of ethyl 1-(5,8-difluoroquinolin-4-yl)-6-(5,5-dimethyl-1 ,3,2-dioxaborinan- 2-yl )-2-methyl-1 H-benzo[d]i midazole-4-carboxylate.

[ 1 , 1 '-B i s(di phenyl phosphi no)f errocene] di chl oropal I adi um( 11 ) compl ex wi th

di chl oromethane (2.74 g, 3.36 mmol) was added to a solution of ethyl 6-bromo-1-(5,8- di f I uoroqui nol i n-4-yl )-2-methyl - 1 H-benzo[ d] i mi dazol e-4-carboxyl ate ( 10 g, 22.4 mmol ), bis(neopentyl glycolato)di boron (7.6 g, 33.6 mmol) and potassium acetate (5.5 g, 56.0 mmol) in dioxane (100 ml_). Nitrogen was bubbled for 10 minutes and the reaction mixture was stirred at refluxing temperature for 24 hours. The reaction mixture was cooled to ambient temperature and the sol id was filtered. The f i Itrate was dry loaded onto silica gel and purified by silica gel column chromatography eluting with 25 to 100% ethyl acetate in hexane to afford ethyl 1 -(5,8-dif I uoroqui noli n-4-yl)-6-(5,5-dimethyl- 1 ,3,2-di oxabori nan-2-yl )-2-methyl - 1 H-benzo[d] i mi dazol e-4-carboxyl ate. ES/M S rrVz = 412.2 (ArB(OH) 2 + H) + . Thefollowing compounds were prepared using a similar procedure:

ethyl 1 -(5,7-dif I uoroqui nol i n-4-yl )-6-(5,5-di methyl -1 ,3,2-di oxabori nan-2-yl )-2-methyl- 1 H-benzo[d] i midazol e-4-carboxyl ate ethyl 1 -(5,8-di chl oroqui nol i n-4-yl )-6-(5,5-di methyl -1 ,3,2-di oxabori nan-2-yl )-2-methyl- 1 H-benzo[d] i midazol e-4-carboxyl ate ethyl 1 -(5-chl oro-8-f I uoroqui nol i n-4-yl )-6-(5,5-di methyl - 1 ,3,2-di oxabori nan-2-yl )-2- methyl - 1 H -benzo[d] i mi dazol e-4-carboxyl ate ethyl 1-(5-chloroquinolin-4-yl)-6-(5,5-dimethyl-1,3,2-dioxaborinan -2-yl)-2-methyl-1H- benzo[ d] i m i dazol e-4-carboxy I ate ethyl 6-(5,5-di methyl -1 ,3,2-di oxabori nan-2-yl )-1-(8-f I uoroqui nol i n-4-yl )-2-methyl-1 H- benzo[d]i mi dazol e-4-carboxyl ate ethyl 1-(8-chloroquinolin-4-yl)-6-(5,5-di methyl -1,3,2-dioxaborinan-2-yl)-2-methyl-1H- benzo[ d] i m i dazol e-4-carboxy I ate ethyl 6-(5,5-di methyl -1 ,3,2-dioxabori nan-2-yl )-1-{5-f I uoroqui nol i n-4-yl )-2-methyl-1 H- benzo[ d] i m i dazol e-4-carboxy I ate ethyl 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-6-(5,5-di methyl - 1 ,3,2-di oxabori nan-2-yl )-2- methyl - 1 H -benzo[d] i mi dazol e-4-carboxyl ate ethyl 1 -(2-(4-(tert-butoxycarbonyl )pi perazi n- 1 -yl )qui nol i n-4-yl )-6-(5,5-di methyl - 1 ,3,2- di oxabori nan-2-yl )-1 H-benzo[d] i mi dazol e-4-carboxyl ate ethyl 6-(5,5-di methyl -1 ,3,2-di oxabori nan-2-yl )- 1 -{2-( 1 -tri tyl - 1 H -py razol -4-yl )qui nol i n- 4-yl )- 1 H -benzo[d] i mi dazol e-4-carboxy I ate tert-butyl 4-(4-(6-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-1H-benzo[d]im idazol-1- yl )qui nol i n-2-yl ) pi perazi ne-1 -carboxyl ate

J. Preparation of ethyl 6-(2-(difluoromethyl)pyridin-4-yl)-1-(5,8-difluoroquinolin-4 -yl)- 2-methyl -1 H-benzo[d] i mi dazol e-4-carboxylate.

Tetrakis(tri phenyl phosphi ne)pal I adium(O) (241 mg, 0.21 mmol ) was added to a solution of ethyl 1 -(5,8-dif I uoroqui nol i n-4-yl )-6-(5,5-di methyl-1 ,3,2-di oxabori nan-2-yl )-2- methyl-1H-benzo[d]imidazole-4-carboxylate (1.0 g, 2.09 mmol), 4-bromo-2- (difluoromethyl)pyridine (521 mg, 2.5 mmol), and potassium phosphate tri basic (1.11 g, 5.22 mmol) in dioxane (10 ml.) and water (3 ml_). Nitrogen was bubbled for 10 minutes and the reaction mixture was stirred at 90 °C for 4 hours. Upon cooling, the reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried with magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography eluting wi th 5 to 100% of (20% methanol i n ethyl acetate) i n hexane to afford ethyl 6-(2- (dif I uoromethyl )pyri di n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl -1 H- benzo[d]imidazole-4-carboxylate. ES/M S m/z = 495.2 (M+H) + .

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure:

ethyl 6-(2-cyanopyridi n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl-1 H- benzo[d]imidazole-4-carboxylate ethyl 1 -(5,8-di f I uoroqui nol i n-4-yl )-2-methyl -6-(2-methy I pyri di n-4-y I )- 1 H- benzo[ d] i m i dazol e-4-carboxy I ate ethyl 1 -(5,8-dif I uoroqui nol i n-4-yl )-6-(2-f I uoro-3-methyl pyri di n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I ate ethyl 1 -(5,8-dif I uoroqui nol i n-4-yl )-6-(2-f I uoro-6-methyl pyri di n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I ate ethyl 6-(3-chloro-2-f I uoropyri di n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl-1 H- benzo[ d] i m i dazol e-4-carboxy I ate ethyl 1 -(5,8-di f I uoroqui nol i n-4-yl )-2-methyl -6-(2, 3,5-tri f I uoropyri di n-4-yl )- 1 H - benzo[d]i mi dazol e-4-carboxyl ate ethyl 1 -(5,8-dif I uoroqui nol i n-4-yl )-6-(2-f I uoro-3-methyl pyri di n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I ate ethyl 1 -(5-chl oro-8-f I uoroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-y I )-2-methy I - 1 H- benzo[ d] i m i dazol e-4-carboxy I ate ethyl 1 -(5-chl oroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I ate ethyl 6-(2-cyanopyridi n-4-yl )-1 -(5,7-dif I uoroqui nol i n-4-yl )-2-methyl-1 H- benzo[ d] i m i dazol e-4-carboxy I ate ethyl 6-(2-cyanopyridi n-4-yl )-1 -(5,8-di chl oroqui nol i n-4-yl )-2-methyl-1 H- benzo[d]i mi dazol e-4-carboxyl ate ethyl 1 8-chl oroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-yl )-2-methyl -1 H- benzo[d] i mi dazol e-4-carboxyl ate ethyl 6 2-cyanopyridi n-4-yl )-1 -(5-f I uoroqui nol i n-4-yl )-2-methyl-1 H- benzo[d] i mi dazol e-4-carboxyl ate ethyl 6 2-cyanopyridi n-4-yl )-1 -(8-f I uoroqui nol i n-4-yl )-2-methyl-1 H- benzo[d] i mi dazol e-4-carboxyl ate ethyl 1 8-chl oro-5-f I uoroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-y I )-2-methy I - 1 H- benzo[d] i mi dazol e-4-carboxyl ate ethyl 6 2-cyanopyri mi di n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl - 1 H- benzo[d] i mi dazol e-4-carboxyl ate ethyl 1 5,8-dif I uoroqui nol i n-4-yl )-2-methyl -6-(2-methy I pyri mi di n-4-y I )- 1 H - benzo[d] i mi dazol e-4-carboxyl ate ethyl 1 5,8-dif I uoroqui nol i n-4-yl )-2-methyl -6-(6-methy I pyri mi di n-4-y I )- 1 H - benzo[d] i mi dazol e-4-carboxyl ate ethyl 6 6-ami no-5-cyanopyri midi n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl-1 H- benzo[d] i mi dazol e-4-carboxyl ate ethyl 1 5,8-dif I uoroqui nol i n-4-yl )-6-(2-f I uoropyri di n-4-y I )-2-methy I - 1 H - benzo[d] i mi dazol e-4-carboxyl ate ethyl 6 2-chl oropy ri di n-4-yl )- 1 -(5,8-di f I uoroqui nol i n-4-yl )-2-methyl - 1 H- benzol i mi dazol e-4-carboxyl ate ethyl 6 2,3-di f I uoropyri di n-4-yl )- 1 -(5,7-di f I uoroqui nol i n-4-yl )-2-methyl - 1 H- benzo[d] i mi dazol e-4-carboxyl ate ethyl 1 2-(4-(tert-butoxycarbonyl )pi perazi n- 1 -yl )qui nol i n-4-yl )-6-(2,3-dif I uoropyri di n- 4-yl)-1 H -benzo[d] i mi dazol e-4-carboxy I ate ethyl 1- 2-(4-(tert-butoxycarbonyl )pi perazi n- 1 -yl )qui nol i n-4-yl )-6-(2-cyanopyri di n-4- y I )- 1 H - benzo[ d] i mi dazol e-4-carboxy I ate ethyl 6-(2-cyanopyridi n-4-yl )-1 -(2-(1-tri tyl-1 H-pyrazol -4-yl )qui nol i n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I ate tert-butyl 4-(4-(6-(2,3-di f I uoropyri di n-4-yl )- 1 H -benzo[d] i mi dazol - 1 -yl )qui nol i n-2- yl )pi perazi ne- 1 -carboxyl ate K. Preparation of 6-(2-(difluoromethyl)pyridin-4-yl)-1-(5,8-difluoroquinolin-4 -yl)-2- methyl - 1 H -benzo[d] i mi dazol e-4-carboxyl i c aci d .

Aqueous 1M lithium hydroxide (3.4 imL) was added to ethyl 6-(2-

(di f I uoromethyl )pyri di n-4-yl )- 1 -(5,8-di f I uoroqui nol i n-4-y I )-2-methy I - 1 H- benzo[d]i mi dazol e-4-carboxyl ate (847 mg, 1.71 mmol) in THF (10 mL). The reaction was stirred at ambient temperature for overnight. The reaction mixture was acidified with 4N HCI i n di oxane. The resulti ng sol uti on was concentrated under reduced pressure to afford 6-(2-(dif I uoromethyl )pyridi n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl - 1 H- benzo[d]i mi dazol e-4-carboxylic acid which was used without further purification for the next step. ESIMS nVz 467.20 (M+H) + .

The f ol lowi ng compounds were prepared usi ng a si mi I ar procedure:6-(2-cyanopyri di n-4- yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl- 1 H-benzo[d] i mi dazol e-4-carboxyl i c aci d

1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl -6-(2-methyl pyri di n-4-yl )-1 H-benzo[d] i mi dazol e- 4-carboxylic acid 1 -(5, 8-difl uoroqui nol i n-4-yl )-6-(2-f I uoro-3-methyl pyri di n-4-yl )-2-methyl - 1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 -(5, 8-difl uoroqui nol i n-4-yl )-6-(2-f I uoro-6-methyl pyri di n-4-yl )-2-methyl - 1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

6-(3-chl oro-2-f I uoropyri di n-4-yl )-1 -(5,8-di f I uoroqui nol i n-4-yl )-2-methyl - 1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d 1-{5,8-difluoroquinolin-4-yl)-2-methyl-6-(2,3,5-trifluoropyr idin-4-yl benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 -{5, 8-di f I uoroqui nol i n-4-yl )-6-(2-f I uoro-3-methyl pyri di n-4-yl )-2-methyl - 1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d 1 -{5-chl oro-8-f I uoroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-yl )-2-methyl - 1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 -{5-chl oroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-y I )-2-methy I - 1 H-benzo[d] i mi dazol e-4- carboxylic acid

6-{2-cyanopyri di n-4-yl )- 1 -(5,7-dif I uoroqui nol i n-4-yl )-2-methyl - 1 H -benzo[d] i mi dazol e- 4-carboxylic acid

6-{2-cyanopy ri di n-4-yl )- 1 -(5,8-di chl oroqui nol i n-4-yl )-2-methyl - 1 H -benzo[ d] i mi dazol e- 4-carboxylic acid

1 -{8-chl oroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-y I )-2-methy I - 1 H-benzo[d] i mi dazol e-4- carboxylic acid 6-{2-cyanopyri di n-4-yl )- 1 -(5-f I uoroqui nol i n-4-yl )-2-methyl - 1 H-benzo[d] i mi dazol e-4- carboxylic acid

6-{2-cyanopyri di n-4-yl )- 1 -(8-f I uoroqui nol i n-4-yl )-2-methyl - 1 H-benzo[d] i mi dazol e-4- carboxylic acid

1 -{8-chl oro-5-f I uoroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-yl )-2-methyl - 1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

6-{2-cyanopy ri mi di n-4-yl )- 1 -(5,8-di f I uoroqui nol i n-4-yl )-2-methyl - 1 H - benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 -{5,8-dif I uoroqui nol i n-4-yl )-2-methyl -6-(2-methyl pyri mi di n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d 1 -{5,8-dif I uoroqui nol i n-4-yl )-2-methyl -6-(6-methyl pyri mi di n-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d 6-{6-ami no-5-cyanopyri mi di n-4-yl )- 1 -(5,8-di f I uoroqui nol i n-4-yl )-2-methyl - 1 H - benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 -{5, 8-di f I uoroqui nol i n-4-yl )-6-(2-f I uoropyri di n-4-yl )-2-methyl - 1 H-benzo[ d] i mi dazol e- 4-carboxylic acid 6-{2-chl oropy ri di n-4-yl )- 1 -(5,8-di f I uoroqui nol in-4-yl)-2-methyl-1H-benzo[d]i mi dazol e- 4-carboxylic acid

6-(2,3-dif I uoropyri di n-4-yl )- 1 -(5,7-dif I uoroqui nol i n-4-yl )-2-methyl -1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d

1 -{2-(4-(tert-butoxycarbonyl )pi perazi n-1-yl )qui nol i n-4-yl )-6-(2,3-dif I uoropyri di n-4-yl )- 1H-benzo[d]imidazole-4-carboxylic add

1 -{2-(4-(tert-butoxycarbonyl )pi perazi n- 1 -yl )qui nol i n-4-yl )-6-(2-cyanopyri di n-4-y I )- 1 H - benzo[ d] i m i dazol e-4-carboxy I i c aci d

6-{2-cyanopyridin-4-yl)-1-(2-(1-trityl-1 H-pyrazol-4-yl)quinol in-4-yl )-1 H- benzo[ d] i m i dazol e-4-carboxy I i c aci d Preparation of the compounds of formula (5) according to reaction Scheme 1

A. Preparation of 6-(2-(dif I uoromethyl )pyri di n-4-yl )-1 -(5,8-di f I uoroqui nolin-4-yl)-2- methyl - 1 H -benzo[d] i mi dazol e-4-carboxami de.

To a sol uti on of 6-(2-(dif I uoromethyl )pyri di n-4-yl )-1 -(5,8-di f I uoroqui nol i n-4-yl )-2- methyl-1H-benzo[d]imidazole-4-carboxylic acid (797 mg, 1.71 mmol) in DM F (8.0 mL) wereadded ammonium chloride (640, 12.0 mmol), 1H-benzo[d][1,2,3]triazol-1-ol (1.31 g, 6.84 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1 ,3-diamine hydrochloride (1.31 g, 6.84 mmol) and di ethyl isopropy I amine (2.98 mL, 17.1 mmol). The mixture was stirred at 50 °C for overnight. The material was predpitated with the addition of water. The resulting solid was filtered, washed with water, and dried under high vacuum for overnight to afford 6-(2-(difluoromethyl)pyridin-4-yl)-1-(5,8- dif I uoroqui nol i n-4-yl )-2-methyl-1 H-benzo[d] i mi dazole-4-carboxamide. ES M S rrVz 466.2 (M+H) + .

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure: 1-{5,8-di chloroqui nol i n-4-yl )-2-methyl-6-(pyridi n-4-yl )-1 H-benzo[d] i mi dazol e-4- carboxamide

6-{2, 5-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl - 1 H - benzo[d] i mi dazol e-4-carboxami de

6-{2, 3-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl - 1 H - benzo[d]imidazole-4-carboxamide

1 -{5,8-dif I uoroqui nol i n-4-yl )-2-methyl -6-(2-methyl pyri di n-4-yl )-1 H-benzo[d] i mi dazol e- 4-carboxamide

1 -{5, 8-di f I uoroqui nol i n-4-yl )-6-(2-f I uoro-3-methyl pyri di n-4-yl )-2-methyl - 1 H- benzo[d] i mi dazol e-4-carboxami de tert-butyl (4-(4-carbamoyl -2-ethyl -1 -(7-f I uoroqui nol i n-4-yl )-1 H-benzo[d] i mi dazol-6- yl )pyridi n-2-yl )carbamate tert-butyl (4-(4-carbamoyl -1 -(7-f I uoroqui nol i n-4-yl )-2-methyl -1 H-benzo[d] i mi dazol -6- yl )pyridi n-2-yl )carbamate tert-butyl (4-(4-carbamoyl -2-ethyl -1 -(5-f I uoroqui nol i n-4-yl )-1 H-benzo[d] i mi dazol -6- yl)pyridin-2-yl)carbamate tert-butyl (4-(4-carbamoyl -1 -(5-f I uoroqui nol i n-4-yl )-2-methyl -1 H-benzo[d] i mi dazol -6- yl )pyridi n-2-yl )carbamate tert-butyl (4-(4-carbamoyl -2-cycl opropyl - 1 -(8-f I uoroqui nol i n-4-yl )-1 H- benzo[d] i mi dazol -6-yl )pyri di n-2-yl )carbamate tert-butyl (4-(4-carbamoyl -1 -(8-f I uoroqui nol i n-4-yl )-2-methyl -1 H-benzo[d] i mi dazol -6- yl )pyridi n-2-yl )carbamate tert-butyl (4-(4-carbamoyl -1-(8-chloro-5-f I uoroqui nol i n-4-yl )-2-cycl opropyl -1 H- benzo[d] i midazol -6-yl )pyri di n-2-yl )carbamate tert-butyl (4-(4-carbamoyl - 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2- propyl - 1 H- benzo[d] i midazol -6-yl )pyri di n-2-yl )carbamate tert-butyl (4-(4-carbamoyl - 1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2- i sopropyl - 1 H - benzo[d] i midazol -6-yl )pyri di n-2-yl )carbamate tert-butyl (4-(4-carbamoyl -1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2-(oxetan-3-yl )-1 H- benzo[d] i midazol -6-yl )pyri di n-2-yl )carbamate tert-butyl (4-(4-carbamoyl -2-cycl opropyl - 1 -(5,8-dif I uoroqui nol i n-4-yl )-1 H- benzo[d] i midazol -6-yl )pyri di n-2-yl )carbamate tert-butyl (4-(4-carbamoyl -1-(5,8-dif I uoroqui nol i n-4-yl )-2-ethyl-1 H-benzo[d] i midazol-6- yl )pyridi n-2-yl )carbamate

1 -(8-chl oro-5-f I uoroqui nol i n-4-yl )-2-cycl opropyl -6-(2,3-di f I uoropyri di n-4-y I )- 1 H - benzo[d] i midazol e-4-carboxami de tert-butyl (4-(4-carbamoyl -2-(cycl opropyl methyl )-1 -(5,8-di f I uoroqui nol i n-4-yl )- 1 H- benzo[d] i midazol -6-yl )pyri di n-2-yl )carbamate tert-butyl (4-(4-carbamoyl -1 -(5,8-dif I uoroqui nol i n-4-yl )-2-propyl -1 H-benzo[d] i mi dazol - 6-yl ) pyri di n-2-yl )carbamate tert-butyl (4-(4-carbamoyl -1 -(8-chl oroqui nol i n-4-yl )-2-(cycl opropyl methyl )-1 H- benzo[d] i midazol -6-yl )pyri di n-2-yl )carbamate tert-butyl (4-(4-carbamoyl - 1 -(8-chl oroqui nol i n-4-yl )-2-cycl opropyl - 1 H - benzo[d] i midazol -6-yl )pyri di n-2-yl )carbamate

6-(2,3-dif I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-propyl -1 H- benzo[d] i midazol e-4-carboxami de 6-(2, 3-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl - 1 H - benzo[d] i midazol e-4-carboxami de 6-{2, 5-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl - 1 H - benzo[d] i midazol e-4-carboxami de

1 -{8-chl oroqui nol i n-4-yl )-2-cycl opropyl -6-(2,3-di f I uoropyri di n-4-yl )- 1 H- benzo[d] i midazol e-4-carboxami de 1 -{8-chl oroqui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-y I )-2-methy I - 1 H -benzo[d] i mi dazol e- 4-carboxamide

2-cycl opropyl -6-(2,3-di f I uoropyri di n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-1 H- benzo[d] i midazol e-4-carboxami de

1 -{8-chl oro-5-f I uoroqui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-yl )-2-methyl - 1 H- benzo[d]imidazole-4-carboxamide

1 - {8-chl oro-5-f I uoroqui nol i n-4-yl )-6-(2,3-dif I uoropyri di n-4-yl )-2-propyl -1 H- benzo[d] i midazol e-4-carboxami de

6-{2, 3-di f I uoropyri di n-4-yl )- 1 -(8-f I uoroqui nol i n-4-yl )-2-propyl -1 H-benzo[d] i mi dazol e- 4-carboxamide 6-{2, 3-di f I uoropyri di n-4-yl )- 1 -(8-f I uoroqui nol i n-4-yl )-2-methyl - 1 H-benzo[ d] i mi dazol e- 4-carboxamide

2- cycl opropyl -6-(2,3-di f I uoropyri di n-4-yl )-1 -(8-f I uoroqui nol i n-4-yl )-1 H- benzo[d] i midazol e-4-carboxami de

1 -{8-chl oro-3-methyl qui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-yl )-2-methyl - 1 H - benzo[d]imidazole-4-carboxamide

1 -{5, 8-di f I uoroqui nol i n-4-yl )-6-(2-f I uoro-6-methyl pyri di n-4-yl )-2-methyl - 1 H- benzo[d] i midazol e-4-carboxami de

6-{3-chl oro-2-f I uoropyri di n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl - 1 H- benzo[d] i midazol e-4-carboxami de 1 -{5, 8-di f I uoroqui nol i n-4-yl )-2-methyl -6-(2,3,5-tri f I uoropyri di n-4-yl )- 1 H- benzo[d] i midazol e-4-carboxami de 1 -{5, 8-di f I uoroqui nol i n-4-yl )-6-(2-f I uoro-3-methyl pyri di n-4-yl )-2-methyl - 1 H- benzo[d] i midazol e-4-carboxami de

1 -{3-chl oro-8-f I uoroqui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-yl )-2-methyl - 1 H- benzo[d] i midazol e-4-carboxami de 6-{2, 3-di f I uoropyri di n-4-yl )- 1 -(5-f I uoroqui nol i n-4-yl )-2-methyl - 1 H-benzo[ d] i mi dazol e- 4-carboxamide

6-{2, 3-di f I uoropyri di n-4-yl )-2-ethyl - 1 -(5-f I uoroqui nol i n-4-yl )- 1 H-benzo[d] i mi dazol e-4- carboxamide

6-{2, 3-di f I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-ethyl - 1 H- benzo[d]imidazole-4-carboxamide

2-{cyclopropyl methyl )-6-(2,3-dif I uoropyri di n-4-yl )-1 -(5,8-dif I uoroqui nol i n-4-yl )-1 H- benzo[d] i midazol e-4-carboxami de

1 -(5-chl oro-8-f I uoroqui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-yl )-2-methyl - 1 H- benzo[d] i midazol e-4-carboxami de 1 -(5-chl oro-8-f I uoroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-yl )-2-methyl - 1 H- benzo[d] i midazol e-4-carboxami de

1 -(5-chl oroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-y I )-2-methy I - 1 H-benzo[d] i mi dazol e-4- carboxamide

6-(2-cyanopyri di n-4-yl )- 1 -(5,7-dif I uoroqui nol i n-4-yl )-2-methyl - 1 H -benzo[d] i mi dazol e- 4-carboxamide

6-(2-cyanopy ri di n-4-yl )- 1 -(5,8-di chl oroqui nol i n-4-yl )-2-methyl - 1 H -benzo[ d] i mi dazol e- 4-carboxamide

1 -(8-chl oroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-y I )-2-methy I - 1 H-benzo[d] i mi dazol e-4- carboxamide 6-(2-cyanopyri di n-4-yl )- 1 -(5-f I uoroqui nol i n-4-yl )-2-methyl - 1 H-benzo[d] i mi dazol e-4- carboxamide 6-{2-cyanopyri di n-4-yl )- 1 -(8-f I uoroqui nol i n-4-yl )-2-methyl - 1 H-benzo[d] i mi dazol e-4- carboxamide

1 -{8-chl oro-5-f I uoroqui nol i n-4-yl )-6-(2-cyanopyri di n-4-yl )-2-methyl - 1 H- benzo[d] i mi dazol e-4-carboxami de 6-{2-cyanopyri mi di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl -1 H- benzo[d] i mi dazol e-4-carboxami de

1 -{5,8-dif I uoroqui nol i n-4-yl )-2-methyl -6-(2-methyl pyri mi di n-4-yl )-1 H- benzo[d] i midazol e-4-carboxami del -(5,8-di f I uoroq ui nol i n-4-yl )-2-methyl -6-(6-methyl pyri mi di n-4-yl )-1 H-benzo[d] i midazol e-4- carboxamide

1 -{5, 8-di f I uoroqui nol i n-4-yl )-6-(2-f I uoropy ri di n-4-yl )-2-methyl - 1 H-benzo[ d] i mi dazol e- 4-carboxamide

6-{2-chloropyridin-4-yl )-1 -(5,8-dif I uoroqui noli n-4-yl)-2-methyl-1H-benzo[d]i mi dazol e- 4-carboxamide 6-{2,3-dif I uoropyridi n-4-yl )-1 -(5,7-dif I uoroqui nol i n-4-yl )-2- methyl -1 H- benzo[d] i midazol e-4-carboxami de tert-butyl 4-(4-(4-carbamoyl-6-(2,3-dif I uoropyridi n-4-yl )- 1 H-benzo[d]i midazol-1- yl )qui nol i n-2-yl ) pi perazi ne-1 -carboxyl ate tert-butyl 4-(4-(4-carbamoyl -6-(2-cyanopyri di n-4-yl )- 1 H-benzo[ d] i mi dazol - 1 - yl )qui nol i n-2-yl ) pi perazi ne-1 -carboxyl ate

6-{2-cyanopy ri di n-4-y I )- 1 -(2-( 1 -tri ty I - 1 H-pyrazol-4-yl)quinol in-4-yl )-1 H- benzo[d] i midazol e-4-carboxami de.

Compounds may be referred to by Example number with reference to the below tables.

B. Preparation of 6-(2-aminopyridin-4-yl)-1-(8-chloroquinolin-4-yl)-2-rnethyl- 1H- benzo[d] i mi dazol e-4-carboxami de.

tert-Butyl (4-(4-carbamoyl-1-(8-chloroquinolin-4-yl)-2-methyl-1H-benzo[ d]imidazol-6- yl)pyridin-2-yl)carbamate (50 mg, 0.10 mmol) was dissolved in dichloromethane (1.0 mL) and trifluoroacetic acid (145μΙ_, 1.89mmol) was added. The reaction mixture was stirred at ambient temperature for 1 hour, after which the reaction was concentrated under reduced pressure. The resultant was purified by HPLC el uti ng with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 6-(2-aminopyridin-4-yl)-1-(8-chloroquinolin-4-yl)-2-methyl-1 H- benzo[d]imidazole-4-carboxamideasa 2,2,2-trifluoroacetic acid salt (Example 23).

C. Preparation of 6-(2-aminc>-3-fluoropyridin-4-yl)-1-{5,8-difluoroquinolin -4-yl)-2- methyl - 1 H -benzo[d] i mi dazol e-4-carboxami de.

NH 2 NH 2 Ammonium hydroxide (28-30% solution in water, 0.75 mL) was added to asolution of 6-(2,3-dif I uoropyri di n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl -1 H- benzo[d]imidazole-4-carboxamide (40 mg, 0.09 mmol) in DMSO (2.0 mL). The sealed tube was closed and reaction mixture was stirred at 100 °C for overnight. The excess ammonia was removed under reduced pressure and the resulting solution was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 6-{2-ami no-3-f I uoropyri din- 4-yl )-1-(5,8-dif I uoroqui nol i n-4-yl )-2-methyl-1 H-benzo[d] i mi dazol e-4-carboxamide as a 2,2,2-trifluoroacetic acid salt (Example26).

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure:

Preparation of the compounds of formula (5) according to reaction Scheme 3

A. Preparation of ethyl 6-bromo-1-(5,8-difluoroquinolin-4-yl)-1H-benzo[d]imidazole-4 - carboxylate

A solution ethyl 2-amino-5-bromo-3-((5,8-difluoroquinolin-4-yl)amino)benzoate (3.7 g, 8.76 mmol , made as descri bed above) i n tri methyl orthof ormate (50 mL ) was ref I uxed for 30 minutes. Upon cooling, the mixture was concentrated under reduced pressure. The resulting solid was triturated with 25 mL of diethyl ether. The sol id was recovered by filtration to afford ethyl 6-bromo-1-(5,8-difluoroquinolin-4-yl)-1 H-benzo[d]imidazole-4- carboxylate. ESWIS nYz= 432.0 (M+H + ).

B. Preparation of 6-bromo-1-(5,8-difluoroquinolin-4-yl)-1H-benzo[d]imidazole-4 - carboxylic acid.

Aqueous 1M lithium hydroxide (3.4 mL) was added to ethyl 6-bromo-1-(5,8- difluoroquinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate (1.19 g, 2.75 mmol) in THF (15 mL). The reaction was stirred at ambient temperature for 1 hour. The reaction mixture was acidified with 4N HCI in dioxane. The resulting solution was concentrated under reduced pressure to afford 6-bromo-1-(5,8-difluoroquinolin-4-yl)-1H- benzo[d]imidazole-4-carboxylic acid which was used without further purification for the next step. ESIMS rrVz 404.0 (M+H) + .

C. Preparation of6-bromo-1-(5,8-dif I uoroqui nol i n-4-yl )-1 H-benzo[d] i mi dazol e-4- carboxamide.

To a sol uti on of 6-bromo- 1 -(5,8-dif I uoroqui nol i n-4-yl )-1 H-benzo[d] i midazol e-4- carboxylic acid (1.11 g, 2.75 mmol) in DM F (9.0 mL) were added ammonium chloride (1.03 g, 19.2 mmol), 1H-benzo[d][1,2,3]triazol-1-ol (2.10 g, 11.0 mmol), N1- ((ethyli mi no)methylene)-N3,N3-di methyl propane-1,3-di amine hydrochloride (2.10 g, 11.0 mmol) and di ethyl isopropyl amine (4.8 mL, 27.5 mmol). The mixture was stirred at 50 °C for overnight. The material was precipitated with the addition of water. The resulting solid was filtered, washed with water, and dried under high vacuum to afford 6- bromo- 1 -(5,8-dif I uoroqui nol i n-4-yl )-1 H-benzo[d] i mi dazol e-4-carboxamide. ES/M S m/z 403.0 (M+H) + . D. Preparation of 1-(5,8-difluoroquinolin-4-yl)-6-(5,5-dimethyl-1,3,2-dioxabor inan-2- yl )- 1 H-benzo[ d] i mi dazol e-4-carboxami de.

[ 1 , 1 '-B i s(di phenyl phosphi no)f errocene] di chl oropal I adi um( 11 ) compl ex wi th

dichloromethane (276 mg, 0.34 mmol ) was added to a solution of 6-bromo- 1 -(5,8- difluoroquinolin-4-yl)-1H-benzo[d]imidazole-4-carboxarriicle (910 mg, 2.26 mmol), bis(neopentyl glycolato)di boron (663 mg, 2.93 mmol) and potassium acetate (554 mg, 5.64 mmol) in dioxane (20 ml_). Nitrogen was bubbled for 10 minutes and the reaction mixture was stirred at refluxing temperature for 24 hours. The reaction mixture was cooled to ambient temperature and the solid was filtered. The solid was washed with water and dried under vacuum to afford 1 -(5,8-dif I uoroqui noli n-4-yl)-6-(5,5-di methyl - 1,3,2-dioxaborinan-2-yl)-1H-benzo[d]imidazole-4-carboxamide. ES/MS m z = 369.2 (ArB(OH) 2 + H) + .

E. Preparation of 6-(2,3-difluoropyridin-4-yl)-1-(5,8-difluoroquinolin-4-yl)-1 H- benzo[d]imidazole-4-carboxamide.

Tetrakis(tri phenyl phosphi ne)pal I adium(O) (146 mg, 0.13 mmol ) was added to asolution of 1 -(5,8-dif I uoroqui nol i n-4-yl )-6-(5,5-di methyl - 1 ,3,2-di oxabori nan-2-yl )-1 H- benzo[d]imidazole-4-carboxamide (550 mg, 1.26 mmol), 4-iodo-2,3-difluoropyridine (365 mg, 1.51 mmol), and potassium phosphate tri basic (669 mg, 3.15 mmol) in dioxane (6.0 mL) and water (1.5 ml_). Nitrogen was bubbled for 10 minutes and the reaction mixture was stirred at 100 °C for 4 hours. Upon cooling, the reaction mixture was partitioned between ethyl acetate and water. The organi c phase was washed with bri ne, dried with magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product was purif i ed by si I i ca gel col umn chromatography el uti ng wi th 5 to 100% of (10% methanol in ethyl acetate) in hexane to afford 6-(2,3-dif luoropyridin-4-yl )-1- (5,8-dif I uoroqui nol i n-4-yl )-1 H-benzo[d] i midazole-4-carboxamide. ES M S m/z = 438.2 (M+H) + .

Preparation of compounds of formula (I M ) A. Preparation of 4-(6-(2-(difluoromethyl)pyridin-4-yl)-2-methyl-4-(4H-1,2,4-t riazol-3- yl )-1 H-benzo[d] i mi dazol-1 -yl )-5,8-dif I uoroqui nol i ne.

6-(2-(di f I uoromethyl )pyridi n-4-yl )- 1 -(5,8-dif I uoroqui nol i n-4-yl )-2-methyl - 1 H- benzo[d]imidazole-4-carboxamide (455 mg, 0.98 mmol) was suspended in 1 ,1- dimethoxy-N,N-di methyl methanamine (6.5 mL, 49 mmol) and stirred at 100 °C for 5 hours. The sol uti on was cool ed to ambi ent temperature, concentrated under reduced pressure and dried under vacuum overnight. The residue was dissolved in acetic acid (5 mL) and hydrazine (92 μΙ_, 2.93 mmol ) was added. The reaction mixture was stirred at 45 °C for 1 hour, after which the reaction was cooled to ambient temperature and concentrated under reduced pressure. The resultant was purified by HPLC eluting with 5- 95% water/ acetonitrile (0.1%v/ trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 4-(6-(2-(difl uoromethyl )pyridin-4-yl )-2-methyl-4-(4H- 1 ,2,4-triazol -3-yl )-1 H-benzo[d] i mi dazol-1 -yl )-5,8-di f I uoroqui nol i ne as a 2,2,2- trifluoroacetic acid salt (Example43).

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure: tert-butyl 4-(4-(6-(2-cyanopyridin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-b enzo[d]imidazol- 1 -yl )qui nol i n-2-y I )pi perazi ne- 1 -carboxyl ate

4-(4-(4H-1,2,4-triazol-3-yl)-1-(2-(1-trityl-1H-pyrazol-4- yl)quinolin-4-yl)-1H- benzo[ d] i m i dazol -6-y I ) pi col i noni tri I e

A. Preparation of tert-butyl (4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol- 3-yl )-1 H-benzo[d] i midazol-6-yl )pyri di n-2-yl )carbamate.

tert-Butyl (4-(4-carbamoyl-1-(8-chloroquinolin-4-yl)-2-methyl-1H-benzo[ d]imidazol-6- yl)pyridin-2-yl)carbamate (120 mg, 0.23 mmol) was suspended in 1,1-dimethoxy-N, Ni- di methyl methanamine (3.0 ml_, 22.7 mmol) and stirred at 100 °C for 3 hours. The solution was cooled to ambient temperature, concentrated under reduced pressure and dried under vacuum for overnight. The residue was dissolved in aceticacid (2 ml.) and hydrazine (28 μΙ_, 0.57 mmol) was added. The reaction mixture was stirred at 45 °C for 1 hour, after which the reaction was cooled to ambient temperature and concentrated under reduced pressure. The resultant was purified by HPLC el uti ng with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford tert-butyl (4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-(4H-1,2,4- tri azol -3-yl )- 1 H-benzo[d] i mi dazol -6-yl )pyri di n-2-yl )carbamate as a 2,2,2-trif I uoroaceti c acid salt. ES/MS nVz= 553.2 (M+H) + . tert-B utyl (4-( 1 -(8-chl oroqui nol i n-4-y I )-2-methy I -4-(4H- 1 ,2,4-tri azol -3-yl )- 1 H- benzo[d]imidazol-6-yl)pyridin-2-yl )carbamate (35 mg of 2,2,2-trif I uoroaceti c acid salt, 0.06 mmol) was dissolved in dichloromethane (0.6 mL) and trifluoroacetic acid (100 μΙ_, 2.93 mmol) was added. The reaction mixture was stirred at ambient temperature for 1 hour, after which the reaction was concentrated under reduced pressure. The resultant was dissolved in a mixtureof acetonitrile and water followed by lyophilization to afford 4-(1 -(8-chl oroqui nol i n-4-yl )-2-methyl -4-(4H- 1 ,2,4-tri azol -3-yl )- 1 H-benzo[d] i mi dazol -6- yl)pyridin-2-amine as a 2,2,2-trif I uoroaceti c acid salt (Example 58).

The f ol I owi ng compounds were prepared usi ng a si mi I ar procedure:

Preparation of compounds of formula (I C) in which R = NH2

A. Preparation of 4-(1-(8-chl oroqui nolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H- benzo[d] i midazol -6-yl )-3-f I uoropyri di n-2-ami ne.

1 -{8-chl oroqui nol i n-4-yl )-6-(2,3-di f I uoropyri di n-4-y I )-2-methy I - 1 H -benzo[d] i mi dazol e- 4-carboxamide (130 mg, 0.29 mmol) was suspended in 1 , 1-dimethoxy-N, Ni- di methyl methanamine ( 1.9 ml_, 14.4 mmol) and stirred at 100 °C for 3 hours. The solution was cooled to ambient temperature, concentrated under reduced pressure and dried under vacuum for overnight. The residue was dissolved in aceticacid (3 mL) and hydrazine (18 μΙ_, 0.58 mmol) was added. The reaction mixture was stirred at 45 °C for 1 hour, after which the reaction was cooled to ambient temperature and concentrated under reduced pressure. The residue was taken up in ethyl acetate, washed with saturated NaHCOa washed with brine, dried with magnesium sulfate, filtered, and concentrated under reduced pressure. Crude 8-chloro-4-(6-(2,3-difluoropyridin-4-yl)-2-methyl-4-(4H- 1 ,2,4-triazol-3-yl )-1 H-benzo[d] i mi dazol -1-yl )qui nol i ne was used without further purification in the next step. ES/MS/r/z 474.2 (M+H) + . Ammonium hydroxide (28-30% solution in water, 0.75 mL) was added to asolution of crude 8-chloro-4-(6-(2,3-difl uoropyridi n-4-yl)-2-methyl-4-(4H-1 ,2,4-triazol-3-yl )-1 H- benzo[d]imidazol-1-yl)quinoline (0.274 mmol) in DMSO (3.0 mL). The reaction vessel was sealed and the reaction mixture was stirred at 100°C overnight. The excess ammonia was removed under reduced pressure and the resulting solution was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 4-(1-(8-chloroquinolin-4-yl)-2-methyl-4- (4H-1 ,2,4-triazol-3-yl)-1 H-benzo[d]imidazol-6-yl )-3-fluoropyridin-2-amine as a 2,2,2- trifluoroacetic acid salt ([Example 80).

The foil owing compounds were synthesized using a similar method: tert-butyl 4-(4-(6-(2-ami no-3-f I uoropyri di n-4-yl )-4-(4H- 1 ,2,4-tri azol -3-yl )- 1 H - benzo[d] i mi dazol - 1 -yl )qui nol i n-2-yl )pi perazi ne- 1 -carboxyl ate

A. Preparation of 4-(6-(2,3-difluoropyridin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H - benzo[d] i midazol-1 -yl )-2-(pi perazi n-1-yl )qui nol i ne.

To a solution of tert-butyl 4-(4-(6-(2,3-difluoropyridin-4-yl)-4-(4H-1,2,4-triazol-3-yl) - 1H-benzo[d]imidazol-1-yl)quinolin-2-yl)piperazine-1-carboxyl ate (41 mg, 0.07 mmol) in DCM (1.0 ml_) was added TFA (0.2 ml_). The mixture was then stirred for 1 hour. After concentration under reduced pressure, the resultant was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 4-(6-(2,3-difluoropyridin-4-yl)-4-(4H-1,2,4- tri azol -3-yl )- 1 H-benzo[ d] i mi dazol - 1 -yl )-2-(pi perazi n- 1 -yl )qui nol i ne as a 2,2 ,2- trifluoroacetic acid salt. ES M S m/z = 510.2 (M+H)+ (Example 164) The foil owing compounds were synthesized using a similar method:

Separation of atropisomers of compounds of formula (I M )

A. Separation of the atropisomers of 4-(1-(5,8-difl uoroqui nolin-4-yl)-2-methyl-4-(4H- 1 ,2,4-triazol-3-yl )-1 H-benzo[d] i midazol-6-yl )pyri di n-2-ami ne.

The atropisomers of Example 48 were separated on OD-H SFC 5μΜ 21x250mm column in 30% EtOH/C0 2 at 60 mL/min to give the two single atropisomers of 4-(1-(5,8- di f I uoroqui nol i n-4-yl )-2-methyl -4-(4H- 1 ,2,4-tri azol -3-yl )- 1 H-benzo[d] i mi dazol -6- yl)pyridin-2-amine (Example 103 and Example 104). Thefollowing compounds were prepared using a similar procedure:

Separation of atropisomers: The atropisomers of were separated on OD-H SFC 5uM 21x250mm column. The conditions for the separation of atropisomers and characterization data are provided i n the table below:

From the foregoing it will be appreciated that, although specific embodiments have been described herein for purposes of illustration, various modifications may be made without deviating from the spi rit and scope of the present appl i cation. Biological Examples

The compounds of formul a (I ) were characterized for thei r enzymati c activity agai nst the PI 3K i sof orms. T he acti vi ti es were measured usi ng a ti me-resol ved f I uorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in

phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site.

Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from M i 11 i pore. PI 3K i sof orms were assayed under i ni ti al rate condi ti ons i n the presence of 25 mM Hepes (pH 7.4), and 2x Km ATP (75-500 μΜ), 2 μΜ PIP2, 5% glycerol, 5 mM MgCI 2 , 50 mM NaCI, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: ΡΙ3Κα, ΡΙ3Κβ, and PI3Kδ between 25 and 50 pM , and PI 3Κγ at 2 nM . The compounds were added to the assay sol uti on and incubated for 30 minutes at 25°C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PI P3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader

(Ex: 340 nm; Em: 615/665 nm; 100 ps delay and 500 [is read window).

The results were normalized based on positive (1 μΜ wortmanin) and negative (DMSO) controls, and the I C50 val ues f or PI3K α, β, δ, and γ were calculated from the fit of the dose-response curves to a four-parameter equation. These assays generally produced results within 3-fold of the reported mean.

From the foregoing it will be appreciated that, although specific embodiments have been described herein for purposes of illustration, various modifications may be made without deviating from the spi rit and scope of the present appl i cation.